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ÖSSZEFOGLALÁS 
 
Patkányban a két artéria carotis communis elzárásával (“two vessel occlusion”= 2VO) krónikus agyi 
hipoperfúzió jön létre. Ez egy széleskörben elfogadott és alkalmazott állatkísérletes modell a 
vaszkuláris eredetű kognitív zavarok és neuropathológiai eltérések vizsgálatára. A 2VO modellben 
létrejövő iszkémiás neuronkárosodás és memória deficit mértékét csökkentő gyógyszeres kezelések 
egyrészt segítik a cerebrovaszkuláris és kardiovaszkuláris eredetű demenciák természetének 
felderítését, másrészt új terápiás megfontolások alapjául is szolgálhatnak. Kísérleteink célja az volt, 
hogy megvizsgáljuk a mitokondriális ATP-szenzitív K+ csatornanyitó diazoxid (DIAZ), valamint a 
nem szelektív- (indometacin) és szelektív ciklooxigenáz gátlók (NS-398 COX-2 gátló) hatását 2VO-
val létrehozott agyi hipoperfúzió különböző fázisaiban. A DIAZ kezelés hatásait az agyi hipoperfúzió 
korai és késői időszakában nátrium-hidroxid (NaOH) és dimetil-szulfoxid (DMSO) oldószerek 
alkalmazásával vizsgáltuk, valamint összehasonlítottuk a DIAZ elő- és utókezelések következményeit. 
Végül az indometacin és az NS-398 hatásait vizsgáltuk az agyi hipoperfúzió korai szakaszában. Hím 
Wistar patkányokon 2VO-t (n=137) vagy áloperációt (n=105) végeztünk, majd vizsgáltuk a térbeli 
tanulási képességet (Morris watermaze teszt), a makroszkópos agyi léziók gyakoriságát, illetve 
szövettani módszerekkel a hippokampuszban és egyes fehérállományi régiókban a neuronális 
károsodás mértékét (krezil- ibolya festés és COX-2-pozitív neuronjelölés), a denritpusztulást 
(mikrotubulus asszociált protein-2 jelölés), asztrocita reakciót (gliális fibrilláris savas protein jelölés) 
és a mikroglia aktivációt (OX-42 jelölés). Eredményeink alapján a hipoperfúzió a korai időszakban 
térbeli tanulási zavart, progresszív neuronális- és dendritkárosodást, valamint a késői időszakban régió 
specifikus asztrocita proliferációt és mikroglia aktivációt okozott. A DMSO-ban oldott DIAZ kezelés 
után, a hipoperfúzió késői fázisában a tanulási képesség alig változott, csökkent a neuron pusztulás 
mértéke és elmaradt a mikroglia aktiváció. A DIAZ jótékony hatását a DMSO feltehetően fokozta. 
2VO után 2 héttel a NaOH-ban oldott DIAZ csak előkezelésként alkalmazva mérsékelte a 
memóriazavart és az idegsejt pusztulást, ami a DIAZ prekondícionáló hatására utal. A COX-gátló 
kezelések közül az NS-398 kivédte a tanulásromlást, ugyanakkor mindkét anyag fokozta a 
hippokampális neuron pusztulást. Feltehetően a COX gátlók protektív hatásukat nem közvetlenül a 
hippokampusz védelmén keresztül fejtik ki. Megfigyeléseink szerint a DIAZ előkezelés hatékony lehet 
bizonyos vaszkuláris eredetű memóriazavarok megelőzésében. A szelektív COX-2 gátlók szintén 
hatásosak lehetnek a kognitív tünetek kezelésében, alkalmazásuk azonban további gondos 
vizsgálatokat igényel.  
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SUMMARY 
 
Permanent bilateral common carotid artery occlusion (2VO) is a suitable model with 
which to investigate chronic cerebral hypoperfusion-related cognitive disturbances and brain 
pathology in the rat. A number of drugs have been demonstrated to reduce ischemic neuronal 
damage and memory deficit in the 2VO model, but there are still relevant pharmacological 
approaches which might help to reveal the nature of dementia of cerebro- or cardiovascular 
origin and might additionally be of therapeutic value. The aim of our investigations was to 
characterize the potential neuroprotective effects of the mitochondrial ATP-sensitive K+ 
channel opener diazoxide (DIAZ) and nonselective (indomethacin) and selective (COX-2) 
cyclooxygeanse-2 inhibitors (NS-398) in the 2VO model at different periods of cerebral 
hypoperfusion. The effect of DIAZ was examined in the early and late phases of cerebral 
hypoperfusion using sodium hydroxide (NaOH) or dimethyl sulphoxide (DMSO) as solvent, 
respectively. We also compared the effects of DIAZ pretreatment with those of post-
treatment. Finally, we compared the effects of indomethacin and NS-398 in the early period 
of cerebral hypoperfusion. Male Wistar rats were exposed to 2VO (n=137) or sham operation 
(n=105). The observed parameters were visuospatial learning (Morris watermaze test), the 
incidence of macroscopic brain lesions, the degree of neuronal damage (cresyl violet staining 
and neuronal COX-2 labeling), dendritic degeneration (microtubule-associated protein-2 
labeling), the astrocytic reaction (glial fibrillary acidic protein labeling) and microglia 
activation (OX-42 labeling) at the level of the hippocampus and some white matter areas, 
detected with histological methods. We found that an impaired learning capacity was 
accompanied by progressive neuronal and dendritic damage, region-specific astrocyte 
proliferation and microglia activation. DIAZ dissolved in DMSO preserved the learning 
capacity, reduced the neuronal damage and alleviated the microglia activation in the observed 
regions at 13 weeks of survival. We assume that the effect of DIAZ was potentiated by 
DMSO. Only pretreatment with DIAZ (dissolved in NaOH) alleviated the memory 
impairment and neuron loss at 2 weeks after 2VO, which suggests its preconditioning effect 
in protection. NS-398, but not indomethacin, prevented the learning impairment, but both 
drugs increased the damage to the hippocampal neuron layers, suggesting that the protective 
action was not directly related to the hippocampus. In conclusion, DIAZ pretreatment could 
be effective in preventing predictable memory failures of cardiovascular origin. Selective 
COX-2 inhibition might also be useful to treat cognitive disturbances, though it requires 
careful patient selection. 
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INTRODUCTION 
 
Epidemiology of cerebral hypoperfusion-related cognitive disorders (incidence, 
Alzheimer’s disease, vascular dementia, cardiac surgery and chronic heart failure) 
 
 Dementia is one of the major challenges in public health worldwide: currently around 
24 million people suffer from various types of cognitive disorders and this number is 
projected to double every 20 years 1. The regional prevalence of dementia in the European 
Union and in the USA is 4% and 6.4%, respectively 2. Dementia is defined as a clinical 
syndrome characterized by progressive deteriorations in multiple cognitive domains that are 
severe enough to interfere with the daily functioning and finally result in a shortening of the 
lifespan in the elderly. Demented patients are compelled to endure a lower quality of life and 
they also impose a heavy burden on the family, the society and industrialized health care.  
 Besides unmodifiable risk factors, such as a genetic predilection 3 or the advance of 
age 4, vascular risk factors and disorders are also involved in the pathogenesis and clinical 
expression of dementia 5. The net result of these vascular events is the development of a 
chronically reduced level of cerebral perfusion. Permanent disturbance of the cerebral 
circulation has been demonstrated in various clinical syndromes accompanied by dementia, 
such as Alzheimer’s disease (AD), vascular dementia, Binswanger disease or cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukencephalopathy 
(CADASIL).  
Patients with a mild cognitive impairment, which is the prodromic phase of AD, 
exhibit a decreased blood flow in the parietotemporal region, including the hippocampus 6,7. 
The degree and pattern of reduction in the cerebral perfusion of various brain regions has been 
demonstrated to correlate well with the incidence of a later AD, and thus, it can be a 
predictive marker for the development of AD 8,9. The causal relationship between the reduced 
cerebral perfusion and the development of neurodegenerative processes is unclear. However, 
an ever-increasing amount of evidence indicates that nongenetic AD is initiated by vascular 
factors that precede the neurodegenerative process 10. A considerable number of experiments 
have revealed that chronic brain hypoperfusion can trigger energy metabolic deficits and 
memory loss before any neuronal structural pathology materializes 11-13. The application of 
experimental models which approach neurodegenerative diseases from the aspect of the 
impaired cerebral circulation cab therefore be expected to be of great benefit in the 
development and testing of potential neuroprotective strategies. 
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A cerebral hypoperfusion-related cognitive impairment also frequently emerges 
following acute cardiovascular crisis states, as a consequence of the low cardiac output. Atrial 
fibrillation, myocardial infarction and coronary bypass surgery are predictors of cognitive 
disturbance and dementia 14-17. An animal model which resembles a rapidly developed, but 
permanently existing global cerebral hypoperfusion can provide useful findings with a view to 
preventing or treating these conditions. 
 
Experimental model for chronic cerebral hypoperfusion in the rat (permanent, bilateral 
common carotid artery occlusion) 
 
 To design an experimental setup that mimics the rheological, histological and 
cognitive disturbances observed in clinical practice, researchers have had to take into account 
considerations such as the question of species, the appropriate surgical method with which to 
induce cerebral hypoperfusion, an acceptable survival rate, good surgical recovery, and 
simple and reproducible behavioral testing 18. The most appropriate model that best fits these 
requirements is the permanent ligation of both common carotid arteries in the rat (“two vessel 
occlusion” = 2VO)18. The rat is a suitable laboratory animal for this purpose as the well-
developed circle of Willis ensures a chronically reduced, but constant blood flow toward the 
forebrain through the vertebral circulatory system following 2VO. 
 
Hemodynamic changes 
 The temporal trace of cerebral blood flow (CBF) changes following 2VO is well 
described by experiments involving a use of an autoradiographic method 19,20, laser Doppler 
flowmetry 21-23 or an arterial spin labeling technique 24. Immediately after the occlusion, there 
is a sudden drop in blood flow in several areas of the forebrain. The greatest reduction has 
been recorded in the parietotemporal cortex and the white matter (WM) areas, with 30-40% of 
the control CBF, while in the hippocampus it was 60% of the control level 19,21-23. A 10-20% 
recovery of the CBF develops by approximately 1 week after 2VO 20, but the successive 
elevation of the CBF subsequently decelerates until it reaches the control level by 8 weeks to 
3 months following 2VO 19,25. Six months after 2VO, CBF measurements reflect a complete 
recovery of perfusion in all cerebral regions 24. Overall, not every period of cerebral 
hypoperfusion after 2VO in rats reflects the CBF pattern observed in demented patients 26. 
However, if we divide the time elapsed from 2VO until complete recovery of the CBF, then 
the first 2-3 days after 2VO is the phase of acute ischemia, followed by the chronic 
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hypoperfusion phase lasting for 3 months, and finally, during the third phase, the CBF returns 
to the original baseline 18. Thereby, each period of the model permits the follow-up and the 
potential treatment of different clinicopathological entities. Although only the second phase 
resembles the hemodynamic, metabolic, histological and cognitive conditions of dementia, 
the changes in the acute period initiate various pathological events that are similar to rapid, 
but mild cerebral hemodynamic disturbances accompanied by memory disorders. Hence, the 
acute phase is useful for the investigation of intermittent acyclia-related memory disorders. 
 
Metabolic disturbances and oxidative stress 
 The brain tissue has a high metabolic rate and is susceptible to reductions in oxygen 
and blood supply. The reduced availability of energy, and in particular of ATP and 
phosphocreatine, impairs the physiological functioning of the neuronal cells and subsequently 
the cellular integrity. In the 2VO model, the suddenly restricted blood flow in the forebrain is 
accompanied by a decreased tissue level of energy-rich phosphates (phosphocreatine and 
ATP), whereas the concentrations of adenosine, lactate and AMP increase immediately after 
the induction of 2VO and remains elevated for at least 2 weeks 27. The glucose utilization 
recovers by the end of the third week, while an enhanced lactate concentration or reduced 
ATPase activity remains detectable from 1 to 8 months following 2VO 27,28. The chronically 
impaired neuronal energy production initiates and sustains a cascade of neuropathologic 
events that underlie an impaired cognitive ability 29. 
 Other sequelae of tissue hypoperfusion include an imbalance between the production 
of oxidative agents and the persisting antioxidant capacity. The temporal alterations in the 
levels of reactive oxidative agents and antioxidant systems in the 2VO model correlate with 
cellular ravage and an inflammatory reaction, emphasizing the role of oxidative stress in the 
pathogenesis of hypoperfusion-induced neurodegeneration. One of the probable reasons for 
the development of oxidative stress even in an oxygen-poor environment is the diminished 
expression of antioxidant enzyme proteins and the failure of the mitochondrial function due to 
the hypometabolic conditions. Twenty-eight days after 2VO, a decreased activity of 
mitochondrial respiratory complex I, a low cytochrome C expression, an elevated hydrogen 
peroxide (H2O2) production, a decreased membrane potential and mitochondrial swelling 
have been demonstrated in isolated mitochondria from the rat hippocampus 30. Another 
possible source of deleterious reactive oxygen species (ROS) production is the activated 
microglia as a major contributor to the ongoing inflammatory reaction during hypoperfusion 
31. These observations suggest that the restriction of oxidative stress by pharmaceutical 
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compounds is one of the mainstream treatment strategies via which to achieve 
neuroprotection in chronic cerebral hypoperfusion 30,32-34. 
 
Learning and memory disturbance (experimental tests, types of learning and memory failures) 
 
 Experimental tests designed for animal models of dementia mainly focus on the 
visuospatial learning skills relevant to a certain widely-used clinical tests 35-37. These learning 
paradigms are suggested to reflect hippocampus-related learning processes 38,39. Hence, the 
application of these tests is suitable in experimental models, e.g. the 2VO model, which affect 
the normal integrity of the hippocampus. One of the most commonly used setups for this 
purpose is the Morris watermaze. Several studies have documented that rats with 2VO display 
a longer swim pathway, and an increased escape latency in the watermaze from 7 days post-
surgery up to 12 months of cerebral hypoperfusion. The memory disturbance is still relapsed 
when the CBF has already been restored 30,40,41. The progressively deteriorated learning 
capacity is therefore presumed to correlate with the ongoing neuropathologic aberrations, 
rather than with the cerebral perfusion, at least in the 2VO model 18. 
 In summary, the histopathological disorders with the learning and memory 
impairments observed in experimental chronic cerebral hypoperfusion are relevant to the 
histological and cognitive alterations observed in clinical dementia, and make this model 
applicable for investigations of the development, progression and potential treatment of these 
diseases. 
 
Histopathologic changes (neuronal damage, white matter injury and inflammatory reaction) 
 
 Various experiments have had the aim of determining which spatial and temporal 
histopathologic aberrations correlate well with impaired learning and memory. The 
neuropathologic changes in the 2VO model are most obvious in those parts of the brain which 
are particularly sensitive to ischemia or which are supplied primarily by the carotid arteries, 
e.g. the hippocampal formation or some WM areas. There are several possibilities to visualize 
the death or microscopic degeneration of neurons, the proliferation and activation of glia cells 
and inflammation. The earliest appearing neurodegeneration in the hippocampus 4 days after 
2VO, was demonstrated with a quantitative RT-PCR method. In those studies, elevated 
amyloid precursor protein mRNA and γ-secretase mRNA levels were measured, markers that 
are also indicative of the pathogenesis of AD 42,43. The earliest detection of neuronal 
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destruction with the conventional hematoxylin-eosin staining method was successful at 2 
weeks, revealing necrotic pyramidal cell loss in the cortex 44. Apoptotic cell death after week 
2 was also detected with terminal deoxynucleotide transferase biotin-dUTP nick end labeling 
(TUNEL) and is localized to the CA1 and CA3 subfields of the hippocampus and to some 
WM areas, such as the optic tract and the fimbria fornix 45,46. This damage gradually 
progresses with time, even up to 190 days following 2VO 40. Immunocytochemical labeling 
of neuronal arborization with microtubule-associated protein-2 (MAP-2) and synaptophysin 
antibody reflected that cerebral hypoperfusion additionally triggers the progressive ruination 
of dendritic processes and synaptic integrity 47. The presence of WM injury is also described 
in this model. 
 Chronic cerebral hypoperfusion is accompanied by a slowly-developing and persistent 
inflammatory reaction in the ischemic brain regions. The most noteworthy histological events 
observed after 2VO which hallmark the ongoing inflammation are reactive gliosis and 
activation of the microglia 48,49. Astrocytic proliferation detected by means of glial fibrillary 
acidic protein (GFAP) immunocytochemistry revealed an augmented GFAP signal in the 
cortex and in WM areas starting from week 1, whereas it was observed only 6 months after 
2VO in the hippocampus 32,50. Immunohistochemical detection of activated ameboid-like 
microglia with lectin- and complement receptor-3 (OX-42) antibody demonstrated an early 
activation of the cells 20 minutes following permanent carotid ligation in the hippocampus 51. 
Microglia activation was also visible in the WM 14 days and 13 weeks following 2VO 52,53. In 
the 2VO model, the microglia is suggested to be responsible for the tissue damage through the 
release of tumor necrosis factor (TNF)-α by inducing apoptosis or via the production of the 
degrading enzyme, matrix metalloproteinase-2 (MMP-2) 12,52,54. Therefore, pharmacological 
inhibition of microglia activation might exert neuroprotection by moderating inflammation-
induced neuronal damage. 
   
Diazoxide – a mitochondrial ATP-sensitive K+ channel opener 
 
 In cerebral ischemia, the imbalance of cellular homeostasis initiates cascade 
mechanisms which finally result in cell death. The mitochondria are known to play an 
essential role in this process. Since they are the main energy suppliers of the cell and regulate 
the cellular Ca2+ homeostasis, the dysfunction of the mitochondria is considered to be a 
pivotal event in brain tissue injury 55,56. The depletion of oxygen and glucose impairs the 
proper functioning of the respiratory chain, leading to restricted ATP production, increased 
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Ca2+ concentration of the mitochondrial matrix, cytochrome C release and the generation of 
free radicals 55. These changes are disastrous for the cell and eventually lead to necrosis or 
apoptosis 57. For this reason, pharmacological intervention regarding the mitochondrial 
function is a promising strategy through which prevent ischemic neuronal injury. 
 The membrane of the mitochondrial matrix is enriched in ATP-sensitive K+ channels 
(mitoKATP) 58. These channels are composed of discrete pore-forming (Kir6.1/Kir6.2) and 
regulatory subunits (presumably the sulphonylurea receptor (SUR)-2). Under physiological 
conditions, at optimal energy and oxygen supply of the cell, the respiratory chain in the inner 
mitochondrial membrane builds up electric and osmotic gradients for the proton between the 
intermembrane space and the matrix 55. Opening the mitoKATP induces early and delayed 
preconditioning effects against ischemic damage that can be abolished by the specific channel 
blocker 5-hydroxydecanoate (5-HD). The early events include K+ influx into the matrix and a 
positive shift of the transmembrane potential. This action stabilizes the volume of both the 
matrix and the intermembrane space, which increases the activity of the electron transport 
chain and hence the chemical proton gradient leads to alkalinization of the matrix. Second, 
mitoKATP-induced mitochondrial swelling is known to improve fatty acid oxidation and ATP 
production 59. In the event of the elevation of the intracellular Ca2+ level to above the 
mitochondrial buffer concentration, the entrance of Ca2+ through the inner membrane initiates 
pernicious events in the matrix. However, the electrogenic transport of Ca2+ is highly 
dependent on the membrane potential, and thus the reduced negativity of the inner membrane 
following the K+ inflow via the mitoKATP prevents Ca2+ accumulation in the matrix 60. In the 
presence of sufficient oxygen, further electron transport generates a mild ROS production 
61,61,62. The concrete role of the free radicals arising from the reaction is not understood, but 
they initiate compensatory mechanisms involving protein kinase C activation, which provide 
protection for the cell against subsequent, otherwise lethal ischemia 63. Short, repetitive 
sublethal ischemic episodes also lead to the opening of the mitoKATP and the emergent ROS 
from the accelerated electron transfer fortify the cell against ischemic damage. This 
phenomenon is called ischemic preconditioning. Pharmacological opening of the mitoKATP 
has also been found to provide ischemic tolerance 64. The preconditioning effect of mitoKATP 
activation has emerged as a nothworthy feature in the development of cardioprotective 
strategies 65. Since the brain contains nearly 7 times as much mitoKATP as does the heart, great 
importance has been attached to the neuroprotective role of mitoKATP for the prevention and 
treatment of ischemic neuronal damage 66. 
 8
 The drug most widely accepted and used to mimic ischemic preconditioning by the 
opening of the mitoKATP is benzothiadizine, or as it is generally called diazoxide (DIAZ). 
This substance has a 2000-fold affinity to mitoKATP relative to the cell surface KATP channels 
64. At first, DIAZ was used for the treatment of hypertensive emergencies 67 as a high 
concentration of the drug hyperpolarizes the cell membrane by opening cell surface KATP 
channels and thereby relaxes the smooth muscles of the resistance vessels. Furthermore, 
DIAZ has proved to inhibit insulin release from pancreatic beta-cells, which has led to 
another application of the drug, in insulinoma therapy 68. 
 For the past twenty years, intensive research has been carried out to describe and 
explain the preconditioning feature of DIAZ in many organs, mostly in the heart and the 
brain. The neuroprotective effects of DIAZ have been demonstrated under in vitro hypoxic 
conditions, in experimental animal models for perinatal hypoxia/ischemia and for transient 
ischemic stroke in adults, respectively. 
 In vitro neuronal and astrocytic cell cultures preincubated with DIAZ exhibit better 
viability after oxygen-glucose deprivation or glutamate exposure 64. The beneficial effects of 
DIAZ were confirmed in hippocampal and cortical slice preparations subjected to 
hypoxic/ischemic conditions 69,70. The mechanism of protection by DIAZ has been associated 
with depolarization of the mitochondria, the prevention of Ca2+ accumulation, anti-apoptotic 
properties and enhanced ROS production 64. 
 DIAZ has been tested in several experimental animal models of cerebral ischemia, in 
both newborn and adult specimens. In newborn piglets, the decrease in the vascular reactivity 
of the pial arterioles by ischemia/reperfusion was prevented by the topical administration of 
DIAZ prior to the ischemia. Pretreatment of 7-day-old rat pups with DIAZ significantly 
reduced the volume of the infarct induced by the reversible ligation of one carotid artery with 
hypoxia 64. Under the same circumstances, DIAZ prevented the activation of the immediate-
early genes c-Fos and c-Jun, down-regulated calpain, an enzymatic mediator of neuronal 
death, and decreased DNA fragmentation in the hippocampus and in the cortex 71. 
Furthermore, the mitochondria in the CA1 area of the hippocampus of newborn piglets which 
underwent ischemia/hypoxia displayed extensive swelling and Ca2+ accumulation which was 
abolished by DIAZ treatment 72. Besides the testing of DIAZ in newborn models of cerebral 
ischemia, it has been approved for stroke models of adult mice and rats. After reversible 
occlusion of the middle cerebral artery, the volume of the infarcted area as indicated by 2,3,5-
triphenyltetrazolium chloride staining, showed a 50% reduction when the rats were treated 
with an intracerebroventricular injection of DIAZ 73. Mitochondria extracted from the neurons 
 9
of the ischemic penumbra revealed a decreased membrane potential and Ca2+ influx, 
mitochondrial swelling, reduced complex-I damage and a decreased formation of transition 
pores through which Ca2+ enters the mitochondria 73. Furthermore, DIAZ also decreased the 
number of TUNEL-positive apoptotic cells in the infarcted territory 74. DIAZ additionally 
improved the astrocytic survival compared to the respective controls 74. Lenzsér et al. (2005) 
imposed reversible occlusion of both common carotid arteries of rats exposed to hypotension. 
Under these severe ischemic conditions, the integrity of the blood brain barrier (BBB) was 
disrupted. However, DIAZ limited the permeability of the BBB, as demonstrated by the 
injection of Evans blue and sodium fluoresceinate into the brain parenchyma 75. Finally, all 
the beneficial effects of DIAZ discussed above could be reversed by the administration of 5-
HD, confirming the contribution of the mitoKATP in the protective mechanisms 64. 
 In the studies of ischemic stroke has invariably been administered DIAZ before the 
onset of ischemia, emphasizing the prevention approach of treatment. These experiments have 
made use of the widely proven concept that DIAZ mediates ischemic preconditioning. 
However, post-treatment strategies may be more desirable, as the occurrence of a cerebral 
ischemic event is most often unpredictable. 
 
The role of the cyclooxygenase system in ischemic brain damage 
 
The localization and physiological role of cyclooxygenase-2 in the central nervous system 
(CNS) 
 Arachidonic acid (AA) is continuously released from membrane phospholipids by 
phospholipase A2.  The AA released is further metabolized to bioactive eicosanoids via 
cyclooxygenases (COXs), lipoxygenases and epoxygenases.  Under normal and pathological 
conditions COX-derived prostanoids – thromboxanes, prostacyclins and prostaglandins (PGs) 
are important mediators of cerebrovascular control in 3 ways: by causing vasodilation, by 
causing vasoconstriction, or by permitting the physiological effects of other vasoactive 
mediator systems. 
 In the central nervous system (CNS), three isoforms of the enzyme have been 
described: COX-1, COX-2 and COX-3, the latter being a splice variant of COX-1 76. COX-1 
is expressed constitutively in most cells of the brain and participates in various homeostatic 
processes. 76,77. The expression of COX-2 in the brain is due to both constitutive and induced 
production. Constitutive production is observed in discrete populations of excitatory neurons 
in the adult brain. There is a high basal level of COX-2 activity in the pyramidal layer of the 
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hippocampal CA1 region, and in the granule cells of the dentate gyrus (DG), while a mild 
level of COX-2 production  has been described in the spinal cord and in the cerebral cortex 
78,79. At a subcellular level, the perinuclear region and dendritic spines are enriched in COX-2, 
indicating its contribution to synaptic signaling 80,81. In the hippocampus, the presence of 
COX-2 in the glutamatergic neurons demonstrates its role in the formation of long-term 
potentiation (LTP) initiated by the activation of N-methyl-D-aspartate (NMDA)-sensitive 
receptors. COX-2 might therefore be important in the evolution of memory. The inhibition of 
COX-2 prevents LTP in the hippocampal dentate neurons, but the addition of PGE2 reverses 
the COX-2-mediated suppression 82,83. The COXs are normally present in the cerebral blood 
vessels. The endothelial cells process COX-1 and COX-2 and there is continuous prostanoid 
production, which may play a significant role in maintaining the resting cerebrovascular tone. 
COX-1 and COX-2 have also been detected in the smooth muscle cells 84. There have been 
several reports that the glia cells produce prostanoids via the COX-2 pathway. Strong 
evidence was recently provided that perivascular axo-dentric synapses were immunopositive 
for COX-2, consequently, the simultaneous release of prostanoids and/or excitatory 
transmitters from a single terminal may affect the neuronal activity and CBF 85. 
 There have been numerous studies of whether the levels of COX-derived metabolites 
are in the vasoactive range in the brain under physiological conditions. Observations on 
piglets 86,87 and in rats 88 indicated that the selective inhibition of COX-2 results in only a 
minor reduction of the resting CBF. Similarly, no reduction in cortical blood perfusion was 
found in mice when COX-2 was inhibited selectively 89. 
 In the cerebral cortex, COX-2 is involved in neuronal activity-dependent functional 
hyperemia. This effect was first demonstrated in the somatosensory cortex of mice where 
selective COX-2 inhibition diminished the vibrissal stimulation-induced blood flow increase, 
whereas the vascular reactivity to other stimuli remained intact 89. Furthermore, the flow 
response to vibrissal stimulation is impaired in the whisker-barrel cortex of COX-2 null-mice 
89.  The highly selective COX-2 inhibitor rofecoxib significantly reduce the increases in 
regional CBF induced by somatosensory stimulation in rats 88.  
 
COX-2 expression in acute ischemic brain damage 
 Various brain pathologies elicit a marked overexpression of COX-2, contributing to 
the development of neuronal injury. Cerebral COX-2 levels are induced globally after focal 
infarction in humans 90,91 and in various animal models alike 92-95.  In the course of focal 
cerebral ischemia, the upregulation of COX-2 mRNA can be detected at 3 hours of 
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reperfusion, while the increased protein levels become apparent after 6 hours, peaking at 12-
24 hours.  COX-2 overexpression in the ischemic penumbra is limited to the neurons, glia and 
vascular endothelial cells 92,96-98. The release of glutamate and inflammatory cytokines from 
damaged neurons may participate in the induction of COX-2 expression under these 
conditions. In  the early phase of ischemia, neuronal/glial COX-2 induction can be triggered 
by the glutamate-induced activation of NMDA receptors with a subsequent Ca2+ inflow that 
activates the transcription of COX-2 mRNA 96,99. The deleterious effect of COX-2 includes 
several downstream mechanisms. The major detrimental impact during an excitotoxic injury 
is putatively mediated by the production of PGE2 through the PG EP1 receptor. The activation 
of the receptor impairs the exchange of Ca2+ for Na+, and the dying neuron is therefore unable 
to eliminate NMDA-induced Ca2+ accumulation 100. Besides the production of PGH2, the 
conversion of AA by COX results in the simultaneous production of a superoxide anion. This 
can play a particularly important role in the brain pathology during the recovery from anoxic 
stresses such as ischemia or asphyxia, when large amounts of radicals are formed. These free 
radicals impair the cerebrovascular responsiveness to various stimuli such as NMDA, 
calcitonin gene-related peptide (CGRP) and the dilator prostanoid, iloprost, and damage the 
BBB transport 101-103, albeit the relative contributions of COX-1 and COX-2-derived 
mediators have not yet been determined.  COX-2-dependent ROS production and oxidative 
damage have also been suggested to occur in the brain after excitotoxic brain injury and 
global cerebral ischemia 104,105 and in the brains of animals subjected to restraint stress 
106,107.The relative parts played by COX-2-derived ROS and prostanoids in neurotoxicity have 
not been clarified either. Besides the direct contribution of COX-2-derived O2-• to excitotoxic 
damage, other sources of production of ROS are noteworthy 108,109. The reaction between O2-• 
and nitric oxide produced by inducible nitric oxide synthase (iNOS) creates peroxynitrite, a 
highly reactive chemical species, which is capable of damaging lipids, proteins and DNA 110-
112. In the later stage of cerebral ischemia, an inflammatory reaction develops at the site of the 
ischemia. The damaged neurons release pro-inflammatory cytokines, such as interleukin-1 or 
TNF-α, which are activators of COX-2 expression in the microglia, and the consequential 
release of prostanoids (PGE2 and thromboxane) and oxygen free radicals exacerbates the 
tissue injury 113-115. 
 The participation of the COX-2 pathway in experimental ischemic brain damage has 
been best revealed by studies in which selective COX-2 inhibitors and COX-2 knockout mice 
(COX-2-/-) or COX-2 overexpressing mice were used. Gene deletion studies of COX-2 
pointed to several extracerebral abnormalities, while the CNS was shown to be unaffected in 
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COX-2-/- mice 116. Additionally, these animals displayed reduced susceptibility to brain 
ischemia and to NMDA toxicity 99,117. Mice overexpressing COX-2 in the brain are more 
susceptible to the brain damage produced by focal cerebral ischemia 118. 
 
COX-2 inhibitors in acute cerebral ischemia 
 Selective COX-2 inhibitors successfully moderate cerebral ischemic lesions or 
excitotoxic injuries in a good number of animal or in vitro models. For example, NS-398, a 
commonly used selective COX-2 inhibitor, ameliorated lipopolysaccharide-induced neuronal 
damage and attenuated TNF-α release in neuronal cell cultures 119. The intraperitoneal 
administration of NS-398 to mice and rats significantly reduced infarct size after transient 
middle cerebral artery occlusion (MCAO) 92. Additionally, NS-398 decreased the lesion size, 
improved the functional outcome and induced dendritic hypertrophy in the pyramidal cells of 
the parietal cortex following the devascularizing lesion of the motor cortex in rats 120. 
Nimesulide, another COX-2 inhibitor, reduced the frequency of neuronal damage in the 
hippocampus, are prevented glutathione depletion and lipid peroxidation in both mice and 
Mongolian gerbils exposed to transient 2VO 117,121. Similar observations have been made for 
other selective COX-2 inhibitors, in particular rofecoxib, DFU and SC-58236 104. 
 However, it must be noted that, even within various stroke models, the distal cellular 
effects of the stroke may be completely different, depending on the exact etiology of the 
injury. Thus, it is likely that the effects of COX-2 inhibitors will also vary, depending on the 
injury model used. Additionally, the time course of COX-2 inhibitor drug administration  can 
result in differential cellular and behavioral effects 122 and should therefore be systematically 
investigated for each injury model. 
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Figure 1. The hypothetic protective action of diazoxide and selective COX-2 inhibition in chronic cerebral 
hypoperfusion-induced neuronal damage. Abbreviations: COX-2: cyclooxygenase-2; GFAP: glial fibrillary 
acidic protein; ROS: reactive oxygen species. 
 
The purpose of our experiments 
 
 The aim of our experiments was to test the potential neuroprotective features of two 
types of widely investigated pharmacological agents (a mitoKATP opener and 
specific/nonspecific COX inhibitors) at various time points (3 days, 2 weeks and 13 weeks) 
during experimental chronic cerebral hypoperfusion. Previously, both treatments had proved 
to be beneficial in acute ischemic circumstances, but had not been investigated in chronic 
ischemia, such as created in the 2VO model. 
 First, we set out to determine the degree of learning dysfunction and 
neurodegeneration at various time points after 2VO induction. We determined the 2VO-
induced visuospatial learning dysfunction, the presence of neuronal damage, dendritic 
ruination, astrocytic proliferation and microglia activation at the level of the hippocampus and 
in some WM areas. The early and late periods of cerebral hypoperfusion (resembling acute 
cardiovascular failures and dementia with vascular components, respectively) were compared.  
 Second, we aimed to describe the putative protective effect of the mitoKATP opener 
DIAZ. We compared the preconditioning effect of DIAZ (administered before 2VO onset) 
with the effect of post-treatment. Within this set of experiments, we proposed to characterize 
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the additive effect of DIAZ and the antithrombotic and ROS scavenger dimethyl sulphoxide 
(DMSO), widely applied as a solvent in the later period (13 weeks) of the 2VO model. 
Third, we tested a nonselective and a selective COX-2 inhibitor (indomethacin and 
NS-398, respectively) on the visuospatial learning and histological changes during 2VO. 
COX inhibitor treatments were evaluated at 3 days and 2 weeks following 2VO. 
 Since both DIAZ and COX-2 inhibitors alleviate oxidative damage, we finally 
distinguished the neuroprotective properties of mitoKATP opening and COX inhibition during 
the early period (2 weeks) of cerebral hypoperfusion. 
 
MATERIALS AND METHODS 
 
Surgical procedure; the induction of chronic cerebral hypoperfusion 
 
 A total of 242 male Wistar rats (260 g± 26 g) were used. All animal experiments were 
approved by the Ethical Committee of the University of Szeged. The animals were 
anesthetized via the i.p. injection of chloral hydrate in a 400 mg/kg dose, followed by 0.05 ml 
0.1% atropine intramuscularly (i.m.) to prevent an autonomic reaction during the operation 
(i.e. mucous secretion blocking the airways). 
 Chronic cerebral hypoperfusion was induced with the same surgical procedure in each 
experiment. Half of the animals underwent permanent bilateral common carotid artery 
occlusion (2VO), while the other half served as sham-operated controls (SHAM). The 
common carotid arteries were exposed via a ventral cervical incision, carefully separated from 
their sheaths and vagal nerves, and permanently ligated with silk sutures (5.0). Lidocaine 
(1%) was applied as local anesthetic. The same procedure was performed on the SHAM 
group, but without the actual ligation of the carotid arteries. 
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Pharmacological treatments 
Table 1. Summary of the treatments at different survival times and their clinical relevance during the three 
experiments. 
Experi-
ment Pharmacon 
Time of 
treatment 
(pre-, post-) 
Type of 
treatment 
(repeated, 
bolus) 
Survival 
time Effect Relevance 
1 
diazoxide in 
DMSO post 
repeated 
(5x) 13 
weeks 
mitoKATP opening + antithrombotic 
effect and free radical scavenging AD 
DMSO repeated (5x) 
antithrombotic effect and free 
radical scavenging 
2 
diazoxide in 
NaOH pre 
repeated 
(5x) 
2 weeks
mitoKATP opening 
acute disruption 
of brain perfusion 
with gradual 
reperfusion 
(atrial fibrillation, 
coronary bypass 
surgery) 
diazoxide in 
NaOH bolus mitoKATP opening 
diazoxide in 
NaOH post 
repeated 
(5x) mitoKATP opening 
3 
NS-398 
post 
repeated 
(3x) 3 days 
COX-2 inhibition 
indomethacin repeated (3x) general COX inhibition 
NS-398 repeated (3x) 2 weeks
COX-2 inhibition 
indomethacin repeated (3x) general COX inhibition 
Table 1. In Experiment 1, nontreated animals served as controls for pharmacological treatments.In Experiments 
2 and 3, the vehicle was administered as control. Abbreviations: AD: Alzheimer’s disease; COX: 
cyclooxygenase; DMSO: dimethyl-sulphoxide; NaOH: sodium hydroxide; mitoKATP: mitochondrial ATP-
sensitive K+ channel.  
 
 Both the SHAM and the 2VO animals were subdivided into further experimental 
groups based on the surgery, the treatment and the survival time. For the experimental 
protocols, see Figure 2. Experiment 1 (Fig. 2A) involved rats with a survival time of 13 
weeks. Group 1 received no treatment following the SHAM operation (SHAM-C-13w, n=6), 
group 2 animals were injected with 0.25 ml DMSO, i.p. (SHAM-DMSO-13w, n=6), while 
group 3 received 5 mg/kg DIAZ in DMSO, i.p. (SHAM-DIAZ+DMSO-13w, n=8). In groups 
4-6, the 2VO rats were treated in the same way as the SHAM animals: the group 4 rats were 
not treated (2VO-C-13w, n=6), group 5 received 0.25 ml DMSO (2VO-DMSO-13w, n=6) and 
the group 6 animals were treated with 5 mg/kg DIAZ in the same volume of DMSO (2VO-
DIAZ+DMSO, n=7). The treatment was applied on 5 consecutive days, starting immediately 
following surgery. 
Experiment 2 (Fig. 2B) involved rats with a survival time of 2 weeks. Nine 
experimental groups were established. Treatment was performed with DIAZ or its vehicle 
(0.1 N NaOH) given as pretreatment (5 groups) or post-treatment (4 groups) to both SHAM 
and 2VO rats. During pretreatment, the first set of SHAM and 2VO animals received 0.5 
mg/kg DIAZ (SHAM-DIAZ pre-2w, n=6; 2VO-DIAZ pre-2w, n=6) or vehicle (SHAM-C pre-
2w, n=5; 2VO-C pre-2w, n=8) in 0.25 ml i.p. on 5 consecutive days prior to surgery. Another 
group was pretreated with one bolus i.p. injection of 5 mg/kg DIAZ 1 day before the 2VO 
operation (SHAM-DIAZ pre bolus-2w, n=5). The post-treated rats were administered daily 
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injections of 0.5 mg DIAZ (SHAM-DIAZ post-2w, n=7; 2VO-DIAZ post-2w, n=6) or the 
solvent (SHAM-C post-2w, n=6; 2VO-C post-2w, n=6) in 0.25 ml for 5 days after surgery, 
the first injection being applied directly after surgery. 
In Experiment 3 (Fig. 2C), the rats were divided into 12 groups immediately after 
surgery. Brain specimens were collected 3 days after surgery in half of the animals (6 groups); 
the other half survived for 2 weeks (6 groups). The first set of these animals received 0.5 ml 
5% sodium hydrogencarbonate (NaHCO3) i.p. as the solvent control on 3 consecutive days 
(SHAM-C-3d, n=7 and 2VO-C-3d, n=8; SHAM-C-2w, n=9 and 2VO-C-2w, n=5). The 
second set of rats were treated with 3 mg/kg indomethacin (n=8) dissolved in 0.5 ml 0.9% 
saline i.p. (SHAM-indo-3d, n=8 and 2VO-indo-3d, n=10; SHAM-indo-2w, n=8 and 2VO-
indo-2w, n=5). The third set of rats were injected i.p. with 15 mg/kg NS-398 (n=9) in 0.5 ml 
5% NaHCO3 (SHAM-NS-398-3d, n=9 and 2VO-NS-398-3d, n=8; SHAM-NS-398-2w, n=7 
and 2VO-NS-398-2w, n=8). The first injection was given immediately following 2VO or 
SHAM surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Time scales of the experimental protocols. Abbreviations: 2VO: bilateral common carotid artery 
occlusion; COX: cyclooxygenase; DIAZ: diazoxide; MM: Morris watermaze test; pre: pretreatment; post: post-
treatment; SHAM: sham-operated control. 
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Spatial learning test 
 
 Depending on the various experimental protocols, the rats were trained in the Morris 
watermaze spatial learning paradigm 1 week or 11 weeks after surgery (Fig. 2). The training 
protocol was the same throughout the whole study: for 5 consecutive days, 2 trials per day 
with a constant interval of 4 hours. In the watermaze, the rats were introduced into a 
swimming pool 160 cm in diameter, 35 cm in height, filled with water (22 οC), facing the wall 
of the tank. The water was made opaque by the addition of milk, so that the rats were unable 
to see underwater. Several extra-maze visual cues and an auditory source were placed around 
the pool to help the orientation. The four quadrant points at which the rats were placed into 
the water were randomly varied at each trial. The animals were then given 2 minutes to find 
the location of a hidden platform submerged 2 cm below the water surface. Those rats which 
failed to find the platform were gently guided to it. After each trial, the animals were allowed 
to sit on the platform for 15 s. The length of the pathway swum by the rats and the escape 
latency were recorded and analyzed at each trial by a computerized video imaging analysis 
system (EthoVision, Noldus Information, The Netherlands). 
 
Immunocytochemistry 
Table 2. Summary of the groups and observed parameters in the three experiments. 
Experiment 
Surgery 
(SHAM, 
2VO) Treatment 
Survival 
time 
Morris 
water- 
maze 
Histology 
Cresyl 
violet 
COX-2 
immuno
MAP-2 
immuno 
GFAP 
immuno 
OX-42 
immuno
1 SHAM 2VO 
C (nontreated) 
13 
weeks 
+  +   + + 
DMSO +  +  + + 
DMSO+DIAZ +   +   + + 
2 SHAM 2VO 
C (NaOH) 
2 weeks
+ +     + + 
DIAZ post + +   + + 
DIAZ pre + +   + + 
DIAZ pre 
bolus + +     + + 
3 SHAM 2VO 
C (NaHCO3) 
3 days  
2 weeks
+ +  + + + 
indomethacin + +  + + + 
NS-398 + +   + + + 
Abbreviations: 2VO: two-vessel occlusion; C: control, COX: cyclooxygenase; DMSO: dimethyl sulphoxide; 
DIAZ: diazoxide; GFAP: glial fibrillary acidic protein; immuno: immunocytochemistry; MAP-2: microtubule 
associated protein-2; pre: pretreatment; post: post-treatment; SHAM: sham operation. 
 
 Depending on the survival times of the experimental protocols (Fig. 2), the animals 
were anesthetized with an overdose of pentobarbital and perfused transcardially with cold 
saline followed by 400 ml of 4% paraformaldehyde or of 3.5% paraformaldehyde and 0.5% 
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picric acid. Subsequently, the brains were carefully removed, and one hemisphere was 
postfixed in the same solution for 1 h, and then stored in 0.1 M phosphate buffer saline (PBS). 
All rat brains were processed for histological experiments. The incidence of macroscopic 
brain lesions was observed and evaluated immediately after the removal of the brain from the 
skull. 
 As the first step of the histological processing, 20-μm-thick free-floating coronal 
sections were cut on a cryostat at the level of the hippocampus (bregma -3.60)123. The first set 
of section from the 3-day and 2-week survival groups were mounted on gelatin-coated 
microscopic slides and stained with cresyl violet (Table 2). 
 Some of the sections from Experiment 1 were labeled with COX-2 antibody as 
follows. First, endogenous peroxidase activity was blocked with 0.3% H2O2. Nonspecific 
binding sites were covered with 5% normal goat serum (NGS), and the membrane 
permeability was enhanced with 0.3% Triton X-100. The sections were incubated for 2 days 
at room temperature (RT) in primary antibody solution containing rabbit anti-COX-2 
antibody (Cayman), 1:2000, 1% NGS, 0.3% Triton X-100 and 0.1% sodium azide in 0.01 M 
PBS (pH 7.4). Next, the sections were rinsed and preincubated in 5% NGS for 1 hour. 
Incubation was performed in goat anti-rabbit biotinylated IgG (Santa Cruz) for 4 hours at RT. 
Finally, the signal was amplified with an ABC–Avidin Kit (1:400) (Vector) for 2 hours at RT. 
The color reaction was developed with diaminobenzidine (DAB) and H2O2. 
 Some sections from Experiment 3 (see Table 2) were immunocytochemically stained 
for MAP-2 to visualize the dendritic integrity. Pretreatment of the slices was performed with 
0.3% H2O2, 20% normal pig serum (NPS), and 0.3% Triton X-100. The samples were then 
incubated overnight in a primary antibody solution containing mouse anti-MAP-2 antibody 
(Sigma), 1:10000, 20% NPS, and 0.03% merthiolate in 0.01 M PBS. The secondary antibody 
solution contained goat anti-mouse biotinylated IgG (Jackson) 1:400, 10% NPS, 0.03% 
merthiolate and 5% normal rabbit serum (NRS) in PBS. Finally, the sections were incubated 
in HRP-Streptavidin (Jackson) 1:1000, 1% NPS and 0.03% merthiolate in Tris buffer 
solution. The color reaction was developed with Ni-DAB and H2O2. 
 In some sections from all three experiments, the astrocytic reaction was 
immunocytochemically labeled with GFAP antibody. After pretreatment with 5% normal 
sheep serum (NShS), 0.3% H2O2 and 0.3% Triton X-100, the sections were incubated 
overnight in a solution containing the mouse anti-GFAP primary antibody (Sigma), 1:200, 1% 
NShS and 0.3% Triton X-100 in 0.01 M PBS. The secondary antibody solution consisted of 
goat anti-mouse biotinylated IgG (Jackson), 1:400, 10% NShS, 5% NRS and 0.03% 
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merthiolate in 0.01 M PBS. Finally, the sections were incubated in HRP-Streptavidin 
(Zymed), 1:200, and the color reaction was developed conventionally with DAB and H2O2.
 To detect and analyze the microglial activation, OX-42 antibody was used on a further 
set of sections. The procedure started with rinsing and pretreatment of the sections with 0.5% 
Triton X-100 and 3% H2O2 in 0.01 M PBS, followed by  reincubation in 20% NPS and 0.5% 
Triton X-100 in 0.01 M PBS for 1 hour. The sections were incubated overnight in a primary 
antibody solution containing biotinylated mouse anti-CD11b antibody (OX-42, Serotec), 
1:500, 20% NPS and 0.03% merthiolate in 0.01 M PBS at RT. Next, the sections were rinsed 
and incubated in a solution of STA-PER (Jackson), 1% NPS and 0.03% merthiolate in 0.1 M 
Tris buffer for 1 hour at RT. Finally, the color reaction was developed with Ni-DAB and 
H2O2. 
All the sections were mounted on gelatin-coated microscopic slides, air-dried, 
dehydrated, and coverslipped with Distrene 80 (dibutyl phthalate with xylene). 
 
Quantitative morphometry 
 On the cresyl violet-stained sections, photographs of the hippocampus CA1 and CA3 
stratum pyramidale and the DG granule cell layer were taken with a computerized image 
analysis system to identify neuronal damage (Olympus BX50 microscope, DP50 digital 
camera, ImagePro Plus software, Media Cybernetics, U.S.A.). On the sections from 
Experiment 2, the number of pyramidal neurons in the hippocampus CA1 region was counted 
with the help of an ocular grid at 40× magnification on a surface of 0.024 mm2 (3 × 10 grid 
holes) that covered the entire width of the CA1 str. pyramidale. Cell counting was performed 
bilaterally on three consecutive brain sections. The six values were averaged, and the average 
was used for further statistical analysis. In Experiment 3, the proportion of animals displaying 
neuronal damage was determined with the help of cresyl violet-stained sections. Hippocampal 
neuronal damage was evaluated at 40x magnification with a light microscope. Damage to a 
hippocampal region was recorded when neurons showed typical signs of necrosis (dark 
staining, shrinkage and a dysmorphic shape). The number of animals exhibiting necrotic 
neuronal injury was counted and expressed as a percentage of the total number of animals in a 
given group. The ratio of affected animals was calculated for each hippocampal region and 
each group. 
COX-2-labeled neuron counting was performed at 20x magnification with the help of 
an ocular grid with 1600 x μm2 holes. Three consecutive coronal sections with a standard 
distance of 160 μm, were examined, starting at Br. -3.60 mm 123. COX-2-positive neurons 
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were counted in the CA3 str. pyramidale and the DG inner and outer str. moleculare on an 
average surface of 0.018 mm2 in each region. Regional cell counts of 3 sections per animal 
were averaged, and the average was used for further statistical analysis. 
The percentage of the area covered by MAP-2-antibody-labeled dendritic processes to 
total area surface was quantified in the CA3 str. lucidum of the hippocampus.  The percentage 
surface area of the GFAP-positive astrocytes was quantified in the dorsal hippocampus, the 
medial corpus callosum and the internal capsule. In the optic tract, the relative optical density 
was computed instead of the percentage area, since the homogenous labeling did not permit 
area measurements. The percentage surface area was measured for the individual 
hippocampal areas (the CA1 str. radiatum, the CA1 str. oriens, the CA3 str. radiatum, the 
CA3 str. oriens, the inner and outer molecular layers of the dentate gyrus, and the hilus) and 
for all three WM regions of interest by using a Quantimet Q-600HR computerized image 
analysis system (Leica, Cambridge, UK) 124. As regards the OX-42 labeling, quantification of 
immunoreactive microglia was performed in a similar manner as for the GFAP-labeled 
sections on a computerized image analysis system (Olympus BX50, DP50; software: 
ImagePro Plus, Media Cybernetics). 
 Briefly, 3 consecutive coronal sections with a standard distance of 160 μm were 
selected for the analysis, starting at Br. -3.60 mm 123. Hippocampal and WM regions of 
interest were manually delineated at 10x magnification, after background subtraction and gray 
scale threshold determination. The area covered by MAP-2-positive dendrites, GFAP-positive 
astrocytes or OX-42-positive microglia was computed as a percentage of the total area 
delineated. The measurements on the 3 sections per animal were averaged, and the average 
was used for further statistical analysis. 
 
Statistical analysis 
The Morris watermaze test results were analyzed statistically by means of a two-way 
repeated measurement model, followed by the least significant difference (LSD) post hoc test 
with the program SPSS. Individual day comparisons were performed with a univariate model 
and LSD post hoc analysis with SPSS. The proportions of failed trials to the total and the 
proportion of animals displaying neuronal damage in the hippocampus were analyzed 
statistically by a chi square test of the program Statistica. The MAP-2, GFAP and OX-42 
immunocytochemical results were analyzed statistically with two-way or three-way ANOVA 
in correspondence with the number of variables (surgery, treatment and survival time), 
followed by the LSD post hoc test. 
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RESULTS 
 
Spatial learning test 
The swimming distance curves (Fig. 3) obtained from the Morris watermaze test 
showed a day-to-day improvement in the performance of the SHAM-control rats, while 
cerebral hypoperfusion resulted in a learning disability in all 2VO-control animals  at a 
survival of either 2 weeks (**P<0.001) or 13 weeks (**P<0.001) (Fig. 3A). This difference 
was obvious on days 2, 3 and 5. No significant difference could be observed between the 
performance of the SHAM–C-2w vs the SHAM-C-13w rats or the 2VO–C-2w vs 2VO-C-13w 
rats. Neither DMSO nor DMSO+DIAZ treatment affected the spatial learning performance of 
the SHAM animals (Fig. 3B). However, DMSO alone and especially together with DIAZ 
significantly decreased the length of the swimming pathway of the 2VO animals throughout 
the whole period of learning in the Morris watermaze (*P<0.040 and **P<0.007, 
respectively) as compared with the control 2VO groups. DMSO+DIAZ treatment created an 
additional improvement in learning skill on days 2 and 3 as compared with DMSO in the 2VO 
animals (Fig. 3C). Both bolus and repeated pretreatment with DIAZ improved the spatial 
learning performance of the 2VO rats at 2 weeks throughout the whole period of the learning 
process, since these animals displayed the same performance as their respective SHAM 
controls (Fig. 3C). In contrast, DIAZ post-treatment was statistically ineffective in improving 
the memory capacity of the 2VO-DIAZ post-treated group. On days 2 and 5, these animals 
swam significantly longer than the SHAM-DIAZ post-treated rats (Fig. 3D). 
The treatment with the COX inhibitors did not alter the learning ability of the SHAM 
animals. The indomethacin-treated 2VO rats (2VO-indo-2w) demonstrated a poor 
performance on days 3 and 4 as compared with the SHAM groups, similar to the vehicle-
treated 2VO group (2VO-C-2w). This was also reflected by the ratio of failed trials (Fig. 3F). 
However, the 2VO-indo-2w animals (unlike the 2VO-C-2w group) attained the SHAM 
performance level by day 5 (Fig. 3E). The administration of NS-398 improved the learning 
capacity of the 2VO rats throughout the whole testing period in the Morris watermaze as 
compared with the 2VO-C-2w group (*P<0.024). The proportion of failed trials also indicated 
the beneficial effect of NS-398: the ratio of failed trials by the 2VO-NS-398-2w group was 
significantly lower than that by the 2VO-C-2w group, and not different from the SHAM 
groups (Fig. 3F). 
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Figure 3. (A-E) Learning curves of the Morris watermaze spatial orientation test. Data are presented as 
means±S.E.M. (F): Proportion of missed trials to total between trials 2-10. Data are expressed as percentage 
averages (%). Statistical F values are based on a two-way repeated measurement ANOVA model (*P<0.05). 
Individual days were analyzed with ANOVA and LSD post hoc test (*P<0.05). *: indicates a difference between 
surgical intervention; # and $: stand for the difference between treatments. Abbreviations: 2VO: bilateral carotid 
artery occlusion; DMSO: dimethyl sulphoxide; DIAZ: diazoxide; indo: indomethacin; pre: pretreatment; post: 
post-treatment; SHAM: sham operation. 
 
The administration of NS-398 resulted in a significantly lower distance swum by the 2VO rats 
throughout the whole testing period in the Morris watermaze as compared with the 2VO-C-
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2w group (*P<0.024). A similar tendency could be observed as concerns the proportion of 
failed trials to the total number (Fig. 3F). The 2VO-solvent group failed to find the platform 
with a significantly higher incidence than the animals from the SHAM groups (*P<0.05), 
while indomethacin moderated, and NS-398 significantly reduced the proportion of failed 
trials relative to the control level (**P<0.0014). 
 
Neuronal damage, dendritic degeneration and macroscopic brain lesions 
 
The integrity of the hippocampal neuronal layers was evaluated by using different 
approaches. In Experiment 2, the number of cresyl violet-stained CA1 pyramidal cells was 
counted in a standard surface. In Experiment 1, the number of COX-2-positive neurons in the 
DG were counted and expressed as neuronal density with a similar method. In Experiment 3, 
the presence of a necrotic process was identified in cresyl violet-stained sections, and the 
proportion of animals displaying necrotic degeneration in the hippocampal CA1, CA3 and 
DG cell layers was calculated for each region and for each experimental group. The integrity 
of the dendritic arborizations was labeled with MAP-2 immunocytochemistry in Experiment 
3. Finally, in Experiment 1, the presence of macroscopic lesions was noted. 
The 2VO-related, progressive neuronal damage in the hippocampus can best be 
characterized in the CA1 region: while only 12.5% of the control 2VO animals displayed 
signs of necrosis, this ratio increased to 40% at the 2-week survival (Fig. 4). The quantitative 
evaluation of the degree of necrotic cell death at 2 weeks indicated an average of 7% loss of 
the CA1 pyramidal cells (Fig. 5). In the CA3 pyramidal cell and DG granule cell layers, the 
higher incidence of necrotic damage (37.5%) was present at 3 days, but then fell to 20% by 
week 2. This indicates a different temporal sensitivity of hippocampal areas to hypoperfusion. 
At 13 weeks, 66.7% of the 2VO rats had a complete hippocampal lesion (complete, unilateral 
loss of the hippocampus; Fig. 7F-I). 
The progressive disintegration of the dendritic arborization was followed from day 3 
to week 2 after 2VO onset in the CA3 str. lucidum of the hippocampus (Fig. 6). While the 
difference in MAP-2-positive fiber density between the SHAM and 2VO groups was 
negligible at day 3, the density of labeled dendrites was decreased significantly in the 2VO 
groups as compared with the SHAM group at 2 weeks. 
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Figure 4. Cresyl violet staining and the proportions of animals displaying neuronal damage in the dorsal 
hippocampus (bregma −3.60). Area of interest: (A): CA1 stratum (str.) pyramidale, (D): CA3 str. pyramidale and 
(G): dentate gyrus outer molecular layer (DG oml). (B-C): Representative photomicrographs of the hippocampal 
CA1, (E-F):CA3 and (H-I): DG at 40× magnification. (J): Semiquantitative data on the proportions of damaged 
CA1, CA3 and DG in the hippocampus. Statistical analysis was performed with a non-parametric chi-square test. 
Significance levels of the post hoc test are given as: *P<0.05, **P<0.01 (2VO-indo-3d vs SHAM-indo-3d), 
$P<0.05 (2VO-NS-398-2w vs 2VO-C-2w), ##P<0.01 (2VO-NS-398-3d vs 2VO-C-3d). Abbreviations: CA: cornu 
ammonis; DG: dentate gyrus; 2VO; permanent, bilateral common carotid artery occlusion (two-vessel 
occlusion); SHAM: sham-operated controls. 
 
 DIAZ treatments showed a number of beneficial effects on hippocampal integrity. 
DIAZ pretreatment prevented the loss of CA1 pyramidal neurons at 2 weeks of survival (Fig. 
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5) Post-treatment with DIAZ in DMSO prevented the total, unilateral degeneration of the 
hippocampus observed in the control 2VO rats at 13 weeks (DMSO alone also reduced the 
incidence of hippocampal lesions) (Fig. 7). However, post-treatment with DIAZ in NaOH 
solution did not exert any beneficial effect on the CA1 pyramidal cell integrity 2 weeks after 
2VO onset (data not shown). 
Figure 5. Cresyl violet staining and cell counting in the hippocampus CA1 str. pyramidale. (A): Quantitative 
data on pyramidal cell viability in the hippocampus CA1 str. pyramidale; area unit is 0.024 mm2 (3×10 grid 
holes at 40× magnification). Data are presented as means ± SEM; *P<0.05. The P value indicated in the graph 
was obtained with a Student t test. (B–D): Representative photomicrographs of the hippocampal CA1 area from 
pretreated animals. Abbreviations: 2VO: permanent, bilateral common carotid artery occlusion (two-vessel 
occlusion); C: control for treatment; DIAZ: diazoxide; pre: pretreatment; SHAM: sham-operated control. 
 
 Post-treatment paradigms with the COX inhibitors indomethacin and NS-398 yielded 
controversial data. Indomethacin increased the number of 2VO rats with CA1 and CA3 
necrotic injury at 3 days (50-60%), but not at 2 weeks (0%) after 2VO onset (Fig. 1). On the 
other hand, NS-398 promoted DG injury, especially at 3 days (100%), but reduced the 
number of animals with CA3 damage at 2 weeks as compared with the 2VO-control animals 
(0% vs 20%) (Fig. 1). Neither of the COX inhibitors affected the 2VO-related injury of the 
MAP-2-positive dendrites (Fig. 6). 
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Figure 6. MAP-2 immunocytochemistry relating to synaptic density. Panel A: Area of interest: CA3 str. lucidum 
in the dorsal hippocampus (bregma −3.60). Panels B–D: Representative photomicrographs of the CA3 area of 
the hippocampus. Panel E: Quantitative data on MAP-2 immunocytochemistry in the hippocampal CA3 str. 
lucidum. Data are presented as means±S.E.M.; *P<0.05; ##P<0.01. The F value indicated in the graph was 
obtained with the LSD (least significant difference) post hoc test. Abbreviations: 2VO: permanent, bilateral 
common carotid artery occlusion (two-vessel occlusion); Sham: sham-operated controls; C: control for 
treatment; CA: cornu ammonis; or: stratum oriens; pyr: stratum pyramidale; rad: stratum radiatum, luc: str. 
lucidum. 
 
Figure 7. Cyclooxygenase-2 (COX-2) immunocytochemistry in the rat hippocampus and macroscopic lesions of 
the brains. (A and B): show neuronal density and COX-2 expression of preserved neurons, respectively. 
Significance values were obtained with the Student t-test (*P<0.05). (C, D and E): COX-2-positive neurons in 
the dentate gyrus inner granular cells. (F- I): representative macroscopic and microscopic images of cortical and 
hippocampal lesions. Abbreviations: 2VO: bilateral carotid artery occlusion (two-vessel occlusion); DMSO: 
dimethyl sulphoxide; DIAZ: diazoxide; SHAM: sham operation. 
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Astrocytic reaction 
 
 
Figure 8. Astrocytic proliferation in the CA1 str. radiatum of the hippocampus labeled by GFAP 
immunocytochemistry. Images were taken at 10x magnification (B–E). Data are presented as means±S.E.M.; 
*P<0.05; ##P<0.01 (E). Abbreviations: 2VO: permanent, bilateral common carotid artery occlusion (two-vessel 
occlusion); SHAM: sham-operated controls; CA: cornu ammonis; or: stratum oriens; pyr: stratum pyramidale; 
rad: stratum radiatum. 
  
The proliferation of GFAP-immunoreactive astrocytes was investigated in the 
hippocampus at all survival time, and in three WM regions (the corpus callosum, the internal 
capsule and the optic tract) 13 weeks after 2VO onset. GFAP immunoreactive astrocytes were 
present in all hippocampal and WM regions and in all experiments. At 3 days and 2 weeks 
following 2VO surgery, the GFAP activity was not altered by 2VO itself in any of the 
hippocampal areas (Fig. 8 and 9). Eleven weeks later (at 13 weeks of survival), the area 
covered by GFAP-positive astrocytes in the hippocampus was reduced in the 2VO animals as 
compared with the SHAM groups. The WM areas at 13 weeks displayed various patterns of 
astrocytic proliferation. The GFAP signal intensity in the corpus callosum and internal 
capsule of the 2VO animals was not different from that of their respective SHAM controls. 
Conversely, in the optic tract, cerebral hypoperfusion induced a consistent ~20% elevation of 
the GFAP signal in the 2VO groups as compared with the SHAM groups (Fig. 10A,B,E). This 
elevation appeared most prominent in the lateral portion of the optic tract, which contained 
more GFAP-positive immunoreactive material than the medial part (Fig. 10B). 
 None of the DIAZ pretreatments influenced the astrocytic proliferation at 2 weeks 
after 2VO onset. In turn, the post-treatment doubled the GFAP signal in both the str. oriens 
and the str. radiatum of the CA1 area in the hippocampus of the 2VO animals at this time 
point (*P<0.05) (Fig. 9). Thirteen weeks after the 2VO surgery, the postsurgical treatment 
with DIAZ administered in DMSO significantly suppressed the GFAP immunoreactivity with 
about 33% in the corpus callosum of both the 2VO and the SHAM rats (Fig. 10F). 
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Figure 9. GFAP immunocytochemistry for astrocyte proliferation in the CA1 area of the hippocampus 2 weeks 
after surgery. (A–C) Representative photomicrographs of the hippocampal CA1 area from post-treated animals. 
(D) Quantitative data on GFAP immunocytochemistry in the hippocampal CA1 str. oriens of the diazoxide post-
treated animals. (E) Quantitative data on GFAP immunocytochemistry in the hippocampal CA1 str. radiatum of 
the diazoxide post-treated animals. Data are presented as means ± SEM; *P<0.05, **P<0.01. Abbreviations: 
2VO: permanent, bilateral common carotid artery occlusion (two-vessel occlusion); C: control for treatment; 
DIAZ: diazoxide; post: post-treatment; SHAM: sham-operated control. 
 
 Indomethacin post-treatment did not alter the proliferation of astrocytes in the str. 
radiatum of area CA1 at 3 days of survival, while the treatment with NS-398 caused a 
significant elevation in the GFAP signal in the 2VO animals (Fig. 8). Conversely, neither of 
the COX inhibitor treatments influenced the hippocampal GFAP immunoglobulin at 2 weeks 
of survival. 
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Figure 10. GFAP immunocytochemistry of the optic tract and corpus callosum 13 weeks after surgery. (A-B): 
Representative microscopic images of GFAP immunoglobulin in the optic tract at 10x magnification. (C-D): 
Representative microscopic images of GFAP immunoglobulin in the corpus callosum at 10x magnification. (E): 
Quantitative data on astrocytic proliferation in the optic tract (**P<0.01). (F): Quantitative data on astrocytic 
proliferation in the corpus callosum (**P<0.01). Abbreviations: 2VO: bilateral carotid artery occlusion; am: 
amygdala complex; cc: corpus callosum; ctx: cerebral cortex; DMSO: dimethyl sulphoxide; DIAZ: diazoxide; 
hpc: hippocampus; ic: internal capsule; SHAM: sham-operated control; th: thalamus. 
 
Microglia activation 
 
 
Figure 11. (A): Quantitative analysis of OX-42 immunocytochemistry indicating microglia activation in the 
hippocampus CA1 str. radiatum. Significance values were obtained with the LSD post hoc test (**P<0.01; 
##P<0.01). (B–D): Representative photomicrographs of the CA1 area of the hippocampus (10× magnification). 
Abbreviations: 2VO: permanent, bilateral common carotid artery occlusion (two-vessel occlusion); SHAM: 
sham-operated controls; CA: cornu ammonis; or: stratum oriens; pyr: stratum pyramidale; rad: stratum radiatum. 
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The activation of the microglia was labeled by means of OX-42 immunocytochemistry 
and was investigated in the hippocampus at all survival times and in 3 WM regions (the 
corpus callosum, the internal capsule and the optic tract) 13 weeks after 2VO onset. 
The OX-42-labeled microglial activation was moderate or barely detectable in the 
hippocampal areas of the SHAM-control animals. Three days and 2 weeks after 2VO onset, 
the microglial activation in the 2VO nontreated groups remained similar to that in the SHAM 
controls (Figs. 11 and 12). Thirteen weeks after 2VO, the microglia activation was 
significantly enhanced in the CA1 area (*F=4.477) (Fig. 13E). At this time point, the 
microglia activation was augmented by 56% by cerebral hypoperfusion in the corpus 
callosum of the 2VO-C-13w rats, as compared with the SHAM-C-13w group (Fig. 13M). The 
most marked elevation in microglia activation was that in the optic tract of the 2VO-C-13w 
group (**P<0.001) (Fig. 13L). The internal capsule was unaffected by 2VO 13 weeks 
following surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. OX-42 immunocytochemistry related to microglia activation. (A–C): Representative 
photomicrographs of the hippocampal CA1 area from post-treated animals. (D): Quantitative data on OX-42 
immunocytochemistry in the hippocampal CA1 str. oriens of the post-treated animals. (E): Quantitative data on 
OX-42 immunocytochemistry in the hippocampal CA1 str. radiatum of the post-treated animals. Data are 
presented as means ± SEM; *P<0.05, **P<0.01. Abbreviations: 2VO: permanent, bilateral common carotid 
artery occlusion (two-vessel occlusion); C: control for treatment; DIAZ: diazoxide; post: post-treatment; SHAM: 
sham-operated control. 
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The pretreatments with DIAZ did not modify the OX-42 labeling in the hippocampus 
of the 2VO rats at 2 weeks of survival (Fig. 12D,E).  
Figure 13. Microglial activation in the rat hippocampus CA3 region, optic tract and corpus callosum labeled by 
means of OX-42 immunocytochemistry. (A-D): Representative photomicrographs of the hippocampus CA3 area. 
(E-G): Quantitative data on microglia activation in the hippocampus CA1, CA3 and DG regions (*P<0.05). (H-
I): Representative photomicrographs of the optic tract. (L): Quantitative data on microglia activation in the optic 
tract (**P<0.01). (J-K): Representative photomicrographs of the corpus callosum. (M): Quantitative data on 
microglia activation in the corpus callosum (*P<0.05). All images were taken at 10x magnification. 
Abbreviations: 2VO: permanent, bilateral carotid artery occlusion; am: amygdala complex; cc: corpus callosum; 
ctx: cerebral cortex; DMSO: dimethyl sulphoxide; DIAZ: diazoxide; hpc: hippocampus; ic: internal capsule; or: 
str. oriens; pyr: str. pyramidale; rad: str. radiatum; SHAM: sham operation; th: thalamus. 
 
In contrast, DIAZ post-treatment doubled the level of microglia activation in the 2VO 
animals as compared with both the SHAM and the vehicle-treated 2VO groups (Fig. 12D,E). 
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At 13 weeks, DIAZ administered in DMSO completely abolished the increase in OX-42 
signal (*P<0.05) (Fig. 13M), which was especially significant in the CA3 region 
(*F=4.097)(Fig. 13F). Similarly, DIAZ dissolved in DMSO reduced the microglia activation 
in the corpus callosum of the 2VO rats (Fig. 13F). In the optic tract, both DIAZ in DMSO and 
DMSO alone reduced the level of microglia activation in the 2VO rats to the SHAM control 
level (*P<0.05 and **P<0.01) (Fig. 13L). 
COX inhibitor treatments were ineffective in combating microglial activation (Fig. 
11E). 
 
DISCUSSION 
 
The effects of 2VO-induced chronic cerebral hypoperfusion on the observed parameters 
 
Changes in the later phase of cerebral hypoperfusion with relevance to AD 
 The clinical symptoms of AD and other dementia consisted in the deficit of several 
domains of cognitive function. The early symptoms are built up from the following elements: 
difficulty in learning semantic and visuospatial information, an impaired retrieval memory, 
disturbance of executive function, and problems in attention and behavioral symptoms 125. 
The neuropathological background of AD exhibits a progressive neurodegeneration involving 
the presence of senile plaques, neurofibrillary tangles, synaptic degeneration and neuronal 
loss in the cortex and the hippocampus 126. Neuroinflammation is responsible for the 
progression of the neuropathological aberrations, but it has recently been suggested to account 
for the initiation of the disease 127. Whether the inflammatory reaction is triggered by 
neurodegeneration or by cerebral hypoperfusion, which is also observed in the early stage of 
AD, has not been elucidated. 
In Experiment 1, the observed cerebral hypoperfusion-related aberrations correspond 
to the cognitive and histopathological disturbances of AD in several domains, leading to the 
suspicion that the impaired cerebral perfusion might initiate progressive inflammation and 
neurodegeneration in coherence with memory failure. Eleven weeks of mild forebrain 
ischemia resulted in a significant learning impairment in the rats, as evidenced by the Morris 
watermaze paradigm. From 3 days to 2 weeks after 2VO, a mild reduction in neuron number, 
progressive dendritic degeneration and increasing incidence of damaged cell layers were 
present in the hippocampus, while 13 weeks following 2VO surgery, even macroscopic brain 
lesions could be detected with high frequency, which indicates the progressive nature of the 
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neurodegenerative process. Thirteen weeks of cerebral hypoperfusion also reduced the 
numbers of COX-2-positive CA1 pyramidal and DG granule cells. Since these cell types are 
known to produce COX-2 constitutively, an ischemia-related nonspecific loss of these 
neurons might contribute to the impaired synaptic plasticity and hence to the impaired 
memory of 2VO rats 82.  
 The GFAP immunocytochemistry in the investigated areas revealed region-specific 
differences as concerns the cerebral hypoperfusion. The astrocytic proliferation was 
significantly elevated in the optic tract and also enhanced in the corpus callosum, which is in 
concert with the observation of other investigators 50. In contrast, the GFAP signal in the 
hippocampus was reduced by 13 weeks of hypoperfusion. Schmidt-Kastner et al. (2005) 
found no change in astrocyte proliferation at the level of the hippocampus until 6 months after 
2VO 50. This result might indicate that the severity of ischemia in the different brain regions 
determines the activity pattern of the astrocytes, since the greatest elevation in the GFAP 
signal was in the optic tract, which receives the lowest perfusion in the 2VO brain. Albeit, the 
persistent hypoperfusion in the hippocampus might caused progressive astrocytic 
degeneration and eventually cell death 53. Interestingly, in the white matter and the frontal 
cortex of demented patients, the GFAP-labeled astrocytes also exhibited disintegration and 
regression, which was associated with ischemia 53. 
The data obtained from OX-42 immunocytochemistry demonstrated a pronounced 
microglia activation in the hippocampal CA1, CA3 and DG regions, the corpus callosum and 
the optic tract, providing evidence for the existence of a continuous neuroinflammatory 
process. In concordance, a significantly elevated microglia activation was detected in the 
hippocampus and enthorinal cortex gray and WM in AD brains, as demonstrated by the 
human leukocyte antigen (HLA)-DR immunostaining of the microglia 128. Our observations 
thus confirm that various neuropathological symptoms of AD and vascular dementia are 
closely connected to chronic cerebral hypoperfusion. 
 
 
Changes in the early phase of cerebral hypoperfusion with clinical relevance to acute 
disruption of cerebral perfusion 
 In clinical cases, the appearance of memory disturbances is related to an acute 
disruption of the systemic circulation. These states can be predictable (planned cardiac 
surgery) or unpredictable (cardiac arrest, atrial fibrillation and myocardial infarction. 
Following coronary bypass surgery, half of the patients suffer a cognitive decline, which 
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persist even 6 months postoperatively in a quarter of the patients. The symptoms include 
primarily an impaired visuospatial orientation, but also the failures in attention and 
concentration 17. In our model, 2 weeks of experimental cerebral hypoperfusion in rats 
likewise resulted in a reproducible visuospatial learning impairment, as demonstrated in 
Experiments 2 and 3. Under clinical conditions, the detection of consequential neuronal 
damage after surgery is restricted to neuroimaging techniques and to the measurement of 
neuronal (neuron-specific enolase) and glia-specific (protein S-100B) chemical markers from 
blood samples to estimate the progression of the cognitive decline 129,130. 
 Our histological observations between 3 days and 2 weeks following carotid-occlusion 
demonstrated mild and selective damage of the hippocampal neurons. Surprisingly, the DG 
outer molecular layer displayed the highest sensitivity to ischemia and to the treatments not 
the CA1 area, which was suggested to be the most ischemia-sensitive region in the 
hippocampus, since it is less safely supplied with an arterial inflow than the CA3 area or the 
DG 131. 
2VO induced progressive dendritic degeneration in the hippocampus. The decrease in 
the MAP-2 signal already appeared on day 3 of 2VO, and 11 days later we found a significant 
loss of dendrites in the CA3 str. lucidum, similarly to our previous observation 34. 
The GFAP and OX-42 labeling in the hippocampus remained unaltered following 
2VO alone in the early period of cerebral hypoperfusion. 
Thus, it can be concluded that the early period of the 2VO model resembles a similar 
cognitive disturbance to that experienced after cardiac surgery and is applicable to 
characterize the neurohistological changes in mild cerebral ischemia in a temporal manner. 
This model is therefore of considerable benefit in the testing of pharmacological 
preconditioning before cardiac surgery, with the aim of alleviating global cerebral ischemia-
related cognitive failure and neuronal damage. 
 
The effects of DIAZ treatments 
 
Effects of DIAZ post-treatment, and comparison of treatments at different periods of cerebral 
hypoperfusion 
 The effects of the post-treatment with DIAZ were investigated after 2 and 13 
weeks of cerebral hypoperfusion. At the 2-week follow-up, DIAZ given after 2VO onset did 
not prevent the spatial memory disturbance and the reduction in the hippocampal CA1 
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pyramidal cell number. In contrast, 13 weeks after 2VO, DIAZ administered in DMSO 
preserved the learning capacity and abolished the appearance of macroscopic brain lesions.  
The immunocytochemical detection of astrocyte proliferation demonstrated no change 
in the hippocampus after 2 weeks of cerebral hypoperfusion; in turn, the GFAP signal was 
enhanced when DIAZ was administered after the induction of 2VO. In general, the astrocytes 
play an essential role in the excitability and homeostasis of the nervous tissue 132. They 
mediate the synaptic plasticity and, as part of the neurovascular unit, provide optimal energy 
metabolism for the proper functioning of the neurons 133. Data on the effects of DIAZ on the 
astrocytes are scarce. When DIAZ was applied to an astrocyte culture, it increased the 
glutamate uptake to 150% relative to the control, but 5-HD reversed this effect, indicating the 
contribution of mitoKATP in the process 134, These data imply a higher functional activity and 
proliferation of the astrocytes on DIAZ treatment. A different approach for the development 
of the astrocytic reaction is based upon a study which proved that, when exposed to ischemia, 
astrocytes express a nonspecific ATP-sensitive Ca2+ channel, which contains the SUR-1 
receptor subunit, the major target of DIAZ 135. Opening of the channel postulates the swelling 
and migration of astrocytes into the hypoxic region 135. In summary, we propose that DIAZ is 
able to augment the activity of astrocytes directly when they have previously been sensitized 
by ischemia. 
At 13 weeks of cerebral hypoperfusion, DIAZ in DMSO reduced the GFAP signal in 
the corpus callosum of SHAM and 2VO rats, but not in the optic tract or in the hippocampus. 
This suggests a region-specific sensitivity of the astrocytes to DIAZ and ischemia. 
 Similarly to its action on astrocyte proliferation, DIAZ post-treatment increased the 
activation of the microglia in the 2VO rats 2 weeks after 2VO onset. During ischemia, the 
microglia act as a double-edged weapon. They provide protection by the phagocytosis of 
cellular debris, but may exert cytotoxicity through the excessive production of ROS and 
cytokines 136,137. Microglia (cultured BV-2 murine microglia cells) express mitoKATP channels 
(Liu et al., 2006), which offers a direct target for DIAZ. DIAZ administered to toxin-activated 
microglia cultures decreased TNFα production and iNOS activity, which indicates that DIAZ 
reduced the activation of the microglia 138. Since DIAZ enhanced the microglial activation in 
our study at the 2-week survival time, we propose that this was not a direct action of DIAZ on 
the microglia cells, but a reaction to a primary event, which cannot be identified with 
certainty. 
 In contrast, the microglia activation in the hippocampus and in the WM areas after 13 
weeks of brain hypoperfusion was alleviated by DIAZ dissolved in DMSO. This suggests that 
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although DIAZ post-treatment in NaOH did not prevent neuron death, but enhanced microglia 
reaction at 2 weeks of survival, the DIAZ together with DMSO probably alleviated the 
microglia activation by preventing the progressive neuronal damage-related 
neuroinflammation. 
The observations that DIAZ in NaOH solution was not neuroprotective when examined 2 
weeks after 2VO onset, whereas in DMSO exerted beneficial effects at 13 weeks after 2VO 
surgery, strongly suggest that DMSO potentiated the action of DIAZ. This suggestion is 
especially relevant because DMSO alone achieved some memory improvement, as assessed in 
the Morris watermaze, prevented the loss of COX-2 positive neurons in the hippocampus and 
reduced the number of animals with macroscopic brain lesions. A number of beneficial effects 
of DMSO have been described which may be responsible for the additional neuroprotection. 
These activities include hydroxyl scavenging, anti-inflammatory and anti-edema effects, the 
impairment of platelet aggregation and adhesiveness, and the prevention of glutamate-induced 
neuronal cell death 139. As the solvent DMSO also provided neuroprotective properties, we 
repeated this experiment exactly the same way as in Experiment 1, but with the use of the 
inorganic vehicle 0.1 N NaOH instead of DMSO to dissolve the DIAZ 140. This experiment 
showed that DIAZ in this inorganic solvent (1) failed to prevent the learning impairment of 
2VO rats in the Morris watermaze, and (2) did not modify the astrocytic proliferation in the 
hippocampus, but (3) reduced the microglia activation induced by 2VO in the CA1 and DG 
regions of the hippocampus 140. The results of the two experiments together allow the 
conclusion that DMSO potentiated the effect of DIAZ in restoring the spatial memory, 
preventing the formation of brain lesions and reducing the astrocytic proliferation, while the 
mitigation of microglia activation seems to be a DIAZ-mediated effect.  
 
The effects of pretreatment with DIAZ, and the comparison of pretreatment with post-
treatment  
Experiment 2 provided evidence, that repeated pretreatment with 0.5 mg/kg DIAZ 
affords neuroprotection in chronic cerebral hypoperfusion in rats by preventing the spatial 
learning disturbance and pyramidal cell loss in the CA1 area of the hippocampus, 2 weeks 
after 2VO. In contrast, post-treatment did not furnish neuroprotection, but enhanced the 
astrocyte proliferation and microglial activation. The most probable reason for the memory-
preserving effect of DIAZ is its preconditioning effect, through which it prevented 
hippocampal neuron loss. In this case, DIAZ caused a transient increase in the level of ROS, 
which activated their scavenging enzymes in the brain. 
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A probable pathway of this action is the facilitating effect of DIAZ and its derivatives 
on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. DIAZ 
has been shown to enhance LTP in the hippocampus both in vitro and in vivo by slowing the 
rate of AMPA-receptor deactivation of the neurons 141. This possibility is questionable since 
the post-treatment was ineffective. However, if we consider that the DIAZ dissolved in NaOH 
did not necessarily reach the brain areas of learning in the 2VO animals in sufficient 
concentration to produce its effect, then DIAZ pretreatment at the optimal brain perfusion 
could act on the learning capacity via the AMPA receptors. 
 
The effects of COX inhibitors in chronic cerebral hypoperfusion 
 
The comparison of nonselective and selective COX-2 inhibition in chronic cerebral 
hypoperfusion 
The major finding of Experiment 3 is that NS-398, but not indomethacin, abolished 
the learning disability induced by 2VO without corresponding, clear protection of the 
hippocampal neurons. Both indomethacin and NS-398 treatment increased the incidence of 
damage in the hippocampal pyramidal and granular cell layers, particularly in the 2VO 
animals, which was especially obvious 3 days after 2VO onset. The drugs did not affect the 
synaptic density, astrocytic proliferation and microglia activity. 
The lack of a correlation between the learning scores and the neuronal injury in the 
hippocampus may stem from the variation in the regional cerebral representation of the spatial 
memory, and the ischemia-related electrophysiological properties of the morphologically 
intact neurons.  The area most frequently associated with spatial learning is the CA1 region of 
the hippocampus. A number of studies have demonstrated a direct correlation between a 
cerebral hypoperfusion-induced memory deficit and CA1 damage 40,41,142. On the other hand, 
others have found no or only a weak correlation between the diminishing CA1 neuron number 
and Morris watermaze performance 143-145. In our Experiment 2, cresyl violet staining 
revealed only a mild reduction in CA1 neuronal cell number in the hippocampus 2 weeks 
after 2VO, which was accompanied by significantly impaired visuospatial learning. These 
findings suggest that areas other than the hippocampal CA1 must also be involved in spatial 
learning, e.g. the entorhinal cortex, the parahippocampal gyrus, and the rhinal and cingular 
gyri 146,147. An interesting study by Mumby et al. (1996) demonstrated in rats that transient 
global cerebral ischemia-induced delayed non-matching to sample task deficits were due to 
extrahippocampal damage, and that prior hippocampal ablation protected against the effects 
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of ischemia by interrupting pathogenic processes that require the presence of the hippocampus 
148. Moreover, the memory deficit correlates with the white matter damage in 2VO rats 149,150. 
In conclusion, a direct link cannot be established between ischemia-induced memory failure 
and a decreased neuron count in the hippocampus CA1. 
Even though the hippocampal neurons are not lost in great numbers early after 2VO 
induction, ischemia can have an impact on the electrophysiological properties of these cells. 
In a model of global cerebral ischemia, Henrich-Noack et al. (2005) demonstrated that 
population spike generation in the DG granular cell layer was greatly decreased as early as 1 
day postischemia, as compared with the pre-ischemic values and those in sham-operated 
animals. The functional impairment was detected despite an apparently intact morphology the 
of granular cells, as evidenced by Nissl staining 151. Therefore, it is probable that at least a 
proportion of the surviving neurons in 2VO animals may be functionally impaired and may 
not exhibit proper LTP. This, in turn, may also limit spatial learning. 
The protective potential of NS-398 on the memory capacity of 2VO rats suggests the 
involvement of COX-2 in the ischemia-induced damage in the brain regions responsible for 
spatial learning. However, the administration of NS-398 to in vitro CA1 pyramidal and DG 
granular cell cultures significantly reduced LTP and long-term depression (LTD) 152. This 
finding suggests that the memory-preserving effect of the COX-2 inhibitor NS-398 is 
probably not related directly to the electrical disturbances of the surviving hippocampal cells. 
Accordingly, we can suggest that NS-398 limited the COX-2-related inflammatory process, 
but preserved the COX-1-related tissue perfusion in the learning areas of the brain. 
 The neuronal damage in the hippocampus showed different temporal and spatial 
distributions following the treatments, reflecting the different properties of the two drugs. 
Although the dose for indomethacin was chosen to be low enough to avoid general vasoactive 
side-effects (3 mg/kg), the detrimental effect of the drug appeared mainly in the ischemic 
2VO rats close in time to the last injection of indomethacin on day 3, but was not present 9 
days after the end of treatment. NS-398 damaged all of the investigated cell layers, especially 
the granule cells in the DG, in both the SHAM and 2VO rats at 3 days and 2 weeks after 2VO, 
respectively. These layers contain a large amount of constitutive COX-2-producing cells 78. It 
is possible that COX-2 inhibition selectively damaged these COX-2-positive cells, which 
appeared as general neuronal damage with cell layer disruption on the cresyl violet-stained 
sections. If this is relevant, the basal COX-2 expression is therefore obligate for the viability 
of these neurons. The role of COX in ischemic neuronal damage has long been controversial. 
Some studies dispute the beneficial effects of selective COX-2 inhibitors due to their general 
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and cerebral side-effects. COX-2 activity is not uniformly deleterious, and treatments based 
on inhibition of the COX-2 pathway should focus on the mediators responsible for the 
deleterious effects of the enzyme, sparing those mediating the beneficial actions 153,154. 
Although COX-2-derived PGE2 has been found to mediate excitotoxic injury in ischemia via 
the prostanoid EP1 receptor 100, PGE2 provides neuroprotection against excitotoxic injury, 
LPS-induced cytotoxicity or oxygen deprivation through the prostanoid EP2 receptor in 
hippocampal and cortical neuronal cultures 155-159. Interestingly, the neuroprotective effects 
are generally observed at concentrations consistent with PGE2 receptor activation (< l M), and 
lower than those required for toxic effects. PGD2, another prostanoid, has been shown to 
prevent neuron loss in response to glutamate excitotoxicity in vitro 160. Treatment with 
iloprost (a stable PGI2 analog) after 2VO prevented hypoperfusion-induced lipid peroxidation 
161. COX-2 participates in memory formation. This results in another disadvantage of the 
drugs. Selective COX-2 inhibitors block the induction of LTP 162 and LDP 152. Administration 
of the selective COX-2 inhibitor NS-398 to adult rats within 2 hours of behavioral training 
was also found to impair memory formation, though delaying the injections until 2 hours after 
the training had no effect on the memory 162,163. 
 Another aspect of neuronal damage in COX-2 inhibition is the elevated turnover of 
AA to eicosanoids by an enhanced lipoxygenase function. 5-Lipoxygenase-derived 
eicosanoids cause neuronal damage in the cortex during 14 days after 1 hour of transient 
MCAO 164. The general disadvantage of the chronic use of COX-2 inhibitors, which led to the 
withdrawal of these drugs from the market in 2004, is that COX-2 inhibitors downregulate 
PGI2 and upregulate thromboxane A2, resulting in a cardiovascular hazard by producing a 
prothrombotic state in several organs 165. Selective COX-2 inhibition can therefore induce 
microvascular thrombosis in the brain. One efficacious approach to restrict COX-mediated 
neuronal damage without considerable side-effects might be the selective targeting of 
prostanoid receptors which mediate cellular damage. 
In conclusion, no relationship could be discerned between the advantageous effects of NS-398 
on the memory capacity and the histological changes in the early period of cerebral 
hypoperfusion. To elucidate the mechanism of action of NS-398 on spatial learning, and to 
detect the differences between NS-398 and indomethacin treatment, further investigations are 
necessary. However, short-term treatment with a selective COX-2 inhibitor might provide 
memory protection in short and mild ischemic brain damage. 
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CONCLUSION 
 
First, our experiments have provided evidence that pretreatment, but not post-
treatment with a safe concentration of DIAZ is able to alleviate the cerebral hypoperfusion-
related memory deficit. However, further experiments are necessary to characterize the effects 
of DIAZ in vivo on the ischemic brain tissue. Moreover, our findings provide a possibility for 
physicians to apply DIAZ in conditions under which the occurrence of an ischemia-related 
memory disturbance is predictable, such as long-term cardiac surgery. 
Second, targeting the COX-2-mediated pathway of neuroinflammatory reaction during 
cerebral hypoperfusion is efficacious in repelling a cognitive disturbance. Furthermore, our 
findings support the hypothesis that the hippocampal pyramidal and granular cells are not 
crucial for visuospatial memory. Finally, we suggest that preserving the constitutive COX-2 
production in the brain should be considered when the COX-mediated pathway is targeted in 
the treatment of brain ischemia. 
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Abstract
Chronic cerebral hypoperfusion, a mild ischemic condition is associated with advancing age and severity of dementia; however, no
unanimous therapy has been established to alleviate related neurological symptoms. We imposed a permanent, bilateral occlusion of the
common carotid arteries of rats (n = 18) to create cerebral hypoperfusion. A mitochondrial ATP-sensitive K+ channel opener diazoxide (DZ, 5
mg/kg) or its solvent dimethyl sulphoxide (DMSO) were administered i.p. (0.25 ml) on five consecutive days after surgery. Sham-operated
animals (n = 18) served as control for the surgery, while nontreated rats were used as control for the treatments. Three months after the onset
of cerebral hypoperfusion, the rats were tested in a hippocampus-related learning paradigm, the Morris water maze. Subsequently, the animals
were sacrificed and neurons, astrocytes and microglia were labeled with immunocytochemistry in the dorsal hippocampus. DMSO and
diazoxide dissolved in DMSO restored cerebral hypoperfusion-related learning dysfunction and prevented cyclooxygenase-2-positive neuron
loss in the dentate gyrus. Cerebral hypoperfusion led to reduced astrocyte proliferation, which was not clearly affected by the treatment.
Microglia activation was considerably enhanced by cerebral hypoperfusion, which was completely prevented by diazoxide dissolved in
DMSO, but not by DMSO alone. We conclude that diazoxide can moderate ischemia-related neuroinflammation by suppressing microglial
activation. Furthermore, we suggest that DMSO is a neuroprotective chemical in ischemic conditions, and it must be considerately used as a
solvent for water-insoluble compounds in experimental animal models.
D 2004 Elsevier B.V. All rights reserved.
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Keywords: Cerebral hypoperfusion; Diazoxide; Dimethyl sulphoxide; Microglia; Spatial learning
1. Introduction
The incidence of chronic cerebral hypoperfusion increases
with advancing age and dementia [15]; moreover, some
researchers have found that decreasing cerebral blood flow
(CBF) values correlate with an increasing degree of cognitive
impairment in Alzheimer’s disease patients [26,43]. In addi-
tion, reduced CBF has been recently suggested as an indicator
for the progression of Alzheimer’s disease [14,41]. Whether
reduced CBF is one of the triggers or the consequence of
neuronal dysfunction cannot be conclusively decided, but
experimental evidence suggests that decreased CBF can lead
to cognitive impairment and neuronal injury [15].
The use of bilateral, permanent occlusion of the common
carotid arteries of rats (2VO) is a well-characterized model to
investigate the cognitive and histopathologic consequences
of chronic cerebral hypoperfusion [15]. The hippocampus
has been shown to be particularly affected because hippo-
campus-related spatial memory, neuronal and microvascular
integrity were predominantly compromised in the region
[8,15,52]. Several studies based on this model were designed
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to test potentially beneficial strategies to delay the progres-
sion of dementia associated with reduced CBF. For example,
pharmacological treatment with cholinesterase inhibitors im-
proved 2VO-related memory dysfunction, CBF, and cerebral
metabolism [36,49]. Administration of plant extracts gained
from Ginkgo biloba or huperzine-A also attenuated 2VO-
induced learning deficit [30,60]. Alternatively, dietary sup-
plements such as polyunsaturated fatty acids and antioxidants
could moderate 2VO-imposed learning impairment or in-
crease G-protein-coupled receptor densities in the hippocam-
pus [11,16]. In our present study, we alsomade use of the 2VO
model of cerebral hypoperfusion to test the potentially neuro-
protective effect of diazoxide (DZ), a putative, mitochondrial
ATP-sensitive potassium channel (mitoKATP) opener.
Diazoxide has proved to be neuroprotective in several
ischemia models. For instance, pretreatment with the agent
could reduce infarct volume after middle cerebral artery
occlusion in rats and mice [31,55]. Further in vivo experi-
ments have provided evidence that diazoxide preserves
NMDA-induced cortical arteriolar dilation after ischemia/
reperfusion in piglets [12]. The mechanism behind these
neuroprotective properties appears to be a selective opening
of mitoKATP because diazoxide effect can be abolished by the
mitoKATP blocker 5-hydroxydecanoate (5-HD) [24,32]. Hip-
pocampal CA1 and CA3 interneurons are richly endowed by
mitoKATP that express region-specific distribution [18]. The
activation of mitoKATP in these cells under glucose depriva-
tion proved to be neuroprotective as demonstrated in hippo-
campal slices [61]. Thus, the hippocampus appears to be a
potential target and diazoxide a promising drug to achieve
neuroprotection in chronic cerebral hypoperfusion.
Because diazoxide dissolves poorly in inorganic solvents,
dimethyl sulphoxide (DMSO) was chosen in this study to
prepare diazoxide solution. DMSO is widely used as a
solvent for water-insoluble compounds in experimental ani-
mal research, yet DMSO itself possesses several vascular and
neuroprotective properties [22,33,51]. For instance, DMSO
can suppress platelet aggregation by antagonizing vasoactive
substance release from platelets, or can scavenge neurotoxic
free radicals [22,51]. Keeping these effects in mind, we also
aimed to characterize and further explore the beneficial
properties of DMSO in experimental cerebral hypoperfusion.
Our objective in the present study was to test the
potentially neuroprotective effect of diazoxide in the 2VO
model of cerebral hypoperfusion. Our prediction was that
daily administration of the drug following carotid occlusion
had beneficial effect on behavioral and neurological out-
come. We were interested to investigate a late onset of
complex changes caused by cerebral hypoperfusion.
In order to demonstrate drug effect in our experimental
setup, we designed a Morris water maze paradigm frequently
used as a standard test to asses hippocampus-related spatial
memory function in 2VO [15]. Furthermore, we aimed to
develop a comprehensive description of cerebral histopath-
ologic changes by using neuronal, astroglial and microglial
markers, of which the latest has not yet been employed in
experimental, chronic cerebral hypoperfusion. Cyclooxyge-
nase-2 (COX-2) labeling was chosen to identify hippocam-
pal neurons involved in ischemic injury because this
inducible form of the enzyme is markedly expressed in
transient ischemia [25,37,42]. Glial fibrillary acidic protein
(GFAP) immunocytochemistry was employed to label astro-
cytes that can react by degeneration to reduced CBF in the
hippocampus [57]. Finally, OX-42 antibody known to rec-
ognize CR3 complement receptors (CD11b) on microglia
was used to identify microglial activation, which is an early
event in ischemia [1,57].
2. Materials and methods
2.1. Surgery and treatment
Fifty-one male Wistar rats (210F 10 g) were used for the
study. All animal experiments were approved by the ethical
committee of the University of Szeged. Experimental cere-
bral hypoperfusion was imposed [16] on half of the animals
by permanent bilateral occlusion of the common carotid
arteries (2VO), the other half served as sham-operated
controls (SHAM). Prior to surgery, the animals were anes-
thetized by 400 mg/kg chloral-hydrate i.p., followed by 0.05
ml atropine i.m. The common carotid arteries were exposed
via a ventral cervical incision, and separated from their
sheaths and vagal nerves. Silk sutures were used for the
ligation. The same procedure was performed on the SHAM
group without the actual ligation. Survival rates for each
group are presented in Table 1.
Both groups were divided into three subgroups (n = 6)
based on postsurgical treatment. The first set of animals of
both SHAM and 2VO groups received 0.25 ml DMSO i.p.,
(SHAM–DMSO, 2VO–DMSO, respectively). The second
set of animals was treated with 5 mg/kg diazoxide [7,31]
given in 0.25 ml DMSO, i.p., (SHAM–DMSO+DZ, 2VO–
DMSO+DZ). The animals were injected on five consecu-
tive days. The first injection was applied directly after
surgery. The last set of animals received no treatment after
the operation and served as controls (SHAM–nontreated,
2VO–nontreated). The final composition of the experimen-
tal groups is presented in Table 1.
Table 1
Survival rate and the incidence of CNS lesions
Experimental group Survival
rate (%)
Unilateral
hippocampal
lesion (%)
Unilateral
cortical
lesion (%)
Nontreated SHAM 75 (6/8) 0.00 (0/6) 0.00 (0/6)
2VO 66.6 (6/9) 66.67 (4/6) 33.34 (2/6)
DMSO SHAM 100 (6/6) 0.00 (0/6) 0.00 (0/6)
2VO 50 (6/12) 16.67 (1/6) 16.67 (1/6)
Diazoxide SHAM 100 (8/8) 0.00 (0/6) 0.00 (0/6)
2VO 87.5 (7/8) 0.00 (0/6) 0.00 (0/6)
Abbreviations: bilateral carotid artery occlusion (2VO), dimethyl sulphoxide
(DMSO), sham operation (SHAM).
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2.2. Spatial learning test
Eleven weeks after surgery, the animals were trained in
the Morris water maze [11]. The water maze consisted of a
polyester circular pool (diameter: 160 cm, height: 35 cm)
filled with water (22 jC), which was made opaque by milk
so that the rats were unable to see an underwater platform.
The hidden platform was submerged 2 cm below water
surface. The water tank was located in an experimental
room with various extra maze cues to enable the rats to learn
the location of the platform. All rats performed two trials per
day with a constant intertrial interval of 4 h, for five
consecutive days. The animals were placed in the water at
one of four starting quadrant points, which was varied
randomly over the trials. The rats were given 2 min to find
the platform and sit on it for 15 s. Rats that failed to find the
location within the given time were guided to the platform
and were allowed to stay on it for 15 s. Swimming paths
were recorded by a computerized video imaging analysis
system (EthoVision, Noldus Information Technology BV,
Wageningen, The Netherlands). At each trial, escape laten-
cy, and swimming distance traveled before reaching the
platform were analyzed.
2.3. Immunocytochemistry
Ten days after the Morris water maze experiments, the
animals were anaesthetized with an overdose of pentobar-
bital, and perfused transcardially with 100 ml saline fol-
lowed by 400 ml 3.5% paraformaldehyde and 0.5% picric
acid in 0.1 M phosphate buffer (PB, pH 7.4). The brains
were removed, one hemisphere was postfixed in the same
solution for up to 1 h, and then stored in 0.1 M PB. Six
brains per group were processed for immunocytochemical
investigation.
Free floating coronal sections at the level of the hippo-
campus were cut at 20-Am thickness on a cryostat. COX-2
labeling was performed on the first set of sections as
follows. First, endogenous peroxidase activity was blocked
with 0.3% H2O2. Nonspecific binding sites were covered
with 5% normal goat serum (NGS) and membrane perme-
ability was enhanced by 0.3% Triton X-100. The sections
were incubated for 2 days at room temperature (RT) in
primary antibody solution containing rabbit anti-COX-2
antibody (Cayman), 1:2000, 1% NGS, 0.3% Triton X-100
and 0.1% sodium azide in 0.01 M PBS (pH 7.4). Next, the
sections were rinsed and preincubated in 5% NGS for 1 h.
Incubation was performed in goat anti-rabbit biotinylated
IgG (Santa Cruz) for 4 h at RT. Finally, the signal was
amplified by an ABC–Avidin Kit (1:400) (Vector) for 2 h at
RT. Color reaction was developed by diaminobenzidine
(DAB) and H2O2.
A second set of sections was immunocytochemically
stained for glial fibrillary acidic protein (GFAP) to visualize
astrocytic proliferation. Briefly, sections were treated with
0.3% H2O2 in PBS, and preincubated in 5% normal sheep
serum (NShS). The samples were then incubated in a
primary antibody solution containing mouse anti-GFAP
antibody (Sigma), 1:200, 1% NShS, and 0.3% Triton X-
100 in 0.01 M PBS, overnight at 37 jC. The secondary
antibody solution consisted of sheep anti-mouse biotiny-
lated IgG (Jackson), 1:200, and 0.3% Triton X-100 in 0.01
M PBS. Finally, the sections were incubated in HRP-
Streptavidine (Zymed), 1:200, and color reaction was con-
ventionally developed with DAB and H2O2.
To detect and analyze microglial activation over the
hippocampal areas, OX-42 antibody was used on a third
set of sections. The procedure started with washing and
pretreating the sections with 0.5% Triton X-100 and 3%
H2O2 in 0.01 M PBS, followed by preincubation in 20%
normal swine serum (NSS) and 0.5% Triton X-100 in 0.01
M PBS for 1 h. The sections were incubated in a primary
antibody solution containing biotinylated mouse anti-
CD11b antibody (OX-42, Serotec), 1:500, 20% NSS, and
0.03% mertiolate in 0.01 M PBS, overnight at RT. Next, the
sections were rinsed, and incubated in a solution of STA-
PER (Jackson), 1% NSS, and 0.03% mertiolate in 0.1 M
Tris-buffer for 1 h at RT. Finally, the color reaction was
developed by Ni-DAB and H2O2. All sections were
mounted on gelatin-coated microscopic slides, air-dried,
dehydrated and coverslipped with DPX.
2.4. Analysis
Percentual surface area of GFAP-positive astrocytes was
quantified in the dorsal hippocampus by using a Quantimet
Fig. 1. Learning curves plotted of the Morris maze spatial orientation test.
Statistic F values are based on a two-way repeated measurement ANOVA
model (*p < 0.05). Individual days were analyzed with ANOVA and LSD
post hoc test (*p < 0.05). (*) indicates difference between SHAM–
nontreated and 2VO–nontreated, (#) stands for the difference between
2VO–nontreated and 2VO–DMSO+DZ. Abbreviations: bilateral carotid
artery occlusion (2VO), dimethyl sulphoxide (DMSO), diazoxide (DZ),
sham operation (SHAM).
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Q-600HR computerized image analysis system (Leica,
Cambridge, UK) with a 469.4-nm emission filter [20].
Briefly, three consecutive coronal sections with a standard
distance of 160 Am, starting at Br. 3.60 mm [46] were
selected for the analysis. Hippocampal regions of interest
were manually delineated at 10 magnification, after
background subtraction and gray scale threshold determi-
nation. The area covered by GFAP-positive astrocytes was
computed as percentage of the total area delineated.
Measurements of the three sections per animal were
averaged, and the average was used for further statistical
analysis.
COX-2-labeled neuron counting was performed at 20
magnification with the help of an ocular mesh with 1600-
Am2 holes. Three consecutive coronal sections with a
standard distance of 160 Am, starting at Br.  3.60 mm
[46] were examined. COX-2-positive neurons were counted
in the CA3 stratum (str.) pyramidale and the dentate gyrus
(DG) inner and outer str. moleculare on an average surface
of 0.018 mm2 in each region. Regional cell counts of three
Fig. 2. Cyclooxygenase-2 enzyme (COX-2) immunocytochemistry in rat hippocampus. Panels A and B show neuronal density and COX-2 expression of
preserved neurons, respectively. Significance values were obtained by Student T-test (*p < 0.05). Panels C, D and E demonstrate COX-2-positive neurons in the
dentate gyrus inner granular cells (arrowheads are pointing at a few labeled neurons). Abbreviations: bilateral carotid artery occlusion (2VO), dimethyl
sulphoxide (DMSO), diazoxide (DZ), sham operation (SHAM).
E. Farkas et al. / Brain Research 1008 (2004) 252–260 255
sections per animal were averaged, and the average was
used for further statistical analysis.
The optical density of COX-2-positive neurons was
measured by using a Quantimet Q-600HR computerized
image analysis system (Leica). The same sections used for
COX-2-labeled cell counting were analyzed again, at 10
magnification. Following background subtraction and gray
scale threshold determination, COX-2-positive neurons
were automatically delineated by the program, and relative
optical density was computed based on a standard gray
scale. As done previously, values of three sections per
animal were averaged, and this value was used for further
statistical analysis.
Quantification of the surface covered by OX-42 immu-
noreactive microglia was performed in a similar manner to
GFAP-labeled sections on a computerized image analysis
system (Olympus BX50, DP50; software: ImagePro Plus,
Media Cybernetics).
The Morris maze test results were statistically analyzed
by a two-way repeated measurement model followed by
LSD post hoc test of the program SPSS. Individual day
comparisons were performed by a univariate model and
LSD post hoc analysis of SPSS. GFAP and OX-42 immu-
nocytochemical results were statistically analyzed with two-
way ANOVA followed by LSD post hoc test.
3. Results
Spatial learning curves obtained in the Morris maze test
(Fig. 1) demonstrated that experimental cerebral hypoper-
fusion induced a marked decrease in learning performance
(**p < 0.002). Moreover, hardly any day-to-day improve-
ment was observed in the nontreated 2VO group over the
5-day training period. Daily comparison of groups revealed
that the nontreated 2VO animals’ memory capacity was
significantly worse than their respective SHAM controls
specifically on days 2, 3, and 5. Conversely, either DMSO
or DMSO+DZ treatment improved learning of 2VO rats
compared to the nontreated 2VO group, (*p < 0.040 and
**p< 0.007, respectively). On the other hand, the agents
did not affect the performance of SHAM animals. Further-
more, statistical analysis of the daily performance showed
significant improvement only in the DMSO-DZ treated
2VO rats compared to the nontreated 2VO group on days
2, and 3.
Fig. 3. Microglial activation in the rat hippocampus CA3 region labeled with OX-42 immunocytochemistry. A: image from a SHAM non-treated animal. B:
image from a 2VO non-treated animal. C: image from a 2VO, DMSO-treated animal. D: image from a 2VO, DMSO+DZ-treated animal. Images were taken at
10 magnification. Abbreviations: 2VO: bilateral carotid artery occlusion, DMSO: dimethyl sulphoxide, DZ: diazoxide, or: str. oriens, pyr: str. pyramidale,
rad: str. radiatum, SHAM: sham-operation.
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Macroscopic evaluation of rat brains demonstrated that
2VO without postoperative treatment induced hippocampal
and cortical lesions (in 66.67% and 33.34% of the animals,
respectively). DMSO application reduced, while DMSO+
DZ completely abolished the occurrence of the lesions
(Table 1).
COX-2 immunocytochemistry in the dorsal hippocampus
labeled neurons in the stratum pyramidale, the hilus and
granular cells of the inner stratum moleculare of the dentate
gyrus (DG-iml) (Fig. 2). The outer stratum moleculare of the
DG contained only very few, scattered labeled neurons. Cell
counting revealed loss of about 50% of COX-2-positive
neurons in the nontreated 2VO group specifically in the
DG-iml. Both DMSO and DMSO+DZ treatments prevented
neuronal loss in the region (Fig. 2A). Optical density
measurements showed that the surviving cells expressed an
unaltered amount of COX-2 (Fig. 2B).
Glial fibrillary acidic protein (GFAP) immunoreactive
astrocytes were present in all hippocampal regions and in
all experimental groups. The area covered by astrocytes
showed a similar tendency to COX-2-positive neuron count-
ing in that astrocytic proliferation was reduced in 2VO
compared to SHAM. However, no clear effect of the treat-
ments could be established (data not shown).
OX-42 positive activated microglia were scarce in the
hippocampus of SHAM animals (Fig. 3A), while a dense
staining could be observed in all hippocampal areas in the
nontreated and DMSO-treated 2VO groups (Fig. 3B and C).
On the other hand, DMSO+DZ but not DMSO alone
diminished OX-42-positive microglia in 2VO rats (Fig.
3D). Quantitative analysis demonstrated that 2VO increased
microglia activation from two to three times in the CA1,
CA3 and DG molecular layers in the nontreated and DMSO-
treated 2VO animals. The increase was statistically signif-
icant in the CA1 region (*F = 4.477). Application of
DMSO+DZ but not DMSO alone reduced microglia acti-
vation to SHAM control level in all investigated regions, but
the preventive effect of DMSO+DZ was statistically sig-
nificant only in the CA3 area (*F = 4.097) (Fig. 4).
4. Discussion
The novel findings of this study are the following.
Chronic administration of DMSO following 2VO can mod-
erate ischemia-related memory failure, and diazoxide in
concert with DMSO can virtually prevent memory dysfunc-
tion. In a similar way, DMSO can confine, and diazoxide
applied in DMSO can completely diminish macroscopic
hippocampal and cortical lesions. Furthermore, DMSO
alone is sufficient to prevent COX-2-positive neuron loss
in the DG. Finally, diazoxide, but not DMSO alone can
attenuate microglia activation in the hippocampus.
Cerebral hypoperfusion created by 2VO has been repeat-
edly described to cause spatial memory dysfunction [8,11,
15,39,45], and apoptotic neuronal death in the hippocampus
of rats [6,19,40]. Similarly, our Morris maze experiment
reproduced earlier observations that chronic 2VO causes
spatial memory impairment [8,15,39,45]. On the other hand,
DMSO, and particularly DMSO +DZ restored learning
skills to nearly SHAM level. To the best of our knowledge,
the effects of diazoxide on learning and memory have not
yet been tested. In addition, only one prior study attempted
to identify the potentially beneficial effect of DMSO on
spatial learning skills, but in that study DMSO was not
administered alone but was combined with fructose 1,6-
diphosphate [10].
In addition, our examination of rat brains following 3
months 2VO revealed macroscopic hippocampal and corti-
Fig. 4. Quantitative analysis of OX-42-positive microglial activation. A:
hippocampus CA1 region. B: hippocampus CA3 region. C: hippocampus
dentate gyrus. Statistic F values are based on a two-way ANOVA model
(*p<0.05). Abbreviations: 2VO: bilateral carotid artery occlusion, DMSO:
dimethyl sulphoxide, DZ: diazoxide, SHAM: sham-operation.
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cal lesions in four out of six untreated animals. The lesions
can very well arise from acute ischemic strokes as reported
by early studies on the 2VO model, and also correlate with
the regional distribution (hippocampus and neocortex), and
ratio of affected animals (35–65%) in previous experiments
[21,34,50]. Chronic treatment with DMSO reduced, while
DMSO +DZ abolished, such ischemic lesions. Because
DMSO can improve hemodynamic variables and CBF
[23,28,59] in addition to its known free radical scavenger
properties [2,51], an increased flow or reduced concentra-
tion of free radicals may underlie the preventive effect of the
agent. Our observation also supports the data that DMSO
could reduce infarct volume in focal cerebral ischemia
[47,54]. Diazoxide was also found to be neuroprotective
in ischemia–reperfusion brain injury [55]. Therefore, the
cumulative effect of DMSO and diazoxide could be respon-
sible for the complete prevention of lesions. Furthermore,
such a protective action accomplished by the drugs corre-
sponds with the treatment-related improvement in spatial
learning skills demonstrated in our study.
The distribution and temporal aspects of COX-2 expres-
sion have been well characterized in the hippocampus after
transient but not permanent forebrain ischemia [25,37,44].
The enzyme was suggested to promote neuronal death
because selective COX-2 inhibitors could prevent ischemic
injury in the hippocampus and other brain areas [13,37,42].
In our permanent cerebral hypoperfusion model, the pattern
of COX-2-positive neurons in the hippocampal CA3 and
DG appeared to be very similar to that seen with in situ
hybridization 3–4 days postischemia, following 5–20 min
global ischemia–reperfusion [25,37]. However, the labeling
was also present in SHAM animals in our studies as well as
other studies [37]. Thus, the data here strongly support the
assumption that the acute onset of ischemia rather than
chronic cerebral hypoperfusion or neuroinflammation is the
condition that induce neuronal COX-2 expression. Further-
more, we detected a drop in COX-2-positive neuron density
in the DG inner granular cells in untreated 2VO rats, which
was not accompanied by altered COX-2 expression in
surviving cells. Because COX-2 had been expected to be
upregulated in ischemia, the lower number of labeled
neurons compared to SHAM control might indicate neuro-
nal death in the COX-2 producing cell population. Both
DMSO and DMSO+DZ treatments prevented neuronal loss
to an equal degree, which suggests that DMSO administra-
tion was sufficient to preserve neuronal integrity in the DG.
We found reduced astrocytic proliferation in 2VO rats,
which corresponds with a previously described dynamics of
astrocytic reaction in the 2VO model. In transient 2VO, no
change was detected in astrocyte number up to 2 weeks in
case of a 5-min occlusion, but a gradual degeneration and
loss of GFAP-positive astrocytes were seen with the longer
duration of the ischemic period or survival time [57].
Because our samples were obtained 3 months after the onset
of permanent 2VO, the decline of GFAP signal could be due
to a similar, progressive loss of astrocytes. Such degenera-
tion of astrocytes can have serious functional consequences
because an interaction between astrocytes, neurons and the
cerebral microcirculation is essential to maintain neural
energy metabolism and synaptic plasticity [3–5].
Finally, microglial activation was remarkably augmented
by 2VO, which could be completely prevented only with
DMSO+DZ, and not with DMSO alone. Microglia acti-
vation is an early response in the neuroinflammatory
reaction to ischemia and was repeatedly detected with
OX-42 immunocytochemistry in the hippocampus during
the acute phase of ischemia [1,38,57]. However, there is no
clear data on microglial reaction in chronic cerebral hypo-
perfusion models. Our results here show that microglial
activation persists over a long period of time after the onset
of chronic ischemia, which may suggest an ongoing neuro-
inflammatory process that accompanies chronic cerebral
hypoperfusion.
Microglia may serve as part of regenerative processes by
scavenging necrotic tissue, but can also promote delayed
neuronal damage by generating cytotoxic agents, such as
proinflammatory cytokines [27,56]. Consequently, the lower
activation state of microglia due to DMSO+DZ in our
study may be interpreted in two alternative ways. The
treatment may have confined neuronal damage that would
recruit microglia to clean up necrotic debris. On the other
hand, microglia activation itself could have been directly
inhibited, which would implicate delayed neuroprotection
via the restricted production of cytotoxic compounds. We
believe the latter is more probable because neuronal damage
that recruits microglia is an early event in stroke, and our
samples were obtained 3 months after the onset of ischemia.
Because DMSO+DZ limited microglia activation but
DMSO alone did not, this effect can be attributed specifi-
cally to diazoxide. The beneficial action of diazoxide on
neurons and astrocytes has been studied in detail [12,31,48],
but no such data is available on microglia. Therefore, these
findings may trigger further experiments to identify through
which pathways diazoxide can alter microglial activation,
and how exactly it may contribute to the outcome of
ischemic insults.
Based on our data, we have no direct evidence as to the
exact mechanism of DMSO and diazoxide that was respon-
sible for the improvement of behavior and neuronal integ-
rity. Yet, we speculate that the two agents achieved
neuroprotection through different, but to some extent com-
plementary pathways. DMSO has long been proposed to be
protective against ischemia by antagonizing platelet aggre-
gation and platelet-related vasoconstriction, or by neutraliz-
ing hydroxyl radicals [9,22]. Conversely, diazoxide has
recently come to the focus for mimicking ischemic precon-
ditioning by selectively opening mitochondrial KATP chan-
nels [58]. Therefore, the target of DMSO could be the
cerebral microcirculation, while diazoxide probably acted
directly on neural compartments.
In spite of its known pharmacological actions, DMSO is
frequently used as a solvent for diazoxide [17,29]. Based on
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our results, and because DMSO itself is a potent neuro-
protective chemical, an alternative method (e.g., NaOH and
saline) is recommended to dissolve diazoxide in future
studies designed for the investigation of neuroprotection
through KATP channel opening.
Finally, diazoxide in this study was used unconvention-
ally as a posttraumatic agent. Diazoxide is usually applied as
pretreatment before CNS insults because the drug is known
to mimic the effects of ischemic preconditioning [12,31,
35,53]. Our data that diazoxide (dissolved in DMSO) can be
potentially neuroprotective given in a posttraumatic manner
may open up new possibilities as to the therapeutic appli-
cation of the drug.
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Abstract
Aging and dementia are accompanied by cerebral white matter (WM) injury, which is considered to be of ischemic origin. A causal link
between cerebral ischemia and WM damage has been demonstrated in rats; however, few attempts appear to have been made to test potential
drugs for the alleviation of ischemia-related WM injury.
We induced cerebral hypoperfusion via permanent, bilateral occlusion of the common carotid arteries of rats. A mitochondrial ATP-sensitive
potassium channel opener diazoxide (5 mg/kg) or its solvent dimethyl sulphoxide (DMSO) was administered i.p. (0.25 ml) on 5 consecutive
days after surgery. Sham-operated animals served as control for surgery, and non-treated rats as controls for treatments. Thirteen weeks after
surgery, the animals were sacrificed and astrocytes and microglia were labeled immunocytochemically in the internal capsule, the corpus
callosum and the optic tract.
The astrocytic proliferation was enhanced by cerebral hypoperfusion in the optic tract, and reduced by diazoxide in DMSO, but not by
DMSO alone in the corpus callosum. After carotid artery occlusion, microglial activation was enhanced two-fold in the corpus callosum and
four-fold in the optic tract. DMSO decreased microglial activation in the optic tract, while diazoxide in DMSO, but not DMSO alone, restored
microglial activation to the control level in the corpus callosum.
In summary, the rat optic tract appeared to be particularly vulnerable to ischemia, while the effect of diazoxide was restricted to the corpus
callosum. We conclude that diazoxide dissolved in DMSO can moderate ischemia-related neuroinflammation by suppressing glial reaction in
selective cerebral WM areas.
© 2004 Elsevier Ireland Ltd. All rights reserved.
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Cerebral white matter lesions have been associated with the
progression of aging and cognitive impairment [2,4]. Further,
these lesions have been suggested to originate from a vari-
ety of vascular causes ranging from hypertension to cerebral
microinfarcts and ischemia [5,7]. To support the ischemic the-
ory of white matter injury, experimental animal models have
been employed, such as bilateral occlusion of the common
carotid arteries of rats [8,17,18]. The findings of such studies
have compellingly demonstrated that chronic cerebral hypop-
∗ Corresponding author. Tel.: +36 62 545 669; fax: +36 62 545 707.
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erfusion can initiate a wide array of neuropathological white
matter changes. For instance, axonal degeneration, myelin
and oligodendrocyte damage, astrogliosis and microglial ac-
tivation have been identified in the optic tract and the corpus
callosum of rats with occluded carotid arteries [8,17,18]. Our
own results emphasized the specific involvement of the optic
tract in ischemic white matter damage in the rat brain, and
pointed to the marked proliferation of the astrocytes and to
the activation of the microglia in the region [8].
A number of pharmacological compounds have been con-
sidered to alleviate neuronal damage after ischemic insults
in the brain, but not too much is known about the pos-
0304-3940/$ – see front matter © 2004 Elsevier Ireland Ltd. All rights reserved.
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sible means of limiting ischemia-related white matter in-
jury. A couple of studies have demonstrated that nimesulide,
a cyclooxygenase-2 inhibitor, and ibudilast, a phosphodi-
esterase inhibitor succesfully limited white matter injury in
the ischemic rat brain shortly after carotid artery occlusion
[19,20].
We have recently demonstrated the neuroprotective effect
of diazoxide and its solvent dimethyl sulphoxide (DMSO) in
chronic experimental cerebral hypoperfusion [9]. Diazoxide
is a putative, mitochondrial ATP-sensitive potassium channel
opener [1] that has proved to be neuroprotective in several
ischemia models. For example, pretreatment with diazoxide
reduced infarct size after middle cerebral artery occlusion
in experimental animals [12,16], and preserved the neuronal
viability in cell cultures after glucose–oxygen deprivation
[11]. Our previous study has predominantly demonstrated
that diazoxide cannot only act on neurons but also pre-
vents ischemia-induced, long-term microglial activation
[9]. On the other hand, its solvent DMSO is itself also
known to possess vascular and neuroprotective properties
[9,14].
In the present study, we set out to evaluate the poten-
tial protective effects of diazoxide and DMSO on the glial
compartments of the cerebral white matter in a rat model of
chronic cerebral hypoperfusion.
The experiments were approved by the ethical committee
of the University of Szeged, Hungary. Fifty-one male Wistar
rats (210± 10 g) were anesthetized with 400 mg/kg chloral
hydrate i.p., followed by 0.05 ml atropine i.m. Experimental
cerebral hypoperfusion was induced by permanent, bilateral
occlusion of the common carotid arteries (2VO) in 26 animals
[9]. The same surgical procedure was performed in the control
group (SHAM), but without the actual ligation. The survival
rate was 78.4%.
Both groups were divided into three subgroups (n= 6) on
the basis of the postsurgical treatment, as described earlier
[9]. The first set of animals was treated with 5 mg/kg diazox-
ide given in 0.25 ml DMSO, i.p. (SHAM-DMSO + DZ, 2VO-
DMSO + DZ). The second set of animals of both SHAM and
2VO groups received 0.25 ml DMSO, i.p. (SHAM-DMSO,
2VO-DMSO, respectively). The last set of animals received
no postoperative treatment and served as controls (SHAM-
non-treated, 2VO-non-treated). The animals were injected
on 5 consecutive days in the initial phase of cerebral hy-
poperfusion. The first injection was applied directly after
surgery.
Thirteen weeks later, the animals were anesthetized with
an overdose of pentobarbital, and perfused transcardially with
100 ml saline, followed by 400 ml 3.5% paraformaldehyde
and 0.5% picric acid in 0.1 M phosphate buffer (PB, pH 7.4).
The brains were removed, and one hemisphere was post-fixed
in the fixative solution for up to 1 h.
Immunocytochemical staining was performed as de-
scribed earlier [8]. Briefly, free-floating coronal sections
at Bregma −3.14 mm were cut at 20m thickness on a
cryostat microtome. Slices were stained immunocytochem-
ically for glial fibrillary acidic protein (GFAP) to visual-
ize astrocytic proliferation. The samples were incubated
in a primary antibody solution containing mouse anti-
GFAP antibody (Sigma), 1:200, 1% normal sheep serum,
and 0.3% Triton X-100 in 0.01 M PBS. The secondary
antibody solution consisted of sheep anti-mouse biotiny-
lated IgG (Jackson), 1:200, and 0.3% Triton X-100 in
0.01 M PBS. Finally, the sections were incubated in HRP-
Streptavidine (Zymed), 1:200, and the color reaction was
conventionally developed with diaminobenzidine (DAB)
and H2O2.
Microglial activation was visualized over the white mat-
ter areas with the cell surface marker CD11b (OX-42). The
sections were incubated in a primary antibody solution con-
taining biotinylated mouse anti-CD11b antibody (OX-42,
Serotec), 1:500, 20% normal swine serum (NSS), and 0.03%
merthiolate in 0.01 M PBS. Next, the sections were incubated
in a solution of STA-PER (Jackson), 1% NSS, and 0.03%
merthiolate in 0.1 M Tris buffer. Finally, the color reaction
was developed by nickel-DAB and H2O2.
The percentage surface area of GFAP-positive astrocytes
was quantified in the medial corpus callosum and the in-
ternal capsule; in the optic tract, relative optical density
was computed instead of the percentage area, since the ho-
mogenous labeling did not permit area measurements. As
regards the OX-42 labeling, the percentage surface area was
measured for all three regions of interest (Olympus BX50,
DP50, software: ImagePro Plus, Media Cybernetics). As in
our previous protocol [8], three consecutive coronal sections
were selected for analysis. Regions of interest were delin-
eated manually at 10× magnification. The area covered by
GFAP-or OX-42-positive glia was computed as a percent-
age of the total area delineated. The measured results on
the three sections per animal were averaged and the aver-
age values were used for further statistical analysis. The data
were analyzed by a two-way ANOVA model of the software
SPSS.
The internal capsule was unaffected by either cerebral hy-
poperfusion or the pharmacological treatment.
In the medial corpus callosum, astrocyte proliferation was
not enhanced by cerebral hypoperfusion, but the postsurgi-
cal treatment, particularly with diazoxide, reduced the area
covered by GFAP-positive processes by 33% in both SHAM
and 2VO groups (Fig. 1A–C). The microglial activation in
the corpus callosum displayed a tendency to be elevated due
to cerebral hypoperfusion; this was manifested as a 56% in-
crease in the non-treated 2VO group compared with the non-
treated SHAM group. The solvent DMSO did not change
this tendency; however, diazoxide treatment restored the mi-
croglial activation in the 2VO animals to the control level
(Fig. 1D–F).
The optic tract was the most clearly affected by cere-
bral hypoperfusion. The astrocytic proliferation was con-
sistently increased by about 20% in the 2VO groups as
compared with their respective SHAM controls, regardless
of pharmacological treatment (Fig. 2A–C). Similarly, the
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Fig. 1. Corpus callosum: photomicrographs and quantitative data on GFAP-
positive astrocytic proliferation and OX-42-positive microglial activation.
Panels A and B: Representative microscopic images of GFAP immunola-
beling; original magnification: 10×. Panel C: Quantitative data on astrocytic
proliferation; **P< 0.01. Panels D and E: Representative microscopic images
of OX-42 immunolabeling; original magnification: 10×. Panel F: Quanti-
tative data on microglial activation. Abbreviations: 2VO: bilateral carotid
artery occlusion, am: amygdala complex, cc: corpus callosum, ctx: cerebral
cortex, DMSO: dimethyl sulphoxide, DZ: diazoxide, hpc: hippocampus,
SHAM: sham-operated control, th: thalamus.
microglial activation was markedly enhanced in the non-
treated 2VO group as compared with the corresponding
SHAM group, but both DMSO and diazoxide restored the
microglial activation in the 2VO animals to the SHAM level
(Fig. 2D–F).
Thus, both cerebral hypoperfusion and the pharmacolog-
ical treatment elicited region-specific changes in astrocyte
proliferation and microglial activation. The optic tract was
predominantly vulnerable to cerebral hypoperfusion, while
diazoxide dissolved in DMSO preferentially exerted an ef-
fect in the corpus callosum.
The findings reported here primarily confirm our previous
observation that chronic cerebral hypoperfusion leads to as-
trocytic proliferation and microglial activation, specifically
in the optic tract [8]. As noted earlier, the varying degree of
blood supply to the different white matter areas in the rat brain
may be responsible for the regional specificity, the optic tract
receiving a direct branch of the internal carotid artery orig-
inating bellow the level of the circle of Willis [15], which
Fig. 2. Optic tract: photomicrographs and quantitative data on GFAP-
positive astrocytic proliferation and OX-42-positive microglial activation.
Panels A and B: Representative microscopic images of GFAP immunola-
beling; original magnification: 10×. Panel C: Quantitative data on astrocytic
proliferation; *P< 0.05. Panels D and E: Representative microscopic images
of OX-42 immunolabeling; original magnification: 10×. Panel F: Quanti-
tative data on microglial activation; *P< 0.05, **P< 0.01. Abbreviations:
2VO: bilateral carotid artery occlusion, am: amygdala complex, ctx: cere-
bral cortex, DMSO: dimethyl sulphoxide, DZ: diazoxide, hpc: hippocampus,
ic: internal capsule, SHAM: sham-operated control, th: thalamus.
makes flow compensation to the optic tract after common
carotid artery occlusion improbable.
The pharmacological treatment applied here also ap-
peared to exert region-specific effects. Diazoxide dissolved
in DMSO reduced the astrocytic proliferation in the corpus
callosum, but not in the optic tract, regardless of the degree
of cerebral perfusion. Diazoxide in DMSO also decreased
the ischemia-induced microglial activation specifically in the
corpus callosum, but not in the optic tract. The pattern of mi-
croglial activation in the corpus callosum, with or without
drug treatment, appeared to be very similar to that previously
seen in the adjacent hippocampus [9].
There can be many reasons why diazoxide detectably at-
tenuated the glial reaction only in the corpus callosum of
the three white matter areas investigated. In the case of mi-
croglial activation, DMSO could possibly obscure the effect
of diazoxide in the optic tract, but not in the corpus callosum,
and it could be DMSO rather than diazoxide that differen-
tially affected the various white matter areas. Conversely, the
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different reactions of the astrocytes in the examined white
matter regions to diazoxide treatment may stem from the
region-specific sensitivity/composition of the mitochondrial
and surface cation channels of the astrocytes, as detailed be-
low.
The mechanism behind the action of diazoxide on the as-
trocytes is a matter of debate. When cultured astrocytes were
incubated with diazoxide, loss of mitochondrial membrane
potential, an elevated free radical production, and protein ki-
nase C activation were observed. These results suggested that
mitochondrial ATP-sensitive potassium channels served as
the target for diazoxide in the astrocytes [13]. On the other
hand, another recent investigation has revealed the possibil-
ity that ATP-sensitive non-selective cation channels on the
surface of reactive astrocytes could be regulated by sulfony-
lurea receptor-1, which is the site of action of diazoxide [3].
These data suggest that diazoxide can target both mitochon-
drial and surface cation channels on the astrocytes, thereby
modulating the astrocytic function, which could explain our
present data.
Very little is known about the effect of diazoxide on
the microglia. We published the first report that diazox-
ide dissolved in DMSO may suppress ischemia-related mi-
croglial activation in the rat hippocampus [9]. Our present
data reveal a similar tendency in the corpus callosum. Al-
though the resting/active state of the microglia is defined
by the cell surface potassium, proton and chloride channels
[6,10,21], there is no experimental evidence that demon-
strates whether sulfonylurea receptors (the target of dia-
zoxide) play a role in the regulation of these ion channels.
It is not clear either how the binding of diazoxide to the
mitochondrial ATP-sensitive potassium channels can alter
the microglial activity, since no direct causal link has been
established between mitochondrial function and microglial
activity. The intracellular pathways of the effects of dia-
zoxide on the microglial functions therefore remain to be
clarified.
In summary, the present results indicate that pharmacolog-
ical intervention can attenuate ischemia-related white matter
injury. The diazoxide and DMSO treatment applied here was
specifically effective in suppressing glial reactivity. Such at-
tenuation of astrocytic proliferation and microglial activa-
tion tends to weaken the ischemia-induced neuroinflamma-
tory responses, and prevent the progression of white matter
lesions.
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Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Dis-
orders
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Abstract: Diazoxide, a mitochondrial ATP-dependent K + channel opener has been investigated as a potential anti-
ischemic agent in the brain. The neuroprotective effect of diazoxide has emerged from in vitro  experiments employing
brain slices and neuronal cell cultures. The intracellular mechanisms that are responsible for the neuroprotective properties
of diazoxide have also been identified in cell cultures and isolated mitochondria. Thus, diazoxide has been shown to de-
polarize mitochondria, preserve mitochondrial matrix volume, block cytochrome C release and Bax translocation, activate
protein kinase C and facilitate the production of reactive oxygen species, which lead to enhanced cell viability and pre-
serve electrophysiological properties of neurons after oxygen and glucose deprivation.
Recently, diazoxide has been administered to experimental animals to examine the drug’s effect on the ischemic brain.
Various animal models of ischemic cerebrovascular disorders such as ischemia/reperfusion injury, stroke and chronic
cerebral hypoperfusion were used to evaluate the neuroprotective properties of diazoxide in vivo. The results of numerous
studies demonstrate that diazoxide limits infarct size after middle cerebral artery or unilateral carotid artery occlusion in
rodents, preserves cerebrovascular function in newborn piglets, and reduces the activation of microglia after permanent,
bilateral common carotid artery occlusion in rats.
This review provides a comprehensive summary of the experimental data on the neuroprotective effects of diazoxide in
animal models. This overview may facilitate drug development in this field.
Keywords: Brain, cerebral hypoperfusion, diazoxide, ischemia, K+-channel, mitochondria, stroke.
INTRODUCTION
Cerebrovascular disorders represent a major group of
neurological diseases, which considerably impair the quality
of life and pose a substantial burden to society and to the
health care system. Ischemia/reperfusion injury, stroke, vas-
cular dementia and chronic cerebral hypoperfusion are
among the most common cerebrovascular disorders, which
are often accompanied by the degeneration of the nervous
tissue, resulting in the loss of executive function and cogni-
tive deficits. Although intensive research has focused on the
development of drugs to prevent the progression of cere-
brovascular diseases and to alleviate the associated symp-
toms, the medications at our disposal are often not potent
enough to limit neuronal damage successfully and to restore
health.
Medical treatments for chronic cerebral hypoperfusion
have targeted the vasoregulatory circuits in the brain (cho-
linergic transmission, nitric oxide-cGMP mediated vasodila-
tion) and hemorheological parameters (blood viscosity,
platelet aggregation) in order to improve cerebral blood flow
[1]. In the management of stroke, L-type calcium channel
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antagonists, for example nimodipine emerged as promising
chemicals to prevent intracellular calcium overload and con-
sequent neuronal death [2,3], but the results of the clinical
trials were inconclusive [4]. Recently, mitochondria have
received increasing attention as a potential target of therapy
that aims to preserve neural integrity and function after an
ischemic insult or under chronic ischemic conditions.
Mitochondria play a pivotal role in the energy metabo-
lism (ATP production) and in the regulation of cellular Ca 2+
homeostasis in the central nervous system [5]. Under cere-
bral ischemic conditions, mitochondrial dysfunction is con-
sidered a central event in neuronal and astrocytic injury [6, 7,
8]. Glucose and oxygen deprivation of the nervous tissue
leads to the disruption of the mitochondrial respiratory chain,
the rapid depletion of ATP, the elevated concentration of
Ca2+ in the mitochondrial matrix, the release of cytochrome
C from the mitochondria and the generation of reactive oxy-
gen species [8,9]. These mitochondria-related pathogenic
processes initiate necrotic or apoptotic cell death in the
ischemic brain [10]. Therefore mitochondria emerge as a
potential target for the prevention of ischemic neural injury.
In order to protect mitochondria in cerebral ischemia,
various approaches have been considered. For example,
blocking the mitochondrial permeability transition pore can
inhibit apoptotic pathways. The use of specific drugs such as
cyclosporin-A (and its analogs) and rasagiline (N-propargyl-
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1R-aminoindan) exploits this possibility [11, 12]. Another
target for mitochondrial protection is the activation of ion
channels, such as the mitochondrial, ATP-sensitive potas-
sium channels (mitoKATP channels). We present an overview
of the efforts to protect mitochondrial function in cerebral
ischemia by activation of the mitoKATP channels.
MITOCHONDRIAL ATP-SENSITIVE POTASSIUM
CHANNELS AND THEIR ROLE IN ISCHEMIA
MitoKATP channels are located in the inner mitochondrial
membrane. Although the exact molecular composition of
mitoKATP channels has not been definitively determined,
mitoKATP channels in the brain are presently known to con-
stitute four pore-forming subunits (probably the inwardly
rectifying potassium channel subunits K IR6.1 and K IR6.2),
and four regulatory subunits (members of the sulphonylurea
receptor family, supposedly the SUR2 type) (Fig. 1) [8, 13,
14, 15].
In general, the primary, endogenous regulator of K ATP
channels on the cell surface appears to be the ratio of
ATP/ADP, which can stabilize the closed state of the chan-
nel if the ATP concentration is high, or to enable the opening
of the channel if ADP concentration increases [16,17]. How-
ever, the opening of mitoK ATP channels may be subjected to
other or additional regulatory mechanisms. Under physio-
logical circumstances, the mitoK ATP channels are closed due
to the high concentration of ATP, which also requires the
presence of Mg 2+. In addition to ATP and ADP, long-chain
acyl-CoA esters have been demonstrated to inhibit mitoK ATP
channels [18,19]. In turn, the inhibited mitoK ATP channels
can be opened by other nucleotide phosphates, such as GTP
and GDP [19]. Finally, protein kinase C and G have also
been suggested as regulators or modulators of mitoK ATP
channels [20, 21, 22].
During ischemia, potassium influx through the mitoK ATP
channels primarily prevents contraction of the matrix and
preserves the intermembrane space, which is essential for the
proper function of the respiratory chain (Fig. 2) [23]. How-
ever, opening of mitoK ATP channels under physiological
conditions leads to mitochondrial matrix alkalization and the
generation of reactive oxygen species. Therefore, mitoK ATP
channels play a significant role in maintaining mitochondrial
function under ischemic conditions and, consequently, pro-
tect cells against ischemic injury. These properties serve as
the basis for ischemic preconditioning that can be achieved
by the activation of the mitoKATP channels [8, 24].
Ischemic preconditioning by mitoKATP channel activation
has been widely investigated as a cardioprotective strategy
[23, 25, 26]. Interestingly, mitochondria extracted from the
brain have been found to contain six to seven times more
mitoKATP channels than cardiomyocytes [21]. This finding
indicates that the mitoK ATP channels may have an accentu-
ated functional significance in the brain, and may serve as an
appropriate target of neuroprotective strategies in cere-
brovascular disorders.
DIAZOXIDE, A MITOCHONDRIAL ATP-SENSITIVE
POTASSIUM CHANNEL OPENER
At present, several exogenous ligands have been identi-
fied that activate K ATP channels. A group of these agents is
non-selective, and can open both surface K ATP channels and
mitoKATP channels. The most prominent, vasorelaxant mem-
bers of this group are cromakalim and its analogs [27], ni-
corandil, which also has a nitrate-like effect [28] and iptaka-
Fig. (1).  The hypothetical, structural organization of the mitoK ATP channels in the inner mitochondrial membrane, and the putative binding
sites of diazoxide. One regulatory subunit is presented to the left, while a pore-forming subunit is indicated to the right. Four regulatory and
four pore-forming subunits constitute a functional, heteromeric, octameric complex [14,16]. Indicated by an asterisk in the schematic image,
succinate dehydrogenase has recently been suggested as a possible component of mitoK ATP channels [24]. Abbreviations: C: C-terminus,
DIAZ: diazoxide, K IR: inwardly rectifying pore-forming channel subunit, M1 & M2: transmembrane helices, N: N-terminus, SUR: sulphon-
ylurea regulatory subunit of the ABC family, TMD: transmembrane domain.
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lim, which preferably acts on small arteries and produces
neuroprotection in ischemic stroke [29,30]. Currently, the
most widely-accepted K ATP channel opener regarded to be
specific for the mitoK ATP channels is the benzothiadiazine
diazoxide (though a novel drug designated as BMS-191095
appears at least as potent as diazoxide [31, 32]).
As a consequence of their different subunit composition,
diazoxide applied at a low concentration has been reported to
have a greater affinity for the mitoK ATP channels than to the
cell surface K ATP channels, [8, 16]. Diazoxide opens the mi-
toKATP channels probably by binding to the SUR regulatory
subunit of the channel (Fig. 1), which is facilitated by ADP
[16]. The action of diazoxide can be abolished by the puta-
tive mitoKATP channel inhibitor 5-hydroxydecanoate (5-HD)
[33]. This pharmacological property is considered as evi-
dence that diazoxide is a specific mitoK ATP channel opener.
However, some other studies have challenged the view that
diazoxide acts exclusively on mitoK ATP channels (e.g. dia-
zoxide opens surface K ATP channels at sufficiently high con-
centration, and can inhibit succinate dehydrogenase) [34, 35,
36, 37], which complicates the interpretation of the physio-
logical responses obtained with the compound.
Diazoxide was first used in clinical practice in hyperten-
sive emergencies [38, 39]. At high concentrations, the drug
acts on cell surface KATP channels of vascular smooth muscle
cells and causes vasodilation by reducing the intracellular
Ca2+ concentration [40]. Another important field of applica-
tion of diazoxide has been the treatment of hyperinsulinemia.
Diazoxide has been shown to inhibit insulin release from
pancreatic beta cells and therefore to exert a beneficial effect
as an anti-hypoglycemic agent [41, 42, 43]. In addition, rap-
idly progressing research has been conducted on the role of
diazoxide in cardiac ischemic preconditioning [33, 37].
These studies demonstrated that diazoxide protects cardiac
muscle in ischemia by acting on the mitoK ATP channels and
consequently, preserves mitochondrial function and cell in-
tegrity [25, 26, 44]. For its well-characterized, preventive
action in cardiac ischemia, diazoxide has become the focus
of recent investigations as a potential anti-ischemic agent in
the brain.
THE NEUROPROTECTIVE EFFECTS OF DIAZ-
OXIDE DEMONSTRATED IN VITRO
The use of neuronal and astrocytic cell cultures and brain
slices provided evidence that diazoxide can effectively pro-
tect nervous tissue against ischemic insults. In cell cultures,
unfavorable conditions that cause cell death were created by
either glutamate exposure or oxygen-glucose deprivation.
Diazoxide preserved the viability of cells in both of these
models of ischemic cell injury [36, 45, 46, 47]. Another ap-
proach examined the effect of diazoxide on oxidative neuron
injury, a pathological component of cerebral ischemia. In
this study, diazoxide successfully increased hippocampal
neuronal survival in a toxic oxidative environment created
by exposure to FeSO4 and b-amyloid peptide [48].
Similarly, in hippocampal and cortical slices exposed to
hypoxic/ischemic conditions, diazoxide prevented cell dam-
age. A major advantage of experimenting with brain slices is
that the neural circuits are partially intact, which enables
electrophysiological recordings. In such an experimental
setup, diazoxide prolonged the latency of ischemic depolari-
zation and depressed hypoxia-induced depolarization [49,
Fig. (2). The theoretical regulation and the consequences of the opening of the mitoK ATP channels; pathways leading to ischemic precondi-
tioning. Abbreviations: DIAZ: diazoxide, mitoKATP channel: mitochondrial, ATP-sensitive potassium channel.
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50, 51, 52]. Furthermore, diazoxide blocked the anoxic de-
polarization in rat CA3 hippocampal neurons exposed to
anoxic episodes [53].
The neuroprotective effect of diazoxide has been associ-
ated with the state of the mitochondria and certain intracel-
lular signaling pathways. For example, diazoxide depolar-
ized mitochondria, abolished mitochondrial swelling, and
prevented Ca2+ accumulation in the mitochondrial matrix in
neurons under ischemic conditions, which maintain the
proper function of the respiratory chain (Fig. 2) [54, 55].
Furthermore, diazoxide inhibited cytochrome C release from
the mitochondria and increased the production of reactive
oxygen species in neuronal cell cultures [46, 54]. Others
observed the activation of protein kinase C due to treatment
of cultured neurons with diazoxide [36]. Diazoxide has also
been shown to induce anti-apoptotic signaling such as the
association of Bcl-2 protein with mitochondria and the pre-
vention of Bax translocation [54]. Finally, the inhibition of
succinate dehydrogenase, a mitoK ATP channel-independent
action of diazoxide was identified in cultured neurons [36].
A few of these intracellular effects of diazoxide, for ex-
ample the generation of reactive oxygen species may seem
controversial, since reactive oxygen species are known to
attack phospholipid membranes. Yet, in healthy cells, a
moderately enhanced production of free radicals can play an
important role in ischemic preconditioning by possibly in-
creasing the levels or the capacity of scavenging enzymes.
Therefore a transient or moderate elevation of the production
of reactive oxygen species by diazoxide is considered as
pharmacological preconditioning [8].
In summary, the experimental evidence obtained in vitro
support the concept of the neuroprotective capacity of dia-
zoxide, and encourage the testing of diazoxide in in vivo
models of cerebral ischemia.
Table 1. Experimental Models for Cerebrovascular Disorders to Assess the Neuroprotective Effect of Diazoxide
Cerebrovascular Disorder Animal Model Species Age Reference
Rat Adult Farkas et al. Brain Res., 2004 [63]
Rat Adult Farkas et al. Neurosci. Lett., 2005 [64]
Chronic, global cerebral hypop-
erfusion
Permanent, bilateral common
carotid artery occlusion
Rat Adult Farkas et al. Neurosci. Lett., 2005 [65]
Transient, bilateral common
carotid artery occlusion
Mouse Adult Munoz et al. Stroke, 2003 [62]
Piglet Newborn Domoki et al. Stroke, 1999 [56]
Piglet Newborn Domoki et al. Brain Res., 2004 [57]
Transient, global ische-
mia/reprefusion
Increased intracranial pressure
Piglet Newborn Domoki et al. Am. J. Physiol. Heart Circ.
Physiol., 2005 [58]
Mouse Adult Liu et al. J. Cereb. Blood Flow Metab., 2002 [54]Transient forebrain ische-
mia/reperfusion
Transient, unilateral middle
cerebral artery occlusion
Rat Adult Shimizu et al. Am. J. Physiol. Heart Circ.
Physiol., 2002 [61]
Transient, global ische-
mia/reperfusion + arterial hy-
potension
Transient, bilateral common
carotid artery occlusion + blood
withdrawal through the femoral
vein
Rat Adult Lenzsér et al. Brain Res., 2005 [67]
Rat 7 days old Rajapakse et al. Neurosci. Lett., 2002 [55]Hypoxic-ischemic brain injury Permanent, unilateral common
carotid artery occlusion + hy-
poxia Rat 7 days old Jiang et al. Mol. Brain Res., 2005 [59]
Hypoxic brain injury Hypothermic circulatory arrest Dog Adult Shake et al. Ann. Thorac. Surg., 2001 [60]
Venous ischemia Cerebrocortical vein occlusion
+ KCl-induced spreading de-
pression
Rat Adult Nakagawa et al. Neurosurg., 2005 [71]
Transient spinal cord ischemia Transient aorta occlusion near
the renal artery takeoff
Rabbit Adult Caparrelli et al. Ann. Thorac. Surg., 2002 [84]
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THE NEUROPROTECTIVE EFFECTS OF DIAZ-
OXIDE IN EXPERIMENTAL ANIMAL MODELS
So far, 16 reports have presented data on the neuropro-
tective capacity of diazoxide in animal models of cere-
brovascular disorders. The comparison and summary of
these studies requires careful inspection, because the ex-
periments were performed with different species, at different
ages of the animals, and with different routes of drug ad-
ministration (Tables 1 and 2). Furthermore, several cere-
brovascular disorder models were used, and various end
points were examined (Tables 1 and 3). Still, the demonstra-
tion of the neuroprotective property of diazoxide is common
in these studies, and the diversity of models strengthens the
conclusion that diazoxide limits the neurodegenerative proc-
esses of cerebrovascular origin.
The studies follow two lines of investigation based on the
clinical condition they reproduce. In newborn or neonatal
animals, diazoxide was administered with the intent to pre-
vent the neural consequences of perinatal ischemia/hypoxia
[55, 56, 57, 58, 59]. In other investigations, the neuroprotec-
tive actions of diazoxide were examined in adult animals
with age-associated cerebral ischemic conditions, such as
ischemic stroke or chronic cerebral hypoperfusion
[54,60,61,62,63,64,65,66,67].
Perinatal Hypoxia/Ischemia
Perinatal hypoxia/asphyxia occurs frequently during
complicated deliveries, and can directly lead to ischemic
brain damage. However, the subsequent impairment of cere-
brovascular function (e.g. impaired regulation of cerebral
blood flow) can indirectly contribute to a poor neurological
outcome, as well [68]. The neuroprotective strategies in-
volving diazoxide focused on two aspects of perinatal
ischemic brain injury. One group of studies examined cere-
brovascular reactivity (the regulation of cerebral blood flow),
while others aimed to investigate the nervous tissue itself.
Table 2. The Various Applications of Diazoxide in Experimental Animal Models
Pre- or Post-
Treatment
Way of Administra-
tion
Concentration Solvent Reference
i.p., bolus 1.9 or 3.8 mg/kg, 100
ml
buffered saline Rajapakse et al. Neurosci. Lett., 2002 [55]
i.p., repeated 6, 20 or 40 mg/kg n.d. Lenzsér et al. Brain Res., 2005 [67]
5 mg/kg saline Caparrelli et al. Ann. Thorac. Surg., 2002 [84]
5 mg/kg n.d. Liu et al. J. Cereb. Blood Flow Metab., 2002 [54]
3 mg/kg saline Domoki et al. Brain Res., 2004 [57]
i.v., bolus
3 mg/kg saline Domoki et al. Am. J. Physiol. Heart Circ. Physiol.,
2005 [58]
0.4 or 2.0 mM; 30ml n.d. Shimizu et al. Am. J. Physiol. Heart Circ. Physiol.,
2002 [61]
0.1 mM/l; 4 ml aCSF Munoz et al. Stroke, 2003 [62]
i.c.v., bolus
2 mmol/l, 15 m l 0.1 mol/l NaOH Nakagawa et al. Neurosurg., 2005 [71]
Pre
brain superfusion 1, 5 or 10 mM/l aCSF Domoki et al. Stroke, 1999 [56]
i.c.v., bolus 1 mg/ml; 5 m l aCSF Jiang et al. Mol. Brain Res., 2005 [59]Pre- or post
i.p., bolus and repeated 5 or 0.5 mg/kg 1N NaOH Farkas et al. unpublished ms, 2005 [66]
Pre- and post i.v., bolus + continuous
infusion
15 mg/kg + 0.5 mg/min Shake et al., Ann. Thorac. Surg., 2001 [60]
5 mg/kg; 0.25 ml DMSO Farkas et al. Brain Res., 2004 [63]
5 mg/kg; 0.25 ml DMSO Farkas et al. Neurosci. Lett., 2005 [64]
Post i.p., repeated
0.5 mg/kg; 0.25 ml 1N NaOH Farkas et al. Neurosci. Lett., 2005 [65]
Abbreviations: aCSF: artificial cerebrospinal fluid; DMSO: dimethyl sulphoxide; i.c.v.: intracerebroventricular;
i.p.: intraperitoneal; i.v.: intravenous; n.d.: no data
258    Vascular Disease Prevention, 2006, Vol. 3, No. 3 Farkas et al.
In order to characterize cerebrovascular reactivity,
changes in pial arteriolar diameter in response to hypercap-
nia and N-methyl-D-aspartate (NMDA) stimulation were
recorded in newborn piglets with the help of a closed cranial
window and intravital microscopy. In piglets, CO 2-induced
vasodilation requires intact endothelial function [69]. Both
hypercapnia and NMDA elicit vasodilation under physio-
logical circumstances, but these vasodilator responses are
considerably impaired after ischemia/reperfusion (I/R).
When diazoxide was applied before the initiation of I/R, the
vasodilator response to hypercapnia and NMDA stimulation
was preserved [56, 58]. In the case of hypercapnia-induced
vasodilation, a direct effect of diazoxide on endothelial mito-
chondria was suggested to account for the preserved func-
tion. In support of this view, endothelial cells in pial arteri-
oles have been strongly implicated in vasodilation [69].
Furthermore, diazoxide was shown to prevent endothelial
dysfunction after I/R in the human forearm [70], and to re-
duce the mitochondrial membrane potential in cultured piglet
cerebral endothelial cells [58]. In the NMDA model, dia-
zoxide preserved neuronal-vascular function probably via a
reduced production of reactive oxygen species from the mi-
tochondria [56]. These results lead to the conclusion that
diazoxide exerts a beneficial effect on the cerebrovascular
component of perinatal ischemic brain injury.
In addition to cerebrovascular reactivity, treatment with
diazoxide also protects nervous tissue in perinatal hy-
poxia/ischemia. The most conspicuous evidence for the neu-
roprotective effect of diazoxide was provided by the meas-
urement of infarct volume. The 2,3,5-triphenyltetrazolium
chloride (TTC) staining of slices prepared from 7-day old
pup brains demonstrated that diazoxide reduced infarct vol-
ume by about 20%, 24 h after the onset of ischemia [55].
Meanwhile, the activation of an enzymatic mediator of neu-
ronal death, calpain was significantly down-regulated in the
cortex and the hippocampus, together with a decrease in
DNA fragmentation [59]. In addition, the expression of the
immediate-early genes c-Fos and c-Jun, which is highly up-
regulated after ischemia, was depressed by diazoxide [59].
These studies proposed that diazoxide mediated its neuro-
protective effect by acting on the mitoK ATP channels and by
preserving mitochondrial function. This assumption gains
support from the finding that hippocampal mitochondria in
newborn piglets undergo extensive swelling and Ca 2+ accu-
mulation after I/R, which can be completely blocked by dia-
zoxide [57]. Also, in order to prove that diazoxide acted on
the mitoK ATP channels, 5-HD (a mitoK ATP channel antago-
nist) was co-applied with diazoxide in the previously men-
tioned experiments; it abolished the beneficial effect of dia-
zoxide (i.e. infarct volume, mitochondrial swelling) [55,57].
In summary, treatment with diazoxide appears to be a
promising strategy for the management of perinatal ischemic
brain injury with some restrictions (concerning dose, the
route and time of application) discussed below.
Age-Associated Conditions - Transient, Ischemic Stroke
Stroke is a leading cause of mortality and neurological
dysfunction in Western societies, therefore the development
of preventive strategies and effective therapy is very impor-
tant. Diazoxide has been tested in experimental animal mod-
els of transient cerebral ischemia for the last five years. In
these stroke models, I/R was created by the transient occlu-
sion of the common carotid or the middle cerebral arteries of
adult rats and mice. Similar to the studies on perinatal hy-
poxia/ischemia, diazoxide reduced infarct volume assessed
with the TTC staining [54, 61, 67, 71]. Furthermore, dia-
zoxide also decreased the number of TUNEL-positive apop-
totic cells in the infracted hemisphere and prevented cell
death in the hippocampus CA1 area [54,62]. In addition, a
higher number of astrocytes appeared in the peri-infarct area
of diazoxide-treated animals as compared with vehicle-
treated controls [54]. Finally, diazoxide limited the ischemia-
induced dramatic increase in blood-brain barrier permeabil-
ity indicated by the leakage of Evan’s blue and sodium fluo-
rescin into the brain parenchyma, and reduced the water
content of the brain tissue [67].
The co-application of 5-HD with diazoxide abolished the
protective effect of diazoxide in these models [54,61], which
indicates that the mitochondrial mitoK ATP channels were
most probably targeted. Yet, beyond this indication, direct,
in vivo  evidence to explain the exact intracellular mecha-
nisms that lead to neuroprotection in the animal studies is
scarce. Therefore, we must rely on the results of the in vitro
experiments presented above.
Studies on ischemic stroke have emphasized the preven-
tive approach; diazoxide was invariably administered before
the onset of ischemia. The design of the experiments made
use of the widely accepted concept that diazoxide mediates
pharmacological preconditioning. For this reason, particular
clinical conditions or patients at high risk for ischemic brain
damage/stroke should be identified, where preconditioning
the brain with diazoxide would afford prevention against a
later ischemic insult.
Age-Associated Conditions - Chronic Cerebral Hypoper-
fusion
Chronic cerebral hypoperfusion has been recognized as a
cerebrovascular condition that accompanies aging and de-
mentia. Chronically reduced cerebral blood flow has been
associated with cognitive decline and a slow degeneration of
brain tissue [72, 73, 74]. To improve brain perfusion and to
alleviate associated cognitive symptoms, acetylcho-
linesterase inhibitors and acetylcholine release enhancers
were applied to increase the availability of acetylcholine in
the synapses of the cerebral vasodilatory circuits [1]. Also,
dietary supplements such as long-chain polyunsaturated fatty
acids and antioxidants that are involved in the constitution
and protection of phospholipid membranes decreased spatial
learning dysfunction and augmented the state of the blood-
brain barrier in chronic cerebral hypoperfusion [75]. Re-
cently, diazoxide has also been considered as a new candi-
date to moderate the consequences of chronic cerebral hy-
poperfusion.
A widely accepted model of chronic cerebral hypoperfu-
sion is the permanent, bilateral occlusion of the common
carotid arteries in rats (2VO). This model creates a repro-
ducible and consistent spatial learning defect that can be
determined from one week up to a year after surgery [72].
When diazoxide was applied before the onset of 2VO,
learning capacity measured one week after the surgery was
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restored almost to control level [66]. However, post-
treatment with diazoxide failed to improve spatial learning
measured either one week or 13 weeks after 2VO surgery
[65, 66]. These data are in agreement with the known phar-
macological preconditioning effect of diazoxide. According
to the working hypothesis, diazoxide given as pretreatment
most probably caused a transient increase in the level of re-
active oxygen species, which activated their scavenging en-
zymes in the brain. A higher level of the scavenging en-
zymes protected the neural tissue against a subsequent
ischemic insult, which was reflected in the cognitive im-
provement.
In the same experiments, treatment with diazoxide
yielded a mismatched pattern of microglial activation. Pre-
treatment did not affect microglial activation in the hippo-
campus one week after 2VO [66]. In post-treatments, how-
ever, diazoxide delivered paradoxical results. One week after
2VO, cerebral hypoperfusion did not alter microglial activa-
tion as compared with the sham-operated control animals,
but post-treatment with diazoxide given directly after sham
and 2VO surgery augmented the basal level of microglial
activation selectively in the 2VO animals [66]. These find-
ings may demonstrate an adverse effect of the post-treatment
by diazoxide in the 2VO model.
In contrast, 13 weeks after 2VO, cerebral hypoperfusion
enhanced microglial activation compared with the sham-
operated controls, which was prevented by treatment with
diazoxide also administered directly after 2VO surgery [63,
65]. Such a reduction of microglial activation by diazoxide is
considered beneficial. Nevertheless, the interpretation of
these results would be premature at this point, since the ex-
istence and function of mitoKATP channels in microglia, or an
alternative binding site of diazoxide on these cells is yet to
be determined. Still, a few, possible links between microglial
activation and the pharmacological effects of diazoxide may
be contemplated as follows.
Microglial activation involves a distinct pattern of in-
wardly rectifying potassium channels and altered potassium
currents [76, 77], but there is no evidence whether diazoxide
can influence microglial potassium currents. Furthermore,
microglial activation entails distinct mitochondrial changes
reflected in the increased number and elongated shape of
mitochondria [78], but a potential role of mitoK ATP channels
in this process has not been identified, yet. Finally, since the
experiments were performed in vivo,  it is difficult to deter-
mine whether the effect of diazoxide on microglia was direct
or secondary to that achieved on neurons in these studies.
The issues raised here may stimulate more experimental
work to elucidate the action of diazoxide on microglial acti-
vation and to describe its temporal pattern. The use of mi-
croglial cell cultures appears to be an appropriate and prom-
ising tool to this end.
CONSIDERATIONS FOR FUTURE DRUG DEVELO-
PMENT
Based on the presented experimental data, treatment with
diazoxide appears to be a potential strategy for the manage-
ment of ischemic brain injury. For future drug development,
however, a few issues must be considered. First, since the
target of the neuroprotective treatment is the central  nervous
Table 3. Read-Outs Taken to Demonstrate the Neuroprotec-
tive Effect of Diazoxide
Read-Out Reference
Farkas et al. Brain Res., 2004 [63]
Farkas et al. Neurosci. Lett., 2005 [65]
Cognitive performance
Farkas et al. unpublished ms, 2005 [66]
Liu et al. J. Cereb. Blood Flow Metab., 2002 [54]
Rajapakse et al. Neurosci. Lett., 2002 [55]
Shimizu et al. Am. J. Physiol. Heart Circ.
Physiol., 2002 [61]
Lenzsér et al. Brain Res., 2005 [67]
Infarct volume
Nakagawa et al. Neurosurg., 2005 [71]
Shake et al. Ann. Thorac. Surg., 2001 [60]
Caparrelli et al. Ann. Thorac. Surg., 2002 [84]
Liu et al. J. Cereb. Blood Flow Metab., 2002 [54]
Munoz et al. Stroke, 2003 [62]
Farkas et al. Brain Res., 2004 [63]
Farkas et al. Neurosci. Lett., 2005 [64]
Farkas et al. Neurosci. Lett., 2005 [65]
Histology
Farkas et al. unpublished ms, 2005 [66]
Mitochondrial mor-
phology
Domoki et al. Brain Res., 2004 [57]
c-Fos/c-Jun expression Jiang et al. Mol. Brain Res., 2005 [59]
DNA fragmentation Jiang et al. Mol. Brain Res., 2005 [59]
m-calpain activation Jiang et al. Mol. Brain Res., 2005 [59]
Domoki et al. Stroke, 1999 [56]Pial arteriolar diameter
Domoki et al. Am. J. Physiol. Heart Circ.
Physiol., 2005 [58]
Blood-brain barrier
permeability
Lenzsér et al. Brain Res., 2005 [67]
Liu et al. J. Cereb. Blood Flow Metab., 2002 [54]
Lenzsér et al. Brain Res., 2005 [67]
Cerebral blood flow
Nakagawa et al. Neurosurg., 2005 [71]
system, it is essential that the drug is able to cross the blood-
brain barrier. It is also of interest from the point of view of
perinatal ischemia, whether diazoxide can cross the blood-
placenta barrier. According to early results, diazoxide readily
crosses the blood-placenta barrier and appears in fetal blood
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[79], but the blood-brain barrier permeability of diazoxide
has been largely ignored. Only indirect evidence (namely
that diazoxide is neuroprotective in vivo ) suggests that dia-
zoxide can probably penetrate the brain parenchyma, but
further studies with a focus on the blood-brain barrier pas-
sage of diazoxide must be conducted to confirm this as-
sumption.
Some of the animal studies discussed above successfully
demonstrated that diazoxide can be administered peripher-
ally (i.v. or i.p., though per os  data is not yet available) in
order to exert a beneficial effect in the brain (Table 2). Nev-
ertheless, the optimal concentration of the drug has yet to be
determined for human patients. The determination of effec-
tive concentration is crucial, since diazoxide at relatively
high concentration exerts pronounced effects on blood pres-
sure and pancreatic b-cell function. The observation that
diazoxide can reduce cerebral blood flow received much
attention, when diazoxide was under development as a blood
pressure reducing agent [80,81]. Therefore, the optimal
therapeutic dose to treat cerebral ischemia should be low
enough not to harm peripheral organs and not to reduce
cerebral blood flow, but sufficiently high enough to achieve
neuroprotection. The results of the animal studies are scarce
but promising in this respect. A recent study identified neu-
roprotective doses of diazoxide (20 mg/kg, i.p.), which did
not have a long-term effect on blood pressure and blood glu-
cose level in rats [67].
The reduced cerebral blood flow may pose a particular
problem when diazoxide is applied in a post-ischemic man-
ner. Application of the drug at this point might decrease the
blood flow to the ischemic site even further, and possibly
enhance neuronal damage. Data available on the action of
diazoxide on cerebral blood flow appears to be conflicting.
Diazoxide given at a concentration of 5 mg/kg (i.v.) with the
purpose to control hypertension was found to reduce cerebral
blood flow in hypertensive patients and rats [80,81]. Never-
theless, the unwanted reduction in cerebral blood flow was
suggested not to be a direct effect of diazoxide, but secon-
dary to a sudden drop in blood pressure, and occurred when
blood pressure decreased below the lower limit of the
autoregulatory capacity of the brain [82]. In contrast, another
set of experiments found no effect of diazoxide on cerebral
blood flow in a model of venous ischemia, in which diazox-
ide (2 mmol/l,intracerebroventricular, i.c.v.) reduced the
infarct volume [71]. Further, diazoxide administered at a
concentration of 3-5 mg/kg (i.v.) increased cerebral blood
flow in goats [83] and preserved the I/R-impaired vasodila-
tory response in piglets [56, 58]. Nevertheless, mean arterial
blood pressure was briefly lowered from 5 to 15 min after
the administration of the drug in the latter experiments [58].
The mechanism behind the cerebral vasodilatory effects of
diazoxide has not yet been definitively determined, but a
direct action on the endothelium as well as on the neural-
vascular unit may play a mediating role [56, 58, 70]. Taken
together, these experiments indicate that care must be taken
to choose the appropriate concentration of the drug, so that a
drop in blood pressure will not challenge the autoregulatory
capacity of the brain. The route of application may also
modify the drug’s effect; in rats, 5 mg/kg diazoxide i.v. re-
duced blood pressure and cerebral blood flow [81], while a
neuroprotective dose of 6-20 mg/kg given i.p. did not [67].
Another consideration is the timing of treatment. Most
studies applied diazoxide as a pretreatment (i.e. before the
onset of cerebral ischemia), because diazoxide has been
known to mediate pharmacological preconditioning. This
approach can be useful in cases of planned surgical proce-
dures (e.g. open heart surgery) that can disturb cerebral
blood flow. In such cases, preconditioning the brain with
diazoxide could prevent or limit neurological insults during
recovery from such surgery.
Nevertheless, post-administration of drugs in general
may have a higher therapeutic value, especially in cases of
perinatal ischemic brain injury, where the prediction of the
incidence and the prevention of ischemia are quite difficult
to realize. Therefore, a few attempts have been taken to
characterize the neuroprotective properties of a post-
treatment with diazoxide. These experiments delivered vari-
ous results. In a study of perinatal ischemia, the application
of diazoxide immediately after the ischemic insult appeared
as effective as pretreatment with the drug [59]. However, in
another set of experiments of chronic cerebral hypoperfusion
in adult rats, only the pretreatment reduced cognitive dys-
function; the post-treatment did not [66]. These conflicting
findings encourage further research to characterize the po-
tential, neuroprotective effects of a post-treatment with dia-
zoxide, and to identify conditions where such approach can
be recommended.
In summary, though the application of diazoxide as a
neuroprotective strategy has only recently been considered,
treatment of cerebrovascular disorders by targeting the mi-
toKATP channels offers broad prospects. The animal studies
gathered consistent data that diazoxide is particularly effec-
tive in models of stroke and I/R, both in newborn and adult
animals. These findings may stimulate further research for
drug development in this field.
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ABBREVIATIONS
2VO = Permanent, bilateral common carotid artery
occlusion (two-vessel occlusion)
5-HD = 5-Hydroxydecanoate
aCSF = Artificial cerebrospinal fluid
ADP = Adenosine diphosphate
ATP = Adenosine triphosphate
DIAZ = Diazoxide
DMSO = Dimethyl sulphoxide
GDP = Guanosine diphosphate
GTP = Guanosine triphosphate
i.c.v. = Intracerebroventricular
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i.p. = Intraperitoneal
i.v. = Intravenous
I/R = Ischemia/reperfusion
KATP = ATP-sensitive potassium channels
channels
KIR = Inwardly rectifying potassium channel
subunit
mitoKATP = Mitochondrial ATP-sensitive potassium
channels channels
NMDA = N-methyl-D-aspartate
SUR = Sulphonylurea receptor
TMD = Transmembrane domain
TTC = Triphenyltetrazolium chloride
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Diazoxide has been identified as a mitochondrial, ATP-dependent K+ channel opener, and a
potentially neuroprotective compound under ischemic conditions. We set out to
characterize the consequences of various treatment strategies with diazoxide in a rat
model of chronic cerebral hypoperfusion. Cerebral hypoperfusion was induced by
permanent, bilateral occlusion of the common carotid arteries (2VO, n = 36), sham-
operated rats serving as controls (SHAM, n = 29). Diazoxide or its vehicle was administered i.
p. daily (5 × 0.5mg/kg/0.25ml) or as a bolus injection (5mg/kg/0.25ml) before surgery or daily
after surgery (5 × 0.5mg/kg/0.25ml). Spatial learning performancewas assessed 1week after
2VO in the Morris maze. Hippocampal pyramidal cell loss was assessed on cresyl violet-
stained sections, while glial reactivity was labeled immunocytochemically. Daily or bolus
pretreatment with diazoxide significantly improved 2VO-related learning impairment,
whereas posttreatmentwas ineffective. The number of CA1 pyramidal neuronswas reduced
by 2VO, which was prevented by repeated or bolus pretreatment with diazoxide. Astrocyte
proliferation and microglial activation were enhanced by posttreatment with diazoxide in
the hippocampus CA1 area of 2VO animals as compared with SHAM. These data
demonstrate that the neuroprotective effect exerted by diazoxide depends on the time of
administration with respect to the onset of ischemia; pretreatment but not posttreatment
with the compound has proved to be neuroprotective in chronic cerebral hypoperfusion.
Thus, pretreatment with diazoxide offers therapeutical prospects for the treatment of
cerebral ischemia.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
Diazoxide, a mitochondrial, ATP-dependent K+ (mKATP)
channel opener, has originally been used in clinical practice
in hypertensive emergencies (Goodman Gilman et al., 1990).
By now, an accumulating body of experimental data has
demonstrated that diazoxide can be used for pharmacolog-
ical preconditioning, attenuating ischemic heart damage
(O'Rourke, 2004). In view of its preventive action in cardiac
ischemia, diazoxide has become the focus of recent
investigation as a potential anti-ischemic agent in the
brain. The growing interest in the pharmacological action
of diazoxide on the central nervous system was encouraged
by the finding that the brain contains a considerably higher
concentration of mKATP channels (the target of diazoxide)
than other peripheral organs (Bajgar et al., 2001).
Compelling evidence of the neuroprotective effect of
diazoxide has emerged from experiments on brain slices or
neuronal cell cultures, where diazoxide applied before
oxygen and glucose deprivation enhanced the cell viability
and preserved the electrophysiological properties of the
hippocampal neurons (Zawar and Neumcke, 2000; Kis et al.,
2003). Although neuroprotection on cell cultures and the
intracellular pathways initiated by diazoxide have been
documented in detail (Busija et al., 2004), little is known
about the neuroprotective potential of diazoxide at the
level of the brain. To date, only a few studies have
administered diazoxide to experimental animals with the
aim of examining the effect of the drug on the ischemic
brain. In this way, diazoxide has been shown to limit the
infarct size after middle cerebral artery occlusion or
unilateral carotid artery occlusion combined with hypoxia
in rodents (Liu et al., 2002; Rajapakse et al., 2002; Shimizu
et al., 2002). Despite these preliminary data, no clear
evidence has been gathered as to whether diazoxide can
actually prevent the cognitive dysfunction after an ische-
mic insult, and whether the cognitive status correlates with
histologic neural markers. Furthermore, most studies have
applied diazoxide as pretreatment because of its known
effects of acute and delayed pharmacologic preconditioning
(Busija et al., 2004). Although diazoxide pretreatment has
thus appeared to be a neuroprotective strategy of promise
in cerebral ischemia, it is of interest from a therapeutic
point of view to establish whether postischemic adminis-
tration of the drug can also exert beneficial effects on the
central nervous system.
In the present study, we followed previously devised
methods (Farkas et al., 2004; 2005a,b) to identify the
potentially neuroprotective effects of diazoxide in a rat
model of chronic cerebral hypoperfusion. Since our previ-
ous work had focused on the effect of diazoxide at a late
phase of chronic cerebral ischemia, our present objective
was to investigate the action of diazoxide at an early
phase of cerebral hypoperfusion. Further, as diazoxide had
been administered only as posttreatment in our previous
experiments (while others had used it only as pretreat-
ment), in the present study, we also set out to compare
the neural effects of pretreatment and posttreatment with
diazoxide.
2. Results
The spatial learning curves obtained with the Morris maze
test demonstrated that 2 weeks of experimental cerebral
hypoperfusion induced a marked decrease in learning
performance in the non-treated 2VO group as compared
with the non-treated SHAM group (Fig. 1A). Both repeated
and bolus pretreatment with diazoxide improved the
spatial memory. The 2VO animals that received either
repeated or bolus diazoxide pretreatment exhibited the
same performance as concerns the average swimming
distance as compared with their respective SHAM controls,
specifically on days 2, 3, and 5 (Figs. 1B and C). Conversely,
the 2VO animals that received diazoxide posttreatment did
not succeed in learning the Morris maze paradigm. On days
2 and 5, the 2VO rats posttreated with diazoxide achieved sig-
nificantly worse results as compared with the corresponding
SHAM posttreated group (Fig. 1D).
Corresponding with the results of the learning test,
cerebral hypoperfusion induced a moderate but constant
loss of hippocampal CA1 pyramidal neurons (Fig. 2).
Although massive necrotic cell death was not detected, the
CA1 str. pyramidale in the 2VO animals displayed a loose
cellular arrangement as compared with the compact struc-
ture of the pyramidal layer in the SHAM animals (Figs. 2A
and B). Cell counting revealed that 2VO decreased pyramidal
cell number with 6%. Both the repeated and the bolus
pretreatment with diazoxide preserved the compact struc-
ture of the CA1 str. pyramidale (Fig. 2C) and prevented
pyramidal cell loss (Fig. 2D).
GFAP-immunoreactive astrocytes were present in all the
hippocampal regions and in all the experimental groups.
Neither 2VO nor pretreatment with diazoxide exerted a
detectable influence on the GFAP immunoreactivity in the
investigated hippocampal areas. However, posttreatment
with diazoxide doubled the GFAP signal in the CA1 str.
radiatum and str. oriens of the 2VO rats (Fig. 3).
Activated microglia labeled with OX-42 were scarce not
only in the SHAM animals but also in the 2VO non-treated rats
in all regions of the hippocampus. In contrast, dense staining
was detected in the CA1 str. oriens and str. radiatum of the
2VO animals posttreated with diazoxide (Figs. 4A–C). Quanti-
tative analysis demonstrated that the application of diazoxide
after 2VO increased the OX-42 signal approximately 2.5-fold in
the CA1 str. oriens and 7-fold in the CA1 str. radiatum as
compared with the SHAM groups (Figs. 4D and E).
3. Discussion
The present study has revealed that pretreatment with dia-
zoxide at the dose of 5 × 0.5 mg/kg or 1 × 5 mg/kg, given i.p. is
neuroprotective as regards chronic cerebral hypoperfusion in
rats. The neuroprotective action of the pretreatment with
diazoxide was reflected in an improvement in spatial learning
performance and the inhibition of pyramidal cell loss in the
hippocampus CA1 region.
Our line of investigation is novel in the sense that the action
of diazoxide on learning andmemory has not previously been
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characterized in cerebral hypoperfusion or ischemia. The
present results demonstrate that diazoxide prevents the
cerebral hypoperfusion-related learning dysfunction when
administered as pretreatment. However, posttreatment with
diazoxide exerted no clear effect on the learning perfor-
mance, similarly as we earlier observed at a later time point
in cerebral hypoperfusion (Farkas et al., 2005a). The finding
that pretreatment with diazoxide has a beneficial effect on
learning, and the integrity of the hippocampal pyramidal
cells is in accord with the pharmacological action of
diazoxide revealed in studies on cultured neurons. The
pretreatment of neurons with diazoxide before oxygen-
glucose deprivation increased their viability as compared
with that of non-treated cultures (Nagy et al., 2004).
Diazoxide is known to depolarize the mitochondria and to
simultaneously elevate the production of reactive oxygen
species, which is assumed to play a significant role in the
preconditioning effect of diazoxide (Busija et al., 2004). The
transient, moderate elevation of the concentration of
reactive oxygen species by diazoxide is suggested to
condition the cells to be able to tolerate a later, robust
ischemic event better. Such preconditioning may account for
the preserved learning performance and enhanced hippo-
campal neuronal viability of 2VO rats following pretreatment
with diazoxide.
The immunocytochemical signals for both astrocytes and
microglia were markedly enhanced by posttreatment with
diazoxide in the 2VO animals, while 2VO or diazoxide alone
had no effect on the glial cells. This suggests that, given the
sequence of 2VO and treatment, diazoxide was able to
stimulate the glial cells, provided that the glia were already
made sensitive by ischemia.
Although the lack of evidence means that it is difficult to
establish a causal link between treatment with diazoxide and
a glial reaction, the intriguing observation was made that a
subpopulation of reactive astrocytes expressed a Ca2+-acti-
vated, ATP-sensitive nonselective cation channel (NCCa-ATP)
under hypoxic conditions. Interestingly, these channels are
controlled by a sulfonylurea regulatory subunit, SUR1, which
is the target of diazoxide. It has been shown that the
treatment of such astrocytes with diazoxide results in
activation of the NCCa-ATP channels, which are suggested to
control the swelling and migration of astrocytes in hypoxic
nervous tissue (Chen et al., 2003). Even though a strict corre-
lation cannot be drawn with our data, a similar mechanism
may play a role in the diazoxide-induced astrocytic prolifer-
ation shown here.
The background of diazoxide-related microglial activation
is even more obscure. Although the activity of the microglia is
dependent on the opening state of the surface ion channels
(Eder, 1998), regulatory SUR subunits (the potential sites of the
action of diazoxide) have not been associated with these
channels. Further, microglial activation is accompanied by an
increased number and elongated shape of mitochondria
(Banati et al., 2004), but a potential contribution of mitochon-
drial K+ currents to these processes has not been identified,
yet. Finally, the existing data on the effect of diazoxide on
microglial activation in cerebral hypoperfusion are inconsis-
tent: posttreatment with diazoxide prevents microglial acti-
vation at a late time point in cerebral hypoperfusion (Farkas et
Fig. 1 – The results of the Morris water maze spatial orientation test. Data are presented as means ± SEM; *P < 0.05, **P < 0.01.
Abbreviations: 2VO: permanent, bilateral common carotid artery occlusion (two-vessel occlusion); C: control for treatment;
DIAZ: diazoxide; post: posttreatment; pre: pretreatment; SHAM: sham-operated control.
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al., 2004, 2005a,b), while the same treatment enhances
microglial activation at an early time point, as shown here.
This may suggest that the effect of diazoxide on ischemia-
relatedmicroglial activation is defined by the time of sampling
with respect to the treatment and the onset of cerebral
hypoperfusion.
The concentration of diazoxide was chosen to be low
enough to exclude potentially harmful side effects such as
hypotension, reduced cerebral blood flow or hyperglycemia,
which are known to potentiate ischemic injury. Recent results
have demonstrated that the plasma glucose level and mean
arterial pressure in rats are not significantly affected by even
6mg/kg diazoxide i.p. (Lenzsér et al., 2005). A selective effect of
a low dose of diazoxide on the brain is probably due to the
distribution and molecular composition of the mKATP chan-
nels. The brain contains a 6–7 times higher concentration of
mKATP channels than the liver or the heart (Bajgar et al., 2001).
Our present observation that a low concentration of diazoxide
attenuates ischemic hypoperfusion-induced brain damage,
yet does not alter the vascular andmetabolic parameters, may
be of therapeutic potential in cerebral ischemia.
In conclusion, we have found that a low dose of diazoxide
that is ineffective on the mean arterial pressure or blood
glucose concentration (Lenzsér et al., 2005) is potent on the
central nervous system. Further, diazoxide prevents an
ischemia-induced learning impairment when the drug is
administered as pretreatment, but not as posttreatment.
Finally, diazoxide potentiates glial reactivity when given as
posttreatment, but not as pretreatment. The present findings
on the glial reaction call for further research on the mechan-
isms of action of diazoxide on glia cells. Our results may
additionally provoke investigations on the neuroprotective
properties of diazoxide with therapeutical prospects in
ischemia.
4. Experimental procedures
Sixty-five male Wistar rats (302 ± 18 g) were used for the
study. All animal experiments were approved by the ethical
committee of the University of Szeged. Chronic, experimen-
tal cerebral hypoperfusion was induced in half of the
animals by permanent bilateral occlusion of the common
carotid arteries (2VO), the other half serving as sham-
operated controls (SHAM) (Farkas et al., 2004). Prior to
surgery, the animals were anesthetized with 400 mg/kg
chloralhydrate i.p., followed by 0.05 ml 0.1% atropine i.m.
The common carotid arteries were exposed via a ventral
cervical incision, carefully separated from their sheaths and
vagal nerves, and permanently ligated with surgical sutures.
Lidocaine (1%) was applied as local anesthetic. The same
procedure was performed on the SHAM group but without
the actual ligation.
The animals were treated with diazoxide or its vehicle
(0.25 ml 0.1 N NaOH), i.p. In the first group, diazoxide (0.5 mg/
kg/0.25 ml) or its vehicle was injected on 5 consecutive days
immediately before 2VO surgery. In the second group,
diazoxide (5 mg/kg/0.25 ml) was administered once (bolus)
the day before 2VO surgery. In the third group, diazoxide
(0.5 mg/kg/0.25 ml) or its vehicle was injected on 5 consec-
utive days after 2VO surgery, the first injection given within
1 h following surgery. The final compositions of the
experimental groups and the survival rates are presented in
Table 1.
One week following 2VO surgery, the animals were
trained in the Morris water maze (Farkas et al., 2004),
which consisted of a circular pool (diameter: 160 cm,
depth: 35 cm) filled with water (22 °C), made opaque with
milk so that the rats were unable to see an underwater
platform 2 cm below the water surface. Invariant visual cues
were placed on the wall of the testing room, and an auditory
source with a fixed location was switched on throughout the
testing. All the rats performed two trials per day, with a
constant inter-trial interval of 4 h, for 5 consecutive days.
The starting positions were selected at random from four
standard entry points. The rats were given 2 min to find the
platform and sit on it for 15 s. Rats that failed to find the
location within the given time were gently guided to the plat-
form and allowed to stay on it for 15 s. Swimming paths were
recorded with a computerized video imaging analysis system
(EthoVision, Noldus Information Technology BV,Wageningen,
Fig. 2 – Cresyl violet staining and cell counting in the
hippocampus CA1 str. pyramidale. (A–C) Representative
photomicrographs of the hippocampal CA1 area from
pretreated animals. (D) Quantitative data on pyramidal cell
viability in the hippocampus CA1 str. pyramidale; area unit
is 0.024 mm2 (3 × 10 grid holes at 40× magnification). Data
are presented as means ± SEM; *P < 0.05. The P value
indicated in the graph was obtained with a Student's t test.
Abbreviations: 2VO: permanent, bilateral common carotid
artery occlusion (two-vessel occlusion); C: control for
treatment; DIAZ: diazoxide; pre: pretreatment; SHAM:
sham-operated control.
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The Netherlands). In each trial, the escape latency and the
swimming distance traveled before the rats reached the
platform were analyzed.
Seven days after the beginning of the Morris water maze
training, and14days after theperformanceof 2VO, theanimals
were reanesthetized with an overdose of chloralhydrate (i.p.)
Fig. 3 – GFAP immunocytochemistry for astrocyte proliferation. (A–C) Representative photomicrographs of the hippocampal
CA1 area from posttreated animals. (D) Quantitative data on GFAP immunocytochemistry in the hippocampal CA1 str. oriens of
the posttreated animals. (E) Quantitative data on GFAP immunocytochemistry in the hippocampal CA1 str. radiatum of the
posttreated animals. Data are presented asmeans ± SEM; *P < 0.05, **P < 0.01. Abbreviations: 2VO: permanent, bilateral common
carotid artery occlusion (two-vessel occlusion); C: control for treatment; DIAZ: diazoxide; post: posttreatment; SHAM:
sham-operated control.
Fig. 4 – OX-42 immunocytochemistry relating to microglia activation. (A–C) Representative photomicrographs of the
hippocampal CA1 area from posttreated animals. (D) Quantitative data on OX-42 immunocytochemistry in the hippocampal
CA1 str. oriens of the posttreated animals. (E) Quantitative data on OX-42 immunocytochemistry in the hippocampal CA1 str.
radiatum of the posttreated animals. Data are presented as means ± SEM; *P < 0.05, **P < 0.01. Abbreviations: 2VO:
permanent, bilateral common carotid artery occlusion (two-vessel occlusion); C: control for treatment; DIAZ: diazoxide; post:
posttreatment; SHAM: sham-operated control.
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and perfused transcardially with 100 ml saline, followed by
400 ml 3.5% paraformaldehyde and 0.5% picric acid in 0.1 M
phosphate buffer (PB, pH 7.4). The brains were removed and
postfixed in the same solution for up to 1 h and then stored in
0.1 M PB containing 0.1% sodium azide.
Free-floating coronal sections at the level of the dorsal
hippocampuswere cut at 20-μmthickness on a cryostat. Three
sections per animal that contained the dorsal hippocampus
(Bregma −3.60, Paxinos and Watson, 1986) were mounted on
gelatine-coated microscopic slides and stained with cresyl
violet.
A second set of sections was stained immunocytoche-
mically for glial fibrillary acidic protein (GFAP) to visualize
the astrocytic proliferation. Briefly, sections were treated
with 3% H2O2 and 0.5 Triton X-100 in 0.01 M PBS and
preincubated in 20% normal pig serum (NPS). The samples
were then incubated overnight at RT in a primary antibody
solution containing mouse anti-GFAP antibody (Sigma), 1:40
000, 20% NPS, and 0.03% merthiolate in 0.01 M PBS. The
secondary antibody solution consisted of goat anti-mouse
biotinylated IgG (Jackson), 1:400, 10% NPS, 5% normal rabbit
serum and 0.03% merthiolate in 0.01 M PBS. Finally, the
sections were incubated in STA-PER (Jackson), 1% NPS, and
0.03% merthiolate in 0.1 M Tris buffer, and the color reaction
was conventionally developed with diaminobenzidine (DAB)
and H2O2.
To detect and analyze the microglial activation over the
hippocampal areas, OX-42 antibody was used on a third set
of sections. The procedure started with rinsing and
pretreating the sections with 0.5% Triton X-100 and 3%
H2O2 in 0.01 M PBS, followed by preincubation in 20%
normal NPS and 0.5% Triton X-100 in 0.01 M PBS for 1 h.
The sections were incubated overnight in a primary
antibody solution containing biotinylated mouse anti-
CD11b antibody (OX-42, Serotec), 1:500, 20% NPS, and 0.03%
merthiolate in 0.01 M PBS at RT. Next, the sections were
rinsed and incubated in a solution of STA-PER (Jackson), 1%
NPS, and 0.03% merthiolate in 0.1 M Tris buffer for 1 h at RT.
Finally, the color reaction was developed with Ni-DAB and
H2O2. All the sections were mounted on gelatin-coated
microscopic slides, air-dried, dehydrated, and coverslipped
with DPX.
The number of pyramidal neurons in the hippocampus
CA1 region was counted with the help of an ocular grid at 40×
magnification on a surface of 0.024mm2 (3 × 10 grid holes) that
covered the entire diameter of the CA1 str. pyramidale. Cell
counting was performed bilaterally on three consecutive brain
sections. The six values were averaged, and the average was
used for further statistical analysis.
The percentage surface areas of GFAP-positive astrocytes
and OX-42-immunoreactive microglia in the dorsal hippo-
campus were quantified by using a computerized image
analysis system (Olympus BX50, DP50, software: ImagePro
Plus, Media Cybernetics, U.S.A.). Briefly, three consecutive
coronal sections at Br. −3.60 mm (Paxinos and Watson, 1986)
were selected for the analysis. Hippocampal regions of interest
were delineated manually at 10× magnification, after back-
ground subtraction and gray scale threshold determination.
The area covered by immunoreactive material was computed
as a percentage of the total area delineated. Measurements
were carried out on both sides of the hippocampus. Six values
per animal per area were averaged, and the average was used
for further statistical analysis. The following areas were
analyzed separately: the CA1 str. radiatum, the CA1 str. oriens,
the CA3 str. radiatum, the CA3 str. oriens, the inner and outer
molecular layers of the dentate gyrus, and the hilus.
TheMorris maze test results were analyzed statistically via
the repeated measures of the general linear model of the
software SPSS. Individual daily comparisons were performed
by analysis of variance (ANOVA) followed by the LSD post hoc
test. The immunocytochemical results were analyzed statis-
tically with two-way ANOVA for surgery and treatment,
followed by the LSD post hoc test.
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Abstract
Chronic cerebral hypoperfusion is related to neurological disorders and contributes to a cognitive decline. Its experimental model in rats is
permanent, bilateral common carotid artery occlusion. The cyclooxygenase (COX) system plays a pivotal role in the evolution of ischemic brain
damage. Several COX inhibitors have proved to be neuroprotective in stroke models. We set out to characterize the effects of COX inhibitors in
rats with permanent cerebral hypoperfusion. Some of the animals were exposed to two-vessel occlusion (n=72), while the others served as sham-
operated controls (n=54). This was followed by a 3-day post-treatment with the nonselective COX inhibitor indomethacin (3 mg/kg) or with the
selective COX-2 inhibitor NS-398 (15 mg/kg) or with the solvent. Some groups of the animals were sacrificed after 3 days, while the remainder
were tested in the Morris watermaze for 5 days, and were sacrificed after 2 weeks. Neurons in the hippocampus were subjected to
immunocytochemical labeling with cresyl violet, the dendrites with microtubule-associated protein-2, astrocytes with glial fibrillary acidic protein
and microglia activation with OX-42 antibody. Two-vessel occlusion induced a learning impairment, mild neuronal damage, marked dendritic
injury and moderate astrocytic reaction in the hippocampus. NS-398, but not indomethacin improved the survival rate and abolished the learning
disability. However, both drugs increased the proportion of animals displaying neuronal damage. Glial markers revealed a time-dependent
elevation in both the sham and the two-vessel occluded group, and were unaffected by the treatments. In summary, NS-398 prevented the
hypoperfusion-induced memory impairment, but not by protecting the hippocampal neurons.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Various clinical observations support the hypothesis that
chronic cerebral hypoperfusion is a major contributor to a
cognitive decline, both in aging and in age-related neurological
disorders (de la Torre, 2006; Kalaria, 2000; Sopala and Danysz,
2001). The persistent decrease in the cerebral blood flow in
Alzheimer's disease, vascular dementia and post-stroke hypo-
perfusion correlates with the severity of memory disturbances
(Komatani et al., 1988). Permanent occlusion of both common
carotid arteries in the rat (two-vessel occlusion) has emerged as a
suitable experimental model for chronic cerebral hypoperfusion;
it allows simultaneous investigation of the cerebral blood flow,
the learning ability and histopathological changes (Farkas et al.,
2007). Studies involving use of the two-vessel occlusion model
have demonstrated that an impaired spatial learning function
coincides with hippocampal damage (Farkas et al., 2007; Otori
et al., 2003; Sarti et al., 2002).
Tissue ischemia leads to the development of inflammatory
reactions, such as reactive gliosis, the migration into and
accumulation of leukocytes in the ischemic brain tissue, and the
production of inflammatory cytokines and reactive oxygen
species due to microglia activation or the release of arachidonic
acid metabolites (Dewar et al., 2003; Wang et al., 2007). These
changes result in a more severe evolution of tissue damage.
Inflammation sets in rapidly after transient ischemia or
ischemia/reperfusion, while a slowly-developing and persistent
reaction occurs in chronic hypoperfusion. Thus, reduction of the
neuronal damage and inflammation is a possible target via
which to alleviate the cognitive symptoms.
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The cyclooxygenase (COX) system plays a critical role in the
progression of ischemic brain injury. Three isoforms of the
enzyme COX have been described: COX-1, COX-2 and COX-
3, the latter being a splice variant of COX-1. COX-1 is ex-
pressed constitutively, and participates in various homeostatic
processes, such as the maintenance of tissue perfusion and
synaptic plasticity (Iadecola et al., 2001; Phillis et al., 2006).
COX-2 production is induced globally in response to brain
infarction in humans (Sairanen et al., 1998) and in various
stroke models in animals (Candelario-Jalil et al., 2003; Collaço-
Moraes et al., 1996; Degi et al., 1998; Nogawa et al., 1997).
Nonsteroid anti-inflammatory drugs (NSAIDs) and selective
COX-2 inhibitors have proved to be neuroprotective in stroke
and ischemia/reperfusion injury. For example, pretreatment
with indomethacin (a nonselective COX inhibitor) reduced the
infarct size following middle cerebral artery occlusion
(MCAO)-induced transient focal ischemia in rats (Buccellati
et al., 1998) and diminished the ischemia-evoked CA1 hip-
pocampal injury in gerbils (Sasaki et al., 1998). NS-398 (N-[2-
(cyclohexyloxy)-4-nitrophenyl]-methanesulphonamide), a se-
lective COX-2 inhibitor, reduced infarcts following MCAO-
induced focal cerebral ischemia (Nogawa et al., 1997). In the
majority of these experiments, the drugs were applied as
pretreatment to prevent subsequent ischemic damage. However,
post-treatment strategies may be more desirable, as the occur-
rence of a cerebral ischemic event is most often unpredictable.
Further, the long-term application of NSAIDs or selective
COX-2 inhibitors results in cardiovascular side-effects, such as
stroke and myocardial infarction (Topol, 2004), and acute
therapy therefore appears preferable.
Since the inhibition of COXs had proved neuroprotective in
various stroke models, but had not been tested in a mild
ischemic condition, the aim of our present study was to char-
acterize the effects of COX inhibition after two-vessel occlusion
in rats. In our experimental setup, the treatment was chosen to
correspond to clinical treatment strategies; thus, indomethacin
and NS-398 were administered as acute 3-day post-treatment
after two-vessel occlusion. We analyzed the changes in the
learning performance and in histological markers such as
neuronal damage (labeled with cresyl violet staining), dendritic
integrity (labeled with microtubule-associated protein-2 (MAP-
2) antibody), astrocytic activation and microglia activation
(labeled with glial fibrillary acidic protein (GFAP) and OX-42
(CD-11b receptor) antibody immunocytochemistry).
2. Materials and methods
2.1. Treatment and surgery
All animal experiments were approved by the Ethical
Committee of the University of Szeged. One hundred twenty-
six male Wistar rats (263±37 g) were used for the study. The
animals were anesthetized with 400 mg/kg chloral hydrate
intraperitoneally (i.p.), followed by 0.05 ml atropine intramus-
cularly (i.m.). Subsequently, experimental cerebral hypoperfu-
sion was induced in some of the animals by two-vessel
occlusion (n=72), while the others served as sham-operated
controls (n=54). The common carotid arteries were exposed via
a ventral cervical incision, and separated from their sheaths and
vagal nerves. Silk sutures (5.0) were used for the ligation. The
same surgical procedure was performed on the sham-occluded
group, but without the actual ligation.
Immediately after surgery, the rats were divided into 12
groups: Groups 1–3 and 7–9 involved sham-occluded animals,
while those in Groups 4–6 and 10–12 had undergone two-
vessel occlusion.
Groups 1–3 served as controls for Groups 4–6. Group 1
(n=7) received 0.5 ml 5% sodiumhydrogencarbonate i.p. on 3
consecutive days, the first injection being applied directly after
surgery.
The Group 2 rats were treated with 3 mg/kg indomethacin
(n=8) dissolved in 0.5 ml 0.9% saline i.p., while 15 mg/kg NS-
398 (n=9) in 0.5 ml 5% sodiumhydrogencarbonate was
administered i.p. to Group 3, likewise for 3 days.
The two-vessel occluded Groups 4–6 received solvent (n=8)
or indomethacin (n=10) or NS-398 (n=8) treatment for 3 days,
respectively, as described for Groups 1–3.
Group 7 (n=9), Group 8 (n=8), Group 9 (n=7) were treated
analogously to Groups 1–3, respectively, with solvent,
indomethacin and NS-398, as were the two-vessel occluded
Groups 10 (n=5), 11 (n=5) and 12 (n=8).
Postoperatively, not all of the rats survived for a sufficiently
long time to receive the third injection on postsurgery day 3.
The data relating to the survival rates in the various groups are
presented in Table 1.
Following completion of the 3-day course of injections, the
surviving animals in Groups 1-6 were sacrificed and subjected
to comparative immunocytochemical examinations, while the
survivors in Groups 7–12 underwent spatial learning tests.
2.2. Spatial learning test
The animals in Groups 7–12 were trained in the Morris
watermaze spatial learning test, starting 7 days after surgery.
The test was carried out in accordance with a previously
established protocol (Farkas et al., 2006). All rats performed 2
trials per day, with a constant interval of 4 h between the trials,
for 5 consecutive days. The water tank (d=160 cm), containing
a hidden platform submerged 2 cm below the water surface,
Table 1
Survival rates in the various experimental groups after 2VO or Sham surgery
Experimental group Survival rate
Groups 1 and 7 Solvent Sham 16/17 (94%)
Groups 4 and 10 2VO 13/26 (50%)
Groups 2 and 8 Indomethacin Sham 16/20 (80%)
Groups 5 and 11 2VO 15/24 (62%)
Groups 3 and 9 NS-398 Sham 16/17 (94%)
Groups 6 and 12 2VO 16/22 (73%)
The various experimental groups were injected with solvent, indomethacin
or NS-398 immediately following the surgical procedure. The survival rate
relates to the animals that survived up to and including the third injection.
Abbreviations: 2VO: permanent, bilateral common carotid artery occlusion
(two-vessel occlusion); Sham: sham-operated control. Survival rate was
expressed as percentage of survived animals to total.
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was located in an experimental room equipped with various
spatial and auditory extra maze cues. The animals were placed
in the water at one of four starting quadrant points, which was
varied randomly over the trials. The rats were given 2 min to
find the platform and sit on it for 15 s. Swimming paths were
recorded by a computerized video imaging analysis system
(EthoVision, Noldus Information Technology BV, Wagenin-
gen, The Netherlands). For each of trials 2–10, the distance
swam before reaching the platform, and the proportion of failed
trials to the total number were analyzed. The distance swam in
the 2 daily trials was calculated as a daily average for further
data analysis.
2.3. Histology
The animals in Groups 1–6 were sacrificed 3 days after the
operation, while those in Groups 7–12 were sacrificed 2 days
after the Morris watermaze experiments (2 weeks after surgery).
The procedures for the preparation of sections followed pre-
viously reported protocols (Farkas et al., 2006). Briefly, after
deep pentobarbital anesthesia, the rats were perfused transcar-
dially with 100 ml saline followed by 400 ml 4% paraformal-
dehyde. The brains were removed, postfixed, and cut to 20 μm
thick, free-floating coronal sections on a cryostat. The first set of
sections was stained with cresyl violet. For each animal 3
sections containing the dorsal hippocampus (bregma −3.60,
Paxinos and Watson, 1986) were mounted on gelatin-coated
microscopic slides and stained with cresyl violet in order to
allow examination of the integrity of the CA1 and CA3
pyramidal cell layers and the DG granule cell layers. The
proportion of animals displaying neuronal damage was de-
termined with the help of the cresyl violet-stained sections
(Annaházi et al., 2007). Hippocampal neuronal damage was
evaluated at 40X magnification with a light microscope by an
investigator blind to the experimental groups. Damage of a
hippocampal region was considered when neurons showed
typical signs of necrosis (dark staining, shrinkage and a dys-
morphic shape). The number of animals showing necrotic
neuronal injury was counted and expressed as percentage for
each hippocampal region and each group.
The second set of sections was immunocytochemically
stained for MAP-2 to visualize the dendritic integrity.
Endogenous peroxidase activity was blocked with 0.3%
H2O2, nonspecific binding sites were covered with 20% normal
swine serum (NSS), and the membrane permeability was en-
hanced with 0.3% Triton X-100. The samples were then incu-
bated overnight in a primary antibody solution containing
mouse anti-MAP-2 antibody (Sigma), 1:10000, 20% NSS, and
0.03% merthiolate in 0.01 M PBS. The secondary antibody
solution consisted of goat anti-mouse biotinylated IgG
(Jackson) 1:400, 10% NSS, 0.03% merthiolate, 5% normal
rabbit serum (NRS) in PBS. Finally, the sections were incubated
in HRP-Streptavidin (Jackson) 1:1000, 1% NSS, 0.03%
merthiolate in Tris–buffer solution (TBS). The color reaction
was developed with Ni-diaminobenzidine (Ni-DAB) and H2O2.
In the third set of sections astrocytic reaction was immu-
nocytochemically labeled with GFAP antibody. After pretreat-
ment with 5% normal sheep serum (NShS), 0.3% H2O2 and
0.3% Triton X-100, the sections were incubated overnight in a
solution containing the mouse anti-GFAP primary antibody
(Sigma), 1:200, 1% NShS and 0.3% Triton-X in 0.01 M PBS.
The secondary antibody solution consisted of goat anti-mouse
biotinylated IgG (Jackson), 1:400, 10% NShS, 5% NRS and
0.03% merthiolate in 0.01 M PBS. Finally, the sections were
incubated in HRP-Streptavidine (Zymed), 1:200, and the color
reaction was developed conventionally with DAB and H2O2.
For the last set of sections, OX-42 antibody was used to
detect and analyze microglia activation over the hippocampal
area. After pretreatments similar to those for GFAP staining, the
sections were incubated overnight in a primary antibody
solution containing a biotinylated mouse anti-CD11b antibody
(OX-42, Serotec), 1:500, 20% NSS and 0.03% merthiolate in
0.01 M PBS. Next, the sections were rinsed, and incubated in a
solution of HRP-Streptavidin (Jackson), 1% NSS and 0.03%
merthiolate in 0.1 M TBS for 1 h. The color reaction was
developed with Ni-DAB and H2O2. All sections were mounted
on gelatin-coated microscopic slides, air-dried, dehydrated and
coverslipped with Distrene 80 (dibutyl phthalate with xylene).
The percentage surface areas of MAP-2 antibody-positive
microtubules, GFAP-positive astrocytes and OX-42-positive
immunoreactive microglia in the dorsal hippocampus were
quantified by using a computerized image analysis system
(Olympus BX50, P50, software: ImagePro Plus, Media
Cybernetics, U.S.A.) as previously described (Farkas et al.,
2004, 2006). Briefly, 3 consecutive coronal sections with a
standard distance of 160 μm, starting at br. −3.60 mm were
examined. After background subtraction and gray scale
threshold determination, hippocampal regions of interest were
delineated manually at 10X magnification. The area covered by
immunopositive structures was computed as a percentage of the
total area delineated. The measurements on the 3 sections per
animal were averaged and the values were used for further
statistical analysis.
2.4. Statistical analysis
The Morris maze test results were analyzed statistically by
means of a two-way repeated measurement model, followed by
the LSD (least significant difference) post hoc test of the
program SPSS. Individual day comparisons were performed
with a univariate model and LSD post hoc analysis of SPSS.
The proportions of failed trials to total and the proportion of
animals displaying neuronal damage in the hippocampus were
analyzed statistically by a chi square test of the program
Statistica. MAP-2, GFAP and OX-42 immunocytochemical
results were analyzed statistically with three-way ANOVA,
followed by the LSD post hoc test.
3. Results
Table 1 presents the survival rates. Two-vessel occlusion
resulted in a survival rate of only 50% in the solvent-treated
groups (Groups 4 and 10) versus 94% in the sham-operated
vehicle-treated groups (Groups 1 and 7). The treatments with
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COX inhibitors did not significantly alter the mortality in the
sham-occluded groups (80% [Groups 2 and 8] and 94% [Group
3 and 9] vs 94% [Groups 1 and 7]). However, the indomethacin
treatment exerted a slightly beneficial effect on the survival rate
of the two-vessel occluded rats 63% (Groups 5 and 11) vs 50%
(Group 4 and 10), while NS-398 improved the survival rate of
the two-vessel occluded rats markedly (73% [Groups 6 and 12]
vs 50% [Groups 4 and 10]).
In the Morris watermaze, the distance swam by the sham-
occluded animals gradually decreased during the 5-day learning
test (Group 7), while the learning capacity of the solvent-treated
two-vessel occluded rats (Group 10) proved significantly worse
(Pb0.001) than that of the sham-occluded controls (Group 7)
(Fig. 1A). The administration of either COX inhibitor did not
affect the learning ability of the sham-occluded animals. NS-
398 treatment significantly improved the performance of the
two-vessel occluded rats throughout the period of learning as
compared with the two-vessel occluded controls (Group 12)
(Pb0.024). The indomethacin-treated two-vessel occluded
group (Group 11) performed poorly on days 3 and 4 as
compared with the sham-occluded groups and Group 12, but
delivered optimal performance by day 5. A similar tendency
could be observed concerning to the proportion of failed trials to
the total number (Fig. 1B).The two-vessel occluded solvent-
treated group (Group 10) displayed a significantly elevated ratio
of failed trials to the total number compared with the sham-
operated animals (Group 7, 8 and 9). Treatment with NS-398
resulted in significantly less failed trials as compared with the
two-vessel occluded controls (Group 12) (Pb0.0014).
Following surgery and COX-inhibitor treatments, the
proportion of animals with neuronal damage in the CA1 and
CA3 pyramidal cell and DG granule cell layers of the
hippocampus exhibited different spatial and temporal distribu-
tions (Fig. 2). The sham operation caused only mild damage in
the CA1,CA3 andDGat either 3 days or 2weeks postoperatively,
affecting 0–22% of the animals (Groups 1 and 7). In contrast,
3 days after two-vessel occlusion (Group 4), neuronal injury was
seen particularly in the CA3 and DG regions (38%). At 2 weeks,
the presence of damaged neurons was less obvious (20%) in the
CA3 and DG, whereas it was more pronounced in the CA1 area
(40%) (Group 10). Both treatments altered the incidence of
neuronal damage in the hippocampus. Indomethacin aggravated
the neuronal injury in the CA1 and CA3 regions at 3 days after
two-vessel occlusion (50–60%) (Group 5), compared with its
sham-occluded control (0–11%) (Group 2) (Pb0.05; Pb0.01),
but reduced the proportion of affected animals 2 weeks after the
onset of two-vessel occlusion (0%) (Group 11). NS-398 displayed
only similar tendencies in the CA1 region, but clearly enhanced
the neuronal injury in the DG both 3 days and 2 weeks after two-
vessel occlusion surgery in comparison with its respective
solvent-treated groups (Group 6 [100%] vs Group 4 [50%],
Pb0.01 and Group 9 [85%] vs Group 7 [22%], Pb0.05,
respectively). However, this finding indicates that the damaged
neurons after 3 days have partially been cleared away by
microglia after 2 weeks in the CA3 and DG regions.
The changes in MAP-2 antibody signal can be in coherence
with cerebral hypoperfusion- and time-related changes in the
stratum lucidum of the hippocampal CA3 region. Two-vessel
occlusion significantly decreased MAP-2 immunoreactivity
(Groups 4 and 10) as compared with the sham-occluded animals
(Groups 1 and 7) both 3 days and 2 weeks following surgery
(Fig. 3). Additionally, the MAP-2 antibody signal decreased in
all the sham and two-vessel occluded groups at 2 weeks
(Groups 7–12) as compared with that at 3 days (Groups 1–6)
after surgery (Fig. 3). The indomethacin and NS-398 treatments
did not prevent the two-vessel occlusion-induced dendritic
injury in this region at either time point.
Three days after the onset of two-vessel occlusion, astrocytic
activation in the CA1 stratum radiatum labeled with GFAP
antibody exhibited a strong basal signal, which increased
Fig. 1. Performance of the rats (n=42) in the Morris watermaze. Panel A: swimming distance (cm) in the Morris maze on each experimental day. Data are
presented as means±S.E.M. Statistical analysis of the acquisition trials was performed with a repeated measures ANOVA model followed by an LSD post hoc
analysis for group comparison of daily performance. Significance levels of the post hoc test are given as: ⁎⁎Pb0.01 (Groups 10, 11, 12 vs Sham), ##Pb0.01
(Group 11 vs Group 10), $$Pb0.01 (Group 12 vs Group 10). Panel B: Proportion of missed trials to total between trials 2–10. Data are expressed as percentage
averages (%). Statistical analysis was performed with a non-parametric chi-square test. Significance levels of the post hoc test are given as: ⁎Pb0.05 (Group 10
vs Sham), $$Pb0.01 (Group 12 vs Group 10). Abbreviations: 2VO: permanent, bilateral common carotid artery occlusion (two-vessel occlusion); Sham: sham-
operated control.
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moderately, particularly in the NS-398-treated two-vessel
occluded group (Group 6) as compared with its sham control
(Group 3) (Fig. 4). The survival time proved to be the most
sensitive parameter for the GFAP antibody labeling. The GFAP
signal was ∼4 times higher at 2 weeks (Groups 7–12) than at
3 days (Groups 1–6) in all experimental groups (Fig. 4). The
COX inhibitors exerted no effect on the GFAP levels at either
time point.
The changes in OX-42 antibody-labeled microglial activa-
tion revealed a pattern similar to that for the GFAP antibody
signal (Fig. 5). Two-vessel occlusion tended to increase the
microglial activation, although the changes were not significant
Fig. 2. Cresyl violet staining and the proportions of animals displaying neuronal damage in the dorsal hippocampus (bregma −3.60). Area of interest: CA1 stratum
(str.) pyramidale (Panel A), CA3 str. pyramidale (Panel D) and dentate gyrus outer molecular layer (DG oml) (Panel G). Representative photomicrographs of the
hippocampal CA1 (Panels B and C), CA3 (Panels E and F) and DG (Panels H and I) at 40× magnification. White arrow heads are pointing at intact pyramidal and
granular neurons. Black arrow heads are pointing at damaged pyramidal and granular neurons. Panel J: Semiquantitative data on the proportions of damaged CA1,
CA3 and DG in the hippocampus. Statistical analysis was performed with a non-parametric chi-square test. Significance levels of the post hoc test are given as:
⁎Pb0.05, P⁎⁎b0.01 (Group 5 vs Group 2), $Pb0.05 (Group 12 vs Group 10), ##Pb0.01 (Group 6 vs Group 4). Abbreviations: CA: cornu ammonis; DG: dentate
gyrus; 2VO; permanent, bilateral common carotid artery occlusion (two-vessel occlusion); Sham: sham-operated controls.
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because of the high individual variation (Group 2, 4 and 6).
Nevertheless, the OX-42 antibody signal rose significantly from
3 days to 2 weeks after surgery in both the sham and the two-
vessel occluded animals (Groups 7–12 vs Groups 1–6). The
treatments did not modify the OX-42 antibody-labeled micro-
glial activation in the experimental groups.
4. Discussion
The effects of the postoperatively applied nonselective COX
inhibitor indomethacin, and the selective COX-2 inhibitor NS-
398 on the learning ability and on the neuronal damage in the
hippocampus were characterized shortly after the onset of two-
vessel occlusion in the rat. The pharmacological effects of the
COX inhibitors were assessed at two postoperative time points,
which additionally allowed visualization of the time-related,
early histological changes in the hippocampus of the two-vessel
occluded rats. A few studies have already set out to investigate
the progression of neurodegenerative processes via the two-
vessel occlusion model, but these focused on late events (i.e.
4 weeks–6 months after the onset of two-vessel occlusion) (Liu
et al., 2005; Schmidt-Kastner et al., 2005), while no data are
available from the early period of hypoperfusion. Our present
experiments permit an analysis of the incidents in the first
2 weeks after the initiation of two-vessel occlusion.
In the first 2 weeks, two-vessel occlusion induced a
detectable spatial learning deficit, mild neuronal damage, injury
to the dendrites and a slight increase in glial cell proliferation,
which correspond with previous observations (Farkas et al.,
2006; Liu et al., 2005; Schmidt-Kastner et al., 2005; Watanabe
et al., 2006).
NS-398 post-treatment improved the survival rate and the
spatial learning ability, but proved detrimental for hippocampal
Fig. 3. MAP-2 immunocytochemistry relating to synaptic density. Panel A: Area
of interest: CA3 str. lucidum in the dorsal hippocampus (bregma −3.60). Panels
B–D: Representative photomicrographs of the CA3 area of the hippocampus.
Panel E: Quantitative data on MAP-2 immunocytochemistry in the hippocampal
CA3 str. lucidum. Data are presented as means±S.E.M.; ⁎Pb0.05; ##Pb0.01.
The F value indicated in the graph was obtained with the LSD (least significant
difference) post hoc test. Abbreviations: 2VO: permanent, bilateral common
carotid artery occlusion (two-vessel occlusion); Sham: sham-operated controls;
CA: cornu ammonis; or: stratum oriens; pyr: stratum pyramidale; rad: stratum
radiatum, luc: str. lucidum.
Fig. 4. Astrocytic proliferation in the CA1 str. radiatum of the hippocampus
labeled by GFAP immunocytochemistry. Images were taken at 10x magnifica-
tion (Panel B–E). Data are presented as means±S.E.M.; ⁎Pb0.05; ##Pb0.01
(Panel E). Abbreviations: 2VO: permanent, bilateral common carotid artery
occlusion (two-vessel occlusion); Sham: sham-operated controls; CA: cornu
ammonis; or: stratum oriens; pyr: stratum pyramidale; rad: stratum radiatum.
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neuronal death in the two-vessel occluded rats. This COX
inhibition had no influence on the dendritic arborization,
astrocytic reaction or microglia activation.
Indomethacin did not improve the survival rate. The
probable reason for this is the direct vasoconstriction of the
cerebral microvessels by indomethacin, which leads to more
severe ischemia in the hypoperfused brain (Hoffmeyer et al.,
2007). The beneficial effects of NS-398 on the survival rate
might be due to a decrease in the inflammatory reaction of the
respiratory tract, arising from vagal nerve manipulation during
two-vessel occlusion surgery. Additionally, NS-398 did not
affect the cerebral perfusion.
NS-398 significantly alleviated the learning deficit of the
two-vessel occluded rats. This finding supposes the role of
COX-2 in the ischemia-induced damage in the brain regions to
be responsible for spatial learning. However, there is no clear-
cut consensus about the regions involved in spatial memory.
The area most frequently observed in connection with spatial
learning is the CA1 region of the hippocampus. A number of
studies have found a direct correlation between a cerebral
hypoperfusion-induced memory deficit and CA1 damage (De
Jong et al., 1999; Nunn and Hodges, 1994; Pappas et al., 1996).
An impaired learning performance 3 weeks after two-vessel
occlusion coincided with a significant pyramidal cell loss in the
CA1 region (Xiong et al., 2006). Others found no or only a
weak correlation between the diminished CA1 neuron number
and the Morris maze performance (Jaspers et al., 1990; Lyeth
et al., 1990; Olsen et al., 1994). Auer et al. reported that only a
neuron loss exceeding 50% in the CA1 pyramidal cell layer
resulted in a memory deficit (Auer et al., 1989). We earlier
demonstrated that only a mild reduction in neuronal cell number
was observed through cresyl violet staining in the hippocampus
2 weeks after two-vessel occlusion (Farkas et al., 2006), when
the extent of apoptotic cell death, as indicated by caspase-3
staining in the hippocampus was negligible (unpublished data).
In a model of global cerebral ischemia, Henrich-Noack et al.
demonstrated that population spike generation in the DG
granular cell layer was greatly decreased as early as 1 day post-
ischemia, when compared to pre-ischemic values and to sham-
operated animals. The functional impairment was detected
despite an apparently intact morphology of granular cells as
evidenced by Nissl-staining (Henrich-Noack et al., 2005).
Therefore it cannot be excluded that at least part of the surviving
neurons in the two-vessel occluded animals may be functionally
impaired and may not exhibit proper long-term potentiation
(LTP). This, in turn, may also limit spatial learning. However,
the administration of NS-398 to in vitro CA1 pyramidal and DG
granular cell culture significantly reduced LTP and long-term
depression (LTD) (Murray and O'Connor, 2003). This finding
suggests that the memory-preserving effect of the COX-2
inhibitor NS-398 is probably not related directly to the electrical
disturbances of the surviving hippocampal cells. The pyramidal
and granular cells in the hippocampus are not the exclusive
participants in spatial memory; other parts of the hippocampal
formation such as the entorhinal cortex, the parahippocampal
gyrus, and the rhinal and cingular gyri are also involved
(Meunier et al., 1996; Wiig and Bilkey, 1994). Moreover, the
memory deficit correlates with the white matter damage in two-
vessel occluded rats (Wakita et al., 1994; Watanabe et al., 2006).
In summary, a direct link cannot be established between
ischemia-induced memory failure and the appearance of
neuronal damage in the hippocampus.
Indomethacin or NS-398 treatment alone increased the
incidence of damage in the hippocampal pyramidal and granular
cell layers in the two-vessel occluded and even in the sham-
operated animals. The role of COX in ischemic neuronal
damage has long been controversial. The functioning of COX
gives rise to the toxic free radical superoxide anion, which can
be a source of neuronal damage. On the other hand, a recent
finding suggests that COX-2 is not the major source of oxygen
radicals after transient cerebral ischemia (Kunz et al., 2007).
The detrimental impact of COX-2 in cerebral ischemia is
putatively mediated by the production of PGE2 through the
prostanoid EP1 receptor (Kawano et al., 2006). Whereas most
Fig. 5. Quantitative analysis of OX-42 immunocytochemistry indicating
microglia activation in the hippocampus CA1 str. radiatum. Significance values
were obtained with the LSD post hoc test (⁎⁎Pb0.01; ##Pb0.01). Panels B–D:
representative photomicrographs of the CA1 area of the hippocampus (10×
magnification). Abbreviations: 2VO: permanent, bilateral common carotid
artery occlusion (two-vessel occlusion); Sham: sham-operated controls; CA:
cornu ammonis; or: stratum oriens; pyr: stratum pyramidale; rad: stratum
radiatum.
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articles are indicative for COX inhibition during ischemia, some
references support the neuroprotective effect of COX-derived
prostanoids. For example, PGE2, which is highly expressed in
the hippocampus, proves neuroprotective by activation of the
prostanoid EP2 receptor in neuron cultures and in organotypic
hippocampal slices against ischemia and oxygen-glucose
deprivation, respectively (de la Torre and Aliev, 2005). Genetic
depletion of the prostanoid EP2 receptor in mice resulted in a
significantly larger infarct after middle cerebral artery occlusion
with reperfusion (McCullough et al., 2004). PGD2, another
prostanoid, has been shown to prevent neuron loss in response
to glutamate excitotoxicity in vitro (Liang et al., 2005).
Treatment with iloprost (a stable PGI2 analog) after two-vessel
occlusion prevented hypoperfusion-induced lipid peroxidation
(Aytac et al., 2006). Since two-vessel occlusion-induced
oligemia does not cause a serious neuron loss, these COX
derivatives may play an important role in the metabolic
adaptation of hippocampal neurons. In this respect, the COX
function is more important as concerns the neuronal viability,
rather than its free radical production in the oligemic state.
Finally, COX-2 inhibitors downregulate PGI2 and upregulate
thromboxane A2, resulting in a prothrombotic state (FitzGerald,
2003); selective COX-2 inhibition can therefore induce
microvascular thrombosis in the hippocampus. Another aspect
of neuronal damage in COX inhibition is the elevated turnover
of arachidonic acid to eicosanoids by an enhanced lipoxygenase
function. 5-Lipoxygenase-derived eicosanoids cause neuronal
damage in the cortex during 14 days after 1 h of transient
MCAO (Zhou et al., 2006). Our results do not substantiate the
neuroprotective action of selective and nonselective COX
inhibitors in mild ischemia, in spite of their beneficial effects on
memory.
In our experimental setup, significant time-dependent
changes could be observed postoperatively in the cellular
markers in the hippocampus. The MAP-2 antibody signaling
exhibited a two-vessel occlusion and time-dependent decrease,
while the results of GFAP and OX-42 immunocytochemistry in
the CA1 str. radiatum indicated extremely enhanced astrocytic
and microglia activation 2 weeks vs 3 days after surgery, in both
the sham and the two-vessel occluded animals.
It was earlier reported that chronic cerebral hypoperfusion
gradually reduces the MAP-2 protein level from 4 weeks to
20 weeks after two-vessel occlusion, this decrease displaying a
linear correlation with the learning impairment in the Morris
maze (Liu et al., 2005). Our results confirm this relationship and
provide evidence of a gradual loss of MAP-2-positive dendrites
even at 3 days after two-vessel occlusion. Further, the present
data are strongly supported by our previous observations that
the density of MAP-2-positive dendrites considerable decreases
2 weeks after the induction of two-vessel occlusion (Annaházi
et al., 2007). However, the current data suggests that surgery
alone also has a significant impact on MAP-2 staining.
Therefore the interaction between treatments and survival
time may obscure treatment-related changes.
Astrocytic activation and proliferation which are known to
develop under ischemic conditions indicates neuronal injury or
affords protection against neurodegeneration (Vibulsreth et al.,
1987). The microglia plays a pivotal role in neurodegeneration.
During ischemia, it acts as a double-edged weapon. It provides
protection by the phagocytosis of cellular detritus, but it exerts
cytotoxicity through reactive oxygen species and cytokine
production (Gehrmann et al., 1995; Kreutzberg, 1996). Cerebral
hypoperfusion alone did not affect these markers significantly
in the early period following two-vessel occlusion, but the
evolution of astrocytic proliferation and microglia activation
can be detected 13 weeks after two-vessel occlusion in various
regions of the rat brain (Farkas et al., 2004; 2005). The parallel
changes in the GFAP antibody and OX-42 antibody signals in
the sham and two-vessel occluded groups are likely to be a
consequence of a similar detrimental impact. Probably the most
damaging event during the sham operation is the procedure of
the separation of carotid artery from the vagal nerve, when the
vessel is compressed for several seconds. However, less than
10 min of hypoxia failed to induce microglia activation in
hippocampus slice preparations (Abraham et al., 2001).
Schmidt-Kastner et al. reported a significantly enhanced
astrocytic proliferation from 1 week to 6 months after two-
vessel occlusion in the optic tract and in the corpus callosum
(Schmidt-Kastner et al., 2005), which supposes a region-
specific distribution of glial activation in this model.
In conclusion, we have provided a description of the changes
in the most important morphological markers in the hippocam-
pus in the first 2 weeks of experimental cerebral hypoperfusion.
Two-vessel occlusion induced a protracted period of neuronal
death, progressive dendritic lesions and astrocytic activation in
the hippocampus. The selective inhibition of COX-2 exerts a
more beneficial effect on the cognitive impairment than that of
the nonselective COX inhibition by indomethacin in the
hypoperfused brain. No relationship could be discerned
between the advantageous effects of NS-398 on the memory
capacity and the histological changes in the early period of
cerebral hypoperfusion. Thus, the presence of hippocampal
neuronal damage alone does not correlate with the spatial
memory impairment in the two-vessel occlusion model. To
elucidate the mechanism of action of NS-398 on spatial
learning, and to detect the differences between NS-398 and
indomethacin treatment, further investigations are necessary.
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